

**Official Title:** A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment who have Inadequate Glycemic Control

**NCT Number:** NCT03242252

**Document Date:** Protocol Version 1: 22-December-2017



## AMENDED CLINICAL TRIAL PROTOCOL NO. 01

**COMPOUND: sotagliflozin/SAR439954**

**A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment who have Inadequate Glycemic Control**

**STUDY NUMBER: EFC14837**

**STUDY NAME: SOTA-CKD3**

**VERSION DATE / STATUS: Approval date (20-Dec-2017) / Approved**

Protocol Amendment 01	Version number: 1 (electronic 1.0)	Date : 20-Dec-2017
Clinical Trial Protocol	Version number: 1 (electronic 2.0)	Date : 11-May-2017
Version Number: 1	EudraCT: 2016-004889-26	
	IND Number: [REDACTED]	
	WHO universal trial number: U11111-1187-8662	
Date: 20-Dec-2017	Total number of pages: 127	

Any and all information presented in this document shall be treated as confidential and shall remain the exclusive property of Sanofi (or any of its affiliated companies). The use of such confidential information must be restricted to the recipient for the agreed purpose and must not be disclosed, published or otherwise communicated to any unauthorized persons, for any reason, in any form whatsoever without the prior written consent of Sanofi (or the concerned affiliated company); 'affiliated company' means any corporation, partnership or other entity which at the date of communication or afterwards (i) controls directly or indirectly Sanofi, (ii) is directly or indirectly controlled by Sanofi, with 'control' meaning direct or indirect ownership of more than 50% of the capital stock or the voting rights in such corporation, partnership or other entity

## **NAMES AND ADDRESSES OF**

### **COORDINATING INVESTIGATOR**

Name:  
Address:

Click here and type

Tel:  
Fax:  
E-mail:

### **MONITORING TEAM'S REPRESENTATIVE**

Name:  
Address:

Click here and type

Tel:  
Fax:  
E-mail:

### **SPONSOR**

Company:  
Address:

Click here and type

### **OTHER EMERGENCY TELEPHONE NUMBERS**

Click here and type

## CLINICAL TRIAL SUMMARY

<b>COMPOUND: sotagliflozin/SAR439954</b>	<b>STUDY No.: EFC14837</b>
<b>TITLE</b>	A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment who have Inadequate Glycemic Control
<b>INVESTIGATOR/TRIAL LOCATION</b>	Multinational
<b>PHASE OF DEVELOPMENT</b>	3
<b>STUDY OBJECTIVES</b>	<p><b>Primary objective:</b></p> <p>To demonstrate the superiority of sotagliflozin 400 mg and 200 mg versus placebo with respect to hemoglobin A1c (HbA1c) reduction at Week 26 in patients with Type 2 diabetes (T2D) who have inadequate glycemic control and moderate renal impairment.</p> <p><b>Secondary objectives:</b></p> <ul style="list-style-type: none"> <li>• To assess the effects of sotagliflozin 400 mg and 200 mg versus placebo, based on: <ul style="list-style-type: none"> <li>- Change from Baseline in fasting plasma glucose (FPG) at Week 26</li> <li>- Change from Baseline in body weight at Week 26</li> <li>- Change from Baseline in systolic blood pressure (SBP) at Week 12 for patients with Baseline SBP <math>\geq</math>130 mmHg</li> <li>- Change from Baseline in SBP at Week 12 for all patients</li> <li>- Percentage change in urine albumin:creatinine ratio (UACR) from Baseline to Week 26 (for patients with Baseline UACR &gt;30 mg/g)</li> <li>- Proportion of patients with HbA1c &lt;6.5%, &lt;7.0% at Week 26.</li> </ul> </li> <li>• To evaluate the safety of sotagliflozin 400 mg and 200 mg versus placebo over the 52 weeks of treatment.</li> </ul> <p><b>Other:</b></p> <p>To compare sotagliflozin 400 mg and 200 mg versus placebo with respect to:</p> <ul style="list-style-type: none"> <li>• Change from Baseline in SBP at Weeks 26 and 52 for patients with Baseline SBP <math>\geq</math>130 mmHg</li> <li>• Change from Baseline in SBP at Weeks 26 and 52 for all patients</li> <li>• Change from Baseline in HbA1c at Week 52</li> <li>• Change from Baseline in FPG at Week 52</li> <li>• Change from Baseline in body weight at Week 52</li> <li>• Change from Baseline in estimated glomerular filtration rate (eGFR).</li> <li>• Change from Baseline on the following endpoints:</li> </ul>

	<ul style="list-style-type: none"> <li>- Cystatin C</li> <li>- Urinary Glucose Excretion (UGE)</li> <li>- Urine Glucose:creatinine ratio (UGCR)</li> <li>- Fructosamine</li> <li>- N-terminal prohormone of brain natriuretic peptide (NT-proBNP).</li> <li>• Progression of kidney disease, based upon changes in eGFR or albuminuria.</li> <li>• Change from Baseline to Week 12 in SBP for patients with Baseline SBP &lt;130 mmHg.</li> <li>• Change from Baseline to Week 12 in diastolic blood pressure (DBP) for all patients and the subset of patients with Baseline DBP ≥80 mmHg.</li> <li>• The proportion of patients requiring rescue for hyperglycemia during 26-week double-blind Treatment Period.</li> <li>• To assess plasma levels of sotagliflozin and sotagliflozin-3-O-glucuronide in the sotagliflozin treatment arms.</li> </ul>
<p><b>STUDY DESIGN</b></p>	<p>This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.</p> <p>Patients with T2D will be included in this study if at Screening they have an HbA1c between 7% and 11%, inclusive, and moderate renal impairment (defined as a Screening Modification of Diet in Renal Disease (MDRD) eGFR of ≥30 to &lt;60 mL/min/1.73 m<sup>2</sup>). Any background antidiabetic therapy (oral or injected including insulin) is permitted with the exception of other sodium-glucose cotransporter type 2 (SGLT2) inhibitors. During the double-blind Treatment Period, the type and the dose of background therapy should not be changed unless for safety concerns.</p> <p>All patients will have a Screening Period comprised of an up to 2-week Screening phase and a 2-week, single-blind placebo Run-in phase prior to randomization. In order to qualify for randomization, patients must demonstrate compliance during the single-blind placebo Run-in phase based upon tablet count (≥80%) and as assessed at the Investigator's discretion.</p> <p>Patients will be randomly assigned 1:1:1 to 1 of 3 treatment arms at Visit 3 (Week 0, Day 1):</p> <ul style="list-style-type: none"> <li>• Placebo</li> <li>• Sotagliflozin 200 mg</li> <li>• Sotagliflozin 400 mg.</li> </ul> <p>Randomization will be stratified by:</p> <ul style="list-style-type: none"> <li>• Screening HbA1c (≤8.5% and &gt;8.5%)</li> <li>• Screening SBP (&lt;130 mmHg and ≥130 mmHg)</li> <li>• Chronic kidney disease stage (either CKD stage 3A [screening eGFR of 45 to &lt;60 mL/min/1.73 m<sup>2</sup>] or CKD stage 3B [screening eGFR of 30 to &lt;45 mL/min/1.73 m<sup>2</sup>]).</li> </ul> <p>To ensure sufficient patients in each CKD stratum, enrollment will be capped for the 1st CKD that reaches 390 patients (either CKD stage 3A or CKD stage 3B). Enrollment for the study will be completed</p>

	<p>when reaching the target number as planned.</p> <p>Following randomization, patients will have a 26-week double-blind Treatment Period, followed by a 26-week double-blind Extension Period, and a 4-week post-treatment Follow-up Visit to collect safety and some efficacy information.</p> <p>Patients will be monitored throughout the double-blind Treatment Period and Extension Period for signs of deterioration in renal function (eg, decrease in eGFR) as well as all other routine clinical and laboratory findings. If at any visit after Randomization up to Week 8 there is a rise in creatinine level (ie, &gt;50% increase from Baseline level, where Baseline level is defined as the mean of creatinine values obtained at Screening and Randomization) or if at any visit after Week 8 there is a rise of &gt;50% above the mean of creatinine values from the previous 2 visits, the Investigator should ensure that no reasonable explanation exists for creatinine increase and in particular the following causes:</p> <ul style="list-style-type: none"><li>• Medications that increase creatinine</li><li>• Decrease in cardiac output</li><li>• Obstructive uropathy</li><li>• Urinary tract infection</li><li>• Volume depletion.</li></ul> <p>If addressing these causes does not reduce the creatinine level below the above stated threshold, the investigational medicinal product (IMP) will be stopped for 2 weeks. If at creatinine recheck the patient has returned to the below threshold, then IMP will be restarted at a reduced dose (ie, dose reduced via interactive response technology to 200 mg for those randomized to 400 mg, maintained to 200 mg for those randomized to 200 mg, and to placebo for those randomized to placebo). If the creatinine does not return to below the threshold, the IMP will be permanently discontinued but the patient will be asked to continue attending all study visits.</p> <p>The HbA1c and FPG results will be masked to study sites and patients after randomization and until study end. To prevent partial unblinding, UGE and UGCR results will also be masked to study sites and patients. Additionally, urinalysis by dipstick will not include the measurement of urine glucose.</p> <p>Quantitative urine glucose, albumin, calcium, phosphorus, magnesium, and creatinine will be measured separately at all on-site visits by the central laboratory.</p> <p><b>Early termination</b></p> <p>If a patient discontinues treatment with IMP early during the Treatment Period, the patient will have a Premature End of Treatment (EOT) visit and a Follow-up Visit 4 weeks after the last dose of IMP. In addition, every effort will be made to have all patients return to the site at the time corresponding to their scheduled visits, particularly the Week 26 and Week 52 visits.</p> <p>If a patient does not agree to site visits, he/she will be contacted by telephone to enquire about their safety information, particularly at the time of the initially scheduled end of study.</p>
--	---

	The study design is presented graphically in <a href="#">Section 1.1</a> .
<p><b>STUDY POPULATION</b></p> <p><b>Main selection criteria</b></p>	<p><b>Inclusion criteria:</b></p> <ul style="list-style-type: none"> <li>• Patients with T2D (drug-naïve or on antidiabetic therapy) and documented moderate renal insufficiency defined by an eGFR (based on the 4 variable MDRD equation) of <math>\geq 30</math> and <math>&lt; 60</math> mL/min/1.73 m<sup>2</sup> (CKD 3A, 3B).</li> <li>• Patient has given written informed consent to participate in the study in accordance with local regulations.</li> </ul> <p><b>Exclusion criteria:</b></p> <ul style="list-style-type: none"> <li>• HbA1c <math>&lt; 7.0\%</math> or HbA1c <math>&gt; 11\%</math> measured by the central laboratory at Screening.</li> <li>• At the time of Screening age <math>&lt; 18</math> years or <math>&lt;</math> legal age of majority, whichever is greater.</li> <li>• Renal-specific exclusions: <ul style="list-style-type: none"> <li>- Renal disease that required treatment with immunosuppressive therapy within the last 12 months, or renal transplant or initiation of chronic dialysis within 4 weeks prior to the Screening Visit or expected to occur during the study duration.</li> <li>- Chronic dialysis or CKD stage 4 or 5 or requiring chronic dialysis within 6 months of Screening</li> <li>- Reversible causes of renal failure such as obstruction within 6 months of Screening.</li> </ul> </li> <li>• Use of a selective SGLT2 inhibitor (eg, canagliflozin, dapagliflozin, or empagliflozin) within 12 months prior to the trial.</li> <li>• Oral antidiabetic agent or insulin use if dose not stable for 8 weeks before randomization (ie, oral agents changed during past 8 weeks or total daily basal insulin dose increased or decreased by more than 20% during the past 4 weeks).</li> <li>• Type 1 diabetes mellitus.</li> <li>• Women of childbearing potential (WOCBP) not willing to use highly effective method(s) of birth control during the study treatment period and the follow-up period, or who are unwilling or unable to be tested for pregnancy (see <a href="#">Appendix A</a>), during the study.</li> <li>• History of gastric surgery including history of gastric banding or inflammatory bowel disease within 3 years prior to the Screening Visit.</li> <li>• History of diabetic ketoacidosis or nonketotic hyperosmolar coma within 12 weeks prior to the Screening Visit.</li> <li>• History of severe hypoglycemia that resulted in unconsciousness, coma, or hospitalization within 6 months prior to the Screening Visit.</li> <li>• Patients with severe anemia, severe cardiovascular (including congestive heart failure New York Heart Association IV), respiratory, hepatic, neurological, psychiatric, or active malignant tumor, or other major systemic disease or patients with short life expectancy that, according to the Investigator, will preclude their safe</li> </ul>

	<p>participation in this study, or will make implementation of the protocol or interpretation of the study results difficult.</p> <ul style="list-style-type: none"> <li>• Mean of 3 separate blood pressure (BP) measurements &gt;180 mmHg (SBP) or &gt;100 mmHg (DBP) (with or without hypertensive medications).</li> <li>• Systolic BP &lt;120 mmHg or DBP &lt;60 mmHg if the patient is on antihypertensive medications.</li> <li>• Known presence of factors that interfere with the Central Lab HbA1c measurement (eg, genetic Hb variants) compromising the reliability of HbA1c assessment or medical conditions that affect interpretation of HbA1c results (eg, blood transfusion or severe blood loss in the last 3 months prior to randomization, any condition that shortens erythrocyte survival)</li> <li>• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;3 times the upper limit of the normal laboratory range (ULN).</li> <li>• Total bilirubin &gt;1.5 times the ULN (except in case of Gilbert's syndrome).</li> <li>• Use of systemic glucocorticoids (excluding topical, intra-articular or ophthalmic application, nasal spray, or inhaled forms) for more than 10 consecutive days within 90 days prior to the Screening Visit.</li> <li>• Patient who has taken other investigational drugs or prohibited therapy for this study within 12 weeks or 5 half-lives from prior to Screening, whichever is longer. Current enrollment in any other clinical study involving an investigational study treatment or any other type of medical research.</li> <li>• Pregnancy or breastfeeding.</li> <li>• Patients unwilling or unable to perform self-monitoring of blood glucose (SMBG; <a href="#">Section 9.2.1.8</a>), complete the patient diary or comply with study visits and other study procedures as required per protocol.</li> </ul>
<b>Total expected number of patients</b>	780 randomized patients
<b>STUDY TREATMENTS</b>	
<b>Investigational medicinal products</b>	<ul style="list-style-type: none"> <li>• Sotagliflozin 200 mg, given as two (2) tablets: 1 sotagliflozin 200-mg tablet and 1 placebo tablet (identical to sotagliflozin in appearance), once daily before the first meal of the day.</li> <li>• Sotagliflozin 400 mg, given as two (2) 200-mg tablets, once daily before the first meal of the day.</li> <li>• Placebo, given as two (2) placebo tablets (identical to sotagliflozin 200 mg in appearance), once daily before the first meal of the day.</li> </ul>
<b>Formulation:</b>	Tablet
<b>Route of administration:</b>	Oral
<b>Dose regimen:</b>	Once daily



<b>Noninvestigational medicinal products</b>	<b>Rescue therapy</b> The thresholds values are defined as follows, depending on study period: <ul style="list-style-type: none"><li>• From Baseline Visit (V3, Day 1) to Visit 6 (Week 8) (including value at Visit 6): FPG &gt;270 mg/dL (15.0 mmol/L).</li><li>• From Visit 6 (Week 8) to Visit 7 (Week 12) (including value at Visit 7): FPG &gt;240 mg/dL (13.3 mmol/L).</li><li>• From Visit 7 (Week 12) up to the EOT Period Visit 11 (Week 52) (including value at Visit 11): FPG &gt;200 mg/dL (11.1 mmol/L) or HbA1c <math>\geq 8.5\%</math> (the 8.5% criterion does not apply if the HbA1c decrease from Baseline was <math>\geq 1.0\%</math>).</li></ul> Routine fasting SMBG and central laboratory alerts on FPG (and HbA1c at Week 12 and onwards) are set up to ensure that glycemic parameters remain under predefined thresholds values (see hereinafter). <ul style="list-style-type: none"><li>• If one fasting SMBG value exceeds the specific glycemic limit on one day, the patient checks it again during the 2 following days. If all the values in 3 consecutive days exceed the specific limit, the patient should contact the Investigator and <b>a central laboratory FPG measurement (and HbA1c at Week 12 and onwards) is performed</b> as soon as possible, preferably within 7 days to confirm the hyperglycemia.</li><li>• Upon receipt of a central laboratory rescue alert <b>a central laboratory re-test must be completed and confirmed as exceeding the criterion</b> for rescue before rescue therapy is initiated. The re-test confirmation should be performed as soon as possible, but within 7 days of receipt by unscheduled visit.</li></ul> In case of a confirmatory FPG and/or HbA1c above the threshold values, the Investigator should ensure that no reasonable explanation exists for insufficient glucose control and in particular that: <ul style="list-style-type: none"><li>• The increased FPG has been tested at a fasting status (ie, no food intake for <math>\geq 8</math> hours).</li><li>• Investigational product is given at the planned dose.</li><li>• Absence of intercurrent disease, which may jeopardize glycemic control (eg, infectious disease).</li><li>• Compliance to treatment is appropriate.</li><li>• Compliance to diet and lifestyle is appropriate.</li></ul> If any of the above can reasonably explain the insufficient glycemic control, the Investigator should consider not initiating rescue medication and should undertake appropriate action, ie: <ul style="list-style-type: none"><li>• Assess plasma glucose in fasting condition (ie, after at least 8 hours fast).</li><li>• Initiate an evaluation and treatment of intercurrent disease (to be reported in adverse event [AE]/concomitant medication parts of the electronic case report form [e-CRF] and the medical record).</li></ul>
--	---

	<ul style="list-style-type: none"> <li>• Stress on the absolute need to be compliant with treatment.</li> <li>• Organize a specific interview with the patient and a Registered Dietician or other qualified nutrition professional and to reinforce on the absolute need to be compliant to diet and lifestyle recommendations, and schedule an FPG/HbA1c assessment at the next visit.</li> </ul> <p>If none of the above mentioned reasons can be found, or if appropriate action fails to decrease FPG/HbA1c under the threshold values, rescue medication may be introduced.</p> <ul style="list-style-type: none"> <li>• Open label rescue medication(s) to treat hyperglycemia must be in accordance with local standard of care and prescribing practice for patients with CKD and will be at the discretion of the investigator. Except for sodium-glucose cotransporter type 2 (SGLT2) inhibitors and medications with specific contraindications in renal impairment, any approved medication(s) including oral antidiabetic drugs or insulin can be considered with appropriate dose modification as indicated.</li> <li>• The patient continues the IMP (blinded) and stays in the study in order to collect efficacy and safety information. The planned visits and assessments should occur until the last scheduled visit.</li> <li>• Rescue therapy is considered a noninvestigational medicinal product. Rescue therapy is to be reported in the e-CRF. This information should include specific drug name, dose, route of administration, and frequency.</li> </ul> <p>If not covered by health insurance, the cost of the rescue therapy will be reimbursed by the Sponsor where permitted by local regulations.</p>
<p><b>ENDPOINTS</b></p>	<p><b>Primary efficacy endpoint:</b></p> <p>Change from Baseline to Week 26 in HbA1c (%) comparing sotagliflozin 400 mg versus placebo in overall population, and in CKD stages 3A and 3B patients sequentially, then comparing sotagliflozin 200 mg versus placebo in overall population, and in CKD stages 3A and 3B patients sequentially.</p> <p><b>Secondary efficacy endpoints:</b></p> <p>To compare sotagliflozin 400 mg and 200 mg versus placebo, respectively, in terms of:</p> <ul style="list-style-type: none"> <li>• Change from Baseline in FPG at Week 26.</li> <li>• Change from Baseline in body weight at Week 26.</li> <li>• Change from Baseline in SBP at Week 12 for patients with Baseline SBP <math>\geq</math>130 mmHg.</li> <li>• Change from Baseline in SBP at Week 12 for all patients.</li> <li>• Percentage change in UACR from Baseline to Week 26 for patients with UACR &gt;30 mg/g at Baseline.</li> <li>• Proportion of patients with HbA1c &lt;6.5%, &lt;7.0% at Week 26.</li> </ul>

	<p><b>Other efficacy endpoints:</b></p> <p>To compare sotagliflozin 400 mg and 200 mg versus placebo, respectively, in terms of:</p> <ul style="list-style-type: none"> <li>• Change from Baseline in SBP at Weeks 26 and 52 for patients with Baseline SBP <math>\geq</math>130 mmHg</li> <li>• Change from Baseline in SBP at Weeks 26 and 52 for all patients</li> <li>• Change from Baseline in HbA1c at Week 52.</li> <li>• Change from Baseline in FPG at Week 52.</li> <li>• Change from Baseline in body weight at Week 52.</li> <li>• Change from Baseline in eGFR.</li> <li>• Proportion of patients requiring rescue for hyperglycemia during 26-week double-blind Treatment Period.</li> <li>• Change from Baseline in:             <ul style="list-style-type: none"> <li>- Cystatin C</li> <li>- UGE</li> <li>- UGCR</li> <li>- Fructosamine</li> <li>- NT-proBNP.</li> </ul> </li> <li>• Proportion of patients with progression to end stage renal disease (ESRD) (dialysis or transplant) at Week 4 or any time later during the trial.</li> <li>• Proportion of patients with &gt;50% decline in eGFR from Baseline at Week 26 and Week 52.</li> <li>• Proportion of patients with progression from normal to microalbuminuria or from microalbuminuria to macroalbuminuria from Baseline at Week 26 and Week 52.</li> <li>• Proportion of patients with improvement from microalbuminuria to normal or from macroalbuminuria to microalbuminuria from Baseline at Week 26 and Week 52.</li> <li>• Change from Baseline in SBP at Week 12 for patients with Baseline SBP &lt;130 mmHg.</li> <li>• Change from Baseline in DBP at Week 12 for all patients and the subset of patients with Baseline DBP <math>\geq</math>80 mmHg.</li> </ul>
	<p><b>Safety endpoints:</b></p> <ul style="list-style-type: none"> <li>• AEs, hypoglycemia (all, severe and/or documented symptomatic hypoglycemia), events of special interest (EOSI), adverse events of special interest (AESI), AEs leading to discontinuation from the IMP, serious adverse events (SAE), and deaths.</li> <li>• Acute Renal Failure.</li> <li>• Clinical laboratory results, vital signs results, electrocardiogram (ECG), and bone mineral density (BMD).</li> <li>• Markers of intestinal transit and absorption.</li> <li>• Markers of bone and calcium metabolism.</li> </ul> <p><b>Pharmacokinetic endpoints:</b></p> <ul style="list-style-type: none"> <li>• Plasma levels of sotagliflozin and sotagliflozin-3-O-glucuronide in the sotagliflozin treatment arms.</li> </ul>


<b>ASSESSMENT SCHEDULE</b>	See Study Flow Chart, <a href="#">Section 1.2</a> .
<b>STATISTICAL CONSIDERATIONS</b>	<p><b>Sample size determination:</b></p> <p>The sample size/power calculations were performed based on the primary endpoint. Assuming a common standard deviation of 1.2% and using a 2-sided test at a 0.05 <math>\alpha</math>-level, 130 patients in each CKD stratum (3A or 3B) in each treatment group will provide the following power:</p> <ul style="list-style-type: none"> <li>• To detect a treatment difference of 0.6% in mean HbA1c change from Baseline to Week 26 between sotagliflozin 400 mg versus placebo: <ul style="list-style-type: none"> <li>- 98% power comparing sotagliflozin 400 mg versus placebo in patients in CKD 3A stratum</li> <li>- 98% power comparing sotagliflozin 400 mg versus placebo in patients in CKD 3B stratum</li> <li>- 99% power comparing sotagliflozin 400 mg versus placebo in overall patient population</li> </ul> </li> <li>• To detect a treatment difference of 0.5% in mean HbA1c change from Baseline to Week 26 between sotagliflozin 200 mg versus placebo: <ul style="list-style-type: none"> <li>- 91% power comparing sotagliflozin 200 mg versus placebo in patients in CKD 3A stratum</li> <li>- 91% power comparing sotagliflozin 200 mg versus placebo in patients in CKD 3B stratum</li> <li>- 99% power comparing sotagliflozin 200 mg versus placebo in overall patient population</li> </ul> </li> <li>• At least 80% overall power to have all 6 above statistical inferences statistically significant based on above treatment effect assumptions.</li> </ul> <p><b>Analysis population:</b></p> <p>Efficacy analyses will be based on the intent-to-treat (ITT) population, defined as all randomized patients irrespective of compliance with the study protocol and procedures. Patients will be analyzed according to the treatment group to which they are randomized.</p> <p><b>Analysis of the primary efficacy endpoint:</b></p> <p>Analysis of the primary efficacy endpoint (change from Baseline to Week 26 in HbA1c) will be performed using the ITT population, using HbA1c measurements obtained during the study, including those obtained after IMP discontinuation or introduction of rescue therapy. The primary efficacy endpoint of change in HbA1c from Baseline to Week 26 will be analyzed with missing values imputed by control-based multiple imputation method under the missing not at random frame work.</p> <ul style="list-style-type: none"> <li>• For placebo patients, missing data will be imputed based on the placebo group data,</li> <li>• For patients in the sotagliflozin groups, missing data will be imputed as if the patients were on placebo group throughout the study, where all patients' measurements including the on-treatment measurements will be considered as if the measurements were from the placebo group in the imputation model.</li> </ul>

	<p>Each of the complete datasets will be analyzed by the analysis of covariance (ANCOVA) model. To compare sotagliflozin 400 mg and 200 mg, respectively, versus placebo in overall patient population (ie, CKD 3A and 3B patients combined), the model will include treatment (sotagliflozin 400 mg, sotagliflozin 200 mg, and placebo), randomization stratum of Screening HbA1c (<math>\leq 8.5\%</math> and <math>&gt; 8.5\%</math>), randomization stratum of Screening SBP (<math>&lt; 130</math> mmHg, <math>\geq 130</math> mmHg), randomization stratum of CKD stage (3A, 3B), and country as fixed effects, and Baseline HbA1c value as a covariate. To compare sotagliflozin 400 mg and 200 mg, respectively, versus placebo in each CKD stratum, the model will include treatment (sotagliflozin 400 mg, sotagliflozin 200 mg, and placebo), randomization stratum of Screening HbA1c (<math>\leq 8.5\%</math> and <math>&gt; 8.5\%</math>), randomization stratum of Screening SBP (<math>&lt; 130</math> mmHg, <math>\geq 130</math> mmHg), randomization stratum of CKD stage (3A, 3B), treatment by randomization stratum of CKD stage, and country as fixed effects, and Baseline HbA1c value as a covariate. Results from each complete dataset will be combined to provide the adjusted mean change in HbA1c from Baseline to Week 26 for each treatment group, as well as the between-group difference (comparing each sotagliflozin group versus placebo) and its associated 95% confidence interval (CI) using contrast statements.</p> <p>Summary statistics (for Screening value, Baseline value, observed values, and observed changes from Baseline) at scheduled visits will be provided for each treatment group and by CKD stages (3A, 3B). The summary will include the number of observations, mean, standard deviation (SD), standard error (SE), minimum, median, and maximum. Graphical presentations will also be used to examine trends over time using mean values (<math>\pm</math>SE) and mean changes from Baseline (<math>\pm</math>SE) at each of the scheduled visits (using observed case [OC]).</p> <p><b>Baseline definition:</b></p> <p>The Baseline value is defined generally as the last available value before the first dose of double-blind IMP or the last available value prior to randomization for patients who were randomized but never exposed to IMP.</p> <p>For serum creatinine (or eGFR), the Baseline value is defined as the mean of creatinine levels (or eGFR) at the Screening and Randomization Visits prior to the first dose of double-blind IMP or prior to randomization for patients who were randomized but never exposed to IMP.</p> <p><b>Analysis of secondary efficacy endpoints:</b></p> <p>The secondary endpoints will be analyzed using a similar approach to the primary efficacy endpoint, with missing values imputed by the control-based multiple imputation method under the missing not at random frame work. For each of the continuous secondary endpoints, each of the complete datasets will be analyzed by the ANCOVA model with treatment groups (sotagliflozin 400 mg, sotagliflozin 200 mg, and placebo), randomization stratum of Screening HbA1c (<math>\leq 8.5\%</math> and <math>&gt; 8.5\%</math>), randomization stratum of Screening SBP (<math>&lt; 130</math> mmHg, <math>\geq 130</math> mmHg), randomization stratum of CKD stage (3A, 3B), and country as fixed effects, and Baseline</p>
--	---

	<p>secondary endpoint value as a covariate. Results from each complete dataset will be combined to provide the adjusted mean change from Baseline to Week 26 (Week 12 for SBP endpoints) for each treatment group, as well as the between-group difference (comparing each sotagliflozin group versus placebo) and its associated 95% CI using contrast statements.</p> <p>The UACR will be log-transformed before the analysis. Change from Baseline to Week 26 of UACR in log scale will be analyzed. Results in the log scale will be back-transformed to provide the ratio and then the percent change of UACR at Week 26 versus Baseline based on the geometric means as well as the corresponding 95% CIs.</p> <p>The categorical secondary efficacy variables of HbA1c &lt;6.5%, &lt;7% at Week 26 will be analyzed using a Cochran-Mantel-Haenszel method stratified by randomization stratum of Screening HbA1c (<math>\leq 8.5\%</math> and <math>&gt; 8.5\%</math>), randomization stratum of Screening SBP (<math>&lt; 130</math> mmHg, <math>\geq 130</math> mmHg), randomization stratum of CKD stage (3A, 3B). For the HbA1c &lt;7% or &lt;6.5% analysis, patients with missing HbA1c data at Week 26 will be considered non-responders in the ITT population.</p> <p>Summary statistics for the secondary endpoints at scheduled visits will be provided for each treatment group and by CKD stages (3A, 3B) as appropriate.</p> <p><b>Analysis of other efficacy endpoints:</b></p> <p>The analysis of other endpoints will be descriptive with no formal testing. Summary statistics at scheduled visits using OC will be provided by each treatment group and by CKD stages (3A, 3B) as appropriate. Graphical presentations will also be used to illustrate trends over time.</p> <p><b>Analyses of safety data:</b></p> <p>All safety summaries will be descriptive; no statistical significance tests will be performed on safety data. These analyses will be based on the safety population, which is defined as all randomized patients who receive at least 1 dose of double-blind treatment, regardless of the amount of treatment administered. Patients will be analyzed for safety analyses according to the treatment actually received.</p>
<p><b>DURATION OF STUDY PERIOD (per patient)</b></p>	<p>Up to 60 weeks, including a 4-week Screening Period (comprised of a 2-week Screening phase and a 2-week single-blind placebo Run-in phase), a 26-week double-blind Treatment Period, a 26-week double-blind Extension Period, and a 4-week post-treatment Follow-up Visit.</p>
<p><b>STUDY COMMITTEES</b></p>	<p><b>Steering Committee:</b> <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No</p> <p><b>Data monitoring committee:</b> <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No</p> <p><b>Clinical Endpoint Committees:</b> <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No</p>

# 1 FLOW CHARTS

## 1.1 GRAPHICAL STUDY DESIGN



Abbreviations: eGFR: estimated glomerular filtration rate; HbA1c: hemoglobin A1c; SBP: systolic blood pressure; T2D: Type 2 diabetes

## 1.2 STUDY FLOW CHART

Visit	Screening Period		Double-blind Treatment Period <sup>a</sup>							Extension Period		Follow Up <sup>b</sup>
	Screening	Run-in	3 (Randomization)	4	5	6	7	8	9	10	11	12
Week	-4	-2	0 Baseline	2	4	8	12	18	26	39	52	56
Day (window [days])		(±3)	1	14 (±5)	28 (±5)	56 (±5)	84 (±5)	126 (±5)	182 (±5)	273 (±5)	364 (±5)	392 (±5)
Informed consent	X											
Inclusion criteria	X											
Exclusion criteria	X		X									
Demographics	X											
Medical/Surgical History	X											
Medication History	X											
Body weight, height <sup>c</sup>	X	X	X	X	X	X	X	X	X	X	X	X
Vital signs <sup>d</sup>	X	X	X	X	X	X	X	X	X	X	X	X
Physical Exam:												
Complete	X								X		X	
Abbreviated <sup>e</sup>		X	X	X								X
Diet & exercise instruction		X	X	X	X				X	X		
Instruction on basic genito-urinary hygiene & hydration	X	X	X		X	X	X	X	X	X		
Interactive response technology (IRT) contact	X	X	X		X	X	X	X	X	X	X	X
Randomization			X									
Dispense glucose meter		X										
Collect glucose meter												X
Dispense diary	X	X	X	X	X	X	X	X	X	X	X	



	Screening Period		Double-blind Treatment Period <sup>a</sup>							Extension Period		Follow Up <sup>b</sup>
	Screening	Run-in	3 (Randomization)	4	5	6	7	8	9	10	11	12
Visit	1	2	0 Baseline	2	4	8	12	18	26	39	52	56
Week	-4	-2	1	14 (±5)	28 (±5)	56 (±5)	84 (±5)	126 (±5)	182 (±5)	273 (±5)	364 (±5)	392 (±5)
Day (window [days])		(±3)										
Collect/review diary		X	X	X	X	X	X	X	X	X		X
Instruction on diabetic ketoacidosis symptoms and glucose testing			X		X	X	X	X	X	X		
Dispense IMP		X	X		X	X	X	X	X	X		
IMP accounting & compliance			X	X	X	X	X	X	X	X	X	
Concomitant medication	X	X	X		X	X	X	X	X	X	X	X
Self-monitored blood glucose <sup>f</sup>		X	X		X	X	X	X	X	X	X	X
12-lead ECG <sup>g</sup>		X							X		X	
<b>Laboratory testing<sup>h</sup></b>												
FPG	X		X		X	X	X	X	X	X	X	
HbA1c	X		X			X	X	X	X	X	X	
Fructosamine			X		X	X	X	X	X	X	X	
Clinical chemistry <sup>i</sup>	X		X	X	X	X	X	X	X <sup>j</sup>	X	X <sup>j</sup>	X
Hematology	X		X	X	X		X		X	X	X	
Cystatin C			X	X	X		X		X	X	X	X
NT-proBNP			X	X	X		X		X	X	X	
Fasting lipids			X						X	X	X	
Pregnancy test (WOCBP) <sup>k</sup>	X		X		X	X	X	X	X	X	X	
Serum follicle stimulating hormone and estradiol (menopausal women only) <sup>k</sup>	X											
Plasma concentration <sup>k</sup>					X			X	X <sup>j</sup>		X <sup>j</sup>	

	Screening Period		Double-blind Treatment Period <sup>a</sup>							Extension Period		Follow Up <sup>b</sup>
	Screening	Run-in	3 (Randomization)	4	5	6	7	8	9	10	11	12
Visit	1	2	0 Baseline	2	4	8	12	18	26	39	52	56
Week	-4	-2	1	14 (±5)	28 (±5)	56 (±5)	84 (±5)	126 (±5)	182 (±5)	273 (±5)	364 (±5)	392 (±5)
Day (window [days])		(±3)	X	X	X				X		X	
Markers of intestinal transit & absorption <sup>m</sup>			X	X	X				X		X	
Markers of bone & calcium metabolism <sup>n</sup>			X	X	X				X		X	
Urinalysis (dipstick and microscopy) <sup>o</sup>		X	X	X	X	X	X	X	X		X	
BMD <sup>p</sup>			X								X	
Collection of home urine for albumin, creatinine, calcium, phosphorus, magnesium, glucose, and albumin-creatinine ratio <sup>q</sup>			X	X	X		X		X		X	
Evaluate for glycemic rescue			To be assessed and reported throughout the Treatment Period									
Evaluate for 50% increase in Creatinine <sup>t</sup>			To be assessed and reported throughout the Treatment Period									
Hypoglycemia	To be assessed and reported throughout the study											
AEs/SAEs/AESI/EOSI	To be assessed and reported throughout the study <sup>u</sup>											

a If a patient discontinues treatment with IMP early during the Treatment Period, the patient will have a Premature EOT Visit (similar to Visit 11, see [Section 10.1.3.2](#)), and a Follow-up Visit, 4 weeks after the last dose of IMP (similar to Visit 12, see [Section 10.1.4.1](#)). However, every effort will be made to have all patients return to the site for all scheduled visits, in particular the Week 26 and Week 52 Visits. If a patient discontinues (or completes) treatment and study at the same time, a single visit for both EOT and follow-up will be performed.

b Four weeks after the last dose of IMP.

c Height to be measured only at Screening.

d Vital sign measurements (sitting BP, heart rate, temperature, and respiratory rate): 3 separate seated BP and heart rate measurements should be taken with at least 1 minute between readings, following a 5-minute rest period and prior to phlebotomy.

e The abbreviated physical exam should focus on cardiac and respiratory systems, as well as any areas important for assessment of AEs if necessary.

f Self-monitored blood glucose (SMBG) is to be performed fasting, at least 3 times per week from start of Run-in until end of Treatment Period including on day of each on-site study visit except Visit 4. Patients will also be requested to self-assess blood glucose levels whenever they experience symptoms of hypoglycemia. The SMBG will be presented as equivalent self-monitoring plasma glucose (SMPG).

g The 12-lead ECG recordings should be obtained prior to IMP administration. The ECG will be evaluated as "normal" or "abnormal".

- h* All laboratory assessments occur prior to dose of double-blind IMP. All visit dates will be scheduled based on the date of randomization with a  $\pm 3$  days visit window allowed during the Treatment Period. Chemistry panel: Hematology panel in [Section 9.2.1.3](#).
- i* Clinical chemistry laboratory tests are outlined in [Table 2](#). Other chemistry tests will include amylase and lipase.
- j* An additional blood sample will be drawn at Week 26 (Visit 9) and Week 52 (Visit 11), 3 hours after administering the dose of IMP for creatinine (for eGFR) and for assessing plasma concentration of sotagliflozin and sotagliflozin-3-O-glucuronide.
- k* Serum pregnancy testing only at Screening; urine pregnancy testing subsequently. Serum pregnancy test results must be reviewed prior to beginning the Run-in phase for all women of childbearing potential (WOCBP). Any positive urine test results must be confirmed based on serum pregnancy test. The Investigator may perform additional tests at their discretion or as required by local regulations. For women of nonreproductive potential ([Appendix A](#)), follicle stimulating hormone (FSH) and/or estradiol levels should be tested if the definition of postmenopausal or premenopausal cannot be satisfied, eg, no medical document of hysterectomy or cessation of menses <12 months without an alternative medical cause.
- l* Plasma concentration samples for sotagliflozin and sotagliflozin-3-O-glucuronide collected on Weeks 4, 18, 26, and 52 may be drawn with the other laboratory assessments but MUST be collected before administration of IMP. The time of the last intake of study drug prior to visits where PK samples are taken should be recorded by the patient in the patient diary. Patients should be reminded of this at visits preceding PK time points to ensure these details are captured. In the case of premature IMP discontinuation, PK samples should not be drawn at the Premature EOT Visit, neither at all subsequent visits.
- m* The markers of intestinal transit and absorption include vitamins B6, B12, K, E, and A, serum folate, and ferritin.
- n* Markers of bone and calcium metabolism include: serum calcium, serum 25-hydroxyvitamin D, serum 1,25-dihydroxyvitamin D, serum phosphorus, serum magnesium, serum parathyroid hormone (iPTH), markers of bone resorption (serum NTX, serum  $\beta$ -CTX-1), bone formation (serum P1NP and osteocalcin) and serum alkaline phosphatase.
- o* Urinalysis includes urine dipstick and microscopy. Dipstick includes assessment of specific gravity, pH, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase. Microscopy includes, but is not limited to, detection of formed cellular elements, casts, bacteria, yeast, parasites, and crystals in centrifuged urine sediment. In the event of abnormal urinalysis findings suspicious of urinary tract infection (UTI), urine culture should be performed. Positive urine culture determination will be based upon the criteria of the reporting laboratory. Additionally, urine culture should be performed if at any point the Principal Investigator suspects the presence of a UTI.
- p* BMD will be assessed locally (with central reading) in all patients at Baseline (Week 0, Day 1  $\pm 7$  days) and at Visit 11 (Week 52, Day 364  $\pm 7$  days).
- q* Patients will collect overnight urine on Weeks 0, 2, 4, 12, 26, and 52. In the night prior to the visits, the urine before sleep will be discarded and the urine during sleep and the first morning urine (after getting up) will be collected. The visits should be rescheduled to allow for urine collection in case a patient missed it. Urinary albumin, total protein, creatinine, calcium (adjusted for creatinine), phosphorus (adjusted for serum phosphorus and creatinine), magnesium (adjusted for serum magnesium and urinary creatinine), and glucose will be assessed.
- t* The 50% increase will be from Baseline value (to Week 8) or from the arithmetic mean of creatinine values from last two visits (after Week 8) only at visits having a measurement of creatinine.
- u* All serious adverse events (SAEs), adverse events (AEs), AEs of special interest (AESI), and events of special interest (EOSI) will be collected starting from signing informed consent and continue until the end of the study. All AEs that occur during treatment should be followed until study completion (or until patients leave the study) or until the event has resolved, the condition has stabilized or the patient is lost to follow-up. All patients will have a Follow-up visit 4 weeks after the last dose of IMP to collect safety and some efficacy information.

## 2 TABLE OF CONTENTS

<b>1</b>	<b>FLOW CHARTS</b> .....	<b>14</b>
1.1	GRAPHICAL STUDY DESIGN .....	14
1.2	STUDY FLOW CHART .....	15
<b>2</b>	<b>TABLE OF CONTENTS</b> .....	<b>19</b>
2.1	LIST OF TABLES.....	25
2.2	LIST OF FIGURES.....	25
<b>3</b>	<b>LIST OF ABBREVIATIONS</b> .....	<b>26</b>
<b>4</b>	<b>INTRODUCTION AND RATIONALE</b> .....	<b>28</b>
4.1	BACKGROUND: SOTAGLIFLOZIN AND DISEASE .....	28
4.2	CLINICAL TRIALS OF SOTAGLIFLOZIN IN HUMANS .....	30
4.3	RATIONALE FOR SELECTION OF DOSE .....	31
4.4	RATIONALE FOR STUDY DESIGN AND CONTROL GROUPS.....	31
4.5	BENEFIT/RISK OF SOTAGLIFLOZIN .....	32
<b>5</b>	<b>STUDY OBJECTIVES</b> .....	<b>34</b>
5.1	PRIMARY .....	34
5.2	SECONDARY .....	34
5.3	OTHER.....	34
<b>6</b>	<b>STUDY DESIGN</b> .....	<b>36</b>
6.1	DESCRIPTION OF THE STUDY .....	36
6.1.1	Screening Period.....	36
6.1.1.1	Screening phase (Visit 1).....	36
6.1.1.2	Run-in phase (Visit 2).....	36
6.1.2	Double-blind Treatment Period (Day 1 to Week 26).....	37
6.1.3	Double-blind Extension Period (Week 27 to Week 52).....	37
6.1.4	Follow-up Period .....	38
6.2	DURATION OF STUDY PARTICIPATION .....	38

6.2.1	Duration of study participation for each patient .....	38
6.2.2	Determination of end of clinical trial (all patients) .....	38
6.3	STUDY COMMITTEES .....	38
6.3.1	Steering committee .....	38
6.3.2	Data monitoring committee .....	39
6.3.3	Clinical endpoint committee .....	39
6.3.4	Safety adjudication of events requiring ongoing monitoring .....	39
<b>7</b>	<b>SELECTION OF PATIENTS</b> .....	<b>40</b>
7.1	INCLUSION CRITERIA.....	40
7.2	EXCLUSION CRITERIA .....	40
7.2.1	Exclusion criteria related to study methodology .....	40
7.2.2	Exclusion criteria related to the diabetes or CKD history and treatment .....	41
7.2.3	Exclusion criteria related to the current knowledge of sotagliflozin .....	42
7.2.4	Additional exclusion criteria during or at the end of the Run-in phase before Randomization.....	42
<b>8</b>	<b>STUDY TREATMENTS</b> .....	<b>44</b>
8.1	INVESTIGATIONAL MEDICINAL PRODUCT(S) .....	44
8.1.1	Dose reduction .....	44
8.2	NONINVESTIGATIONAL MEDICINAL PRODUCT .....	45
8.2.1	Rescue therapy .....	45
8.3	BLINDING PROCEDURES.....	46
8.3.1	Methods of blinding .....	46
8.3.1.1	First step data analysis .....	47
8.3.2	Randomization code breaking during the study.....	47
8.4	METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP .....	48
8.5	PACKAGING AND LABELING .....	49
8.6	STORAGE CONDITIONS AND SHELF LIFE .....	49
8.7	RESPONSIBILITIES .....	49
8.7.1	Treatment accountability and compliance.....	50
8.7.2	Return and/or destruction of treatments .....	50
8.8	CONCOMITANT MEDICATION.....	50
8.8.1	Prohibited prior and concomitant medications .....	51
8.8.2	Concomitant diabetes therapy .....	51

8.9	POSTSTUDY TREATMENT .....	52
<b>9</b>	<b>ASSESSMENT OF INVESTIGATIONAL MEDICINAL PRODUCT .....</b>	<b>53</b>
9.1	EFFICACY ENDPOINT .....	53
9.1.1	Primary efficacy endpoint.....	53
9.1.2	Secondary efficacy endpoints .....	53
9.1.3	Other efficacy endpoints .....	53
9.1.4	Assessment methods of efficacy endpoints.....	54
9.1.4.1	Hemoglobin A1c.....	54
9.1.4.2	Blood pressure measurements .....	54
9.1.4.3	Body weight measurement .....	54
9.1.4.4	Fasting plasma glucose measurement .....	55
9.1.4.5	Kidney function parameter assessments.....	55
9.1.4.6	Fructosamine, NT-proBNP and Cystatin C.....	55
9.1.4.7	Use of rescue medication for hyperglycemia.....	55
9.1.4.8	Proportion of patients with progression of renal disease.....	55
9.2	SAFETY ENDPOINTS .....	56
9.2.1	Assessment methods of safety endpoints .....	57
9.2.1.1	Adverse events .....	57
9.2.1.2	Hypoglycemia.....	57
9.2.1.3	Laboratory safety variables .....	57
9.2.1.4	Urinalysis.....	59
9.2.1.5	Vital signs and physical exam.....	59
9.2.1.6	Electrocardiogram variables .....	59
9.2.1.7	Bone Mineral Density.....	60
9.2.1.8	Self-monitoring of blood glucose.....	60
9.3	OTHER ENDPOINTS.....	61
9.3.1	Pharmacokinetics of sotagliflozin.....	61
9.3.1.1	Sampling time .....	61
9.3.1.2	Pharmacokinetics handling procedure.....	61
9.3.1.3	Bioanalytical method .....	62
	.....	62
	.....	62
	.....	63
9.5	APPROPRIATENESS OF MEASURES .....	63
<b>10</b>	<b>STUDY PROCEDURES .....</b>	<b>65</b>
10.1	VISIT SCHEDULE.....	65
10.1.1	Screening Period.....	65
10.1.1.1	Screening phase .....	65
10.1.1.2	Run-in phase.....	67

10.1.2	Double-blind randomized Treatment Period (Day 1 to Week 26)	68
10.1.2.1	On-site Randomization Visit 3 on Day 1 (Baseline; Week 0)	68
10.1.2.2	On-site visit at Week 2 (Visit 4)	70
10.1.2.3	On-site visits at Week 4 to Week 18 (Visit 5 to Visit 8)	71
10.1.2.4	On-site visit at Week 26 (Visit 9)	72
10.1.3	Double-blind Extension Period (Week 27 to Week 52)	73
10.1.3.1	On-site visit at Week 39 (Visit 10)	74
10.1.3.2	On-site visit at Week 52 (Visit 11) – End of Treatment	75
10.1.4	Post-treatment Follow-up Period	76
10.1.4.1	Follow-up Visit at Week 56 (Visit 12) – End of Study or 4 weeks after Premature End of Treatment	76
10.2	DEFINITION OF SOURCE DATA	77
10.2.1	Source data to be found in patient's file	77
10.2.2	Source data verification requirements for screen failures	78
10.3	HANDLING OF PATIENT TEMPORARY OR PERMANENT TREATMENT DISCONTINUATION AND OF PATIENT STUDY DISCONTINUATION	78
10.3.1	Temporary treatment discontinuation with investigational medicinal product	78
10.3.2	Permanent treatment discontinuation with investigational medicinal product	79
10.3.3	List of criteria for permanent treatment discontinuation	79
10.3.4	Handling of patients after permanent treatment discontinuation	80
10.3.5	Procedure and consequence for patient withdrawal from study	80
10.4	OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING	81
10.4.1	Definitions of adverse events	81
10.4.1.1	Adverse event	81
10.4.1.2	Serious adverse event	81
10.4.1.3	Adverse event of special interest	82
10.4.1.4	Events of special interest	83
10.4.2	General guidelines for reporting events	83
10.4.3	Instructions for reporting serious adverse events	84
10.4.4	Guidelines for reporting adverse events of special interest	85
10.4.5	Guidelines for reporting events of special interest	85
10.4.6	Guidelines for management of specific laboratory abnormalities	85
10.5	OBLIGATIONS OF THE SPONSOR	85
10.6	SAFETY INSTRUCTIONS	86
10.6.1	Hypoglycemia	86
10.6.2	Deterioration of renal function	88
10.7	ADVERSE EVENTS MONITORING	89

<b>11</b>	<b>STATISTICAL CONSIDERATIONS</b>	<b>90</b>
11.1	DETERMINATION OF SAMPLE SIZE	90
11.2	DISPOSITION OF PATIENTS	90
11.3	ANALYSIS OF POPULATIONS	91
11.3.1	Efficacy populations	91
11.3.1.1	Intent-to-treat population	91
11.3.2	Safety population	92
11.4	STATISTICAL METHODS	92
11.4.1	Extent of study treatment exposure and compliance	92
11.4.1.1	Extent of investigational medicinal product exposure	93
11.4.1.2	Compliance	93
11.4.2	Analyses of efficacy endpoints	93
11.4.2.1	Analysis of primary efficacy endpoint(s)	93
11.4.2.2	Analyses of secondary efficacy endpoints	95
11.4.2.3	Analyses of other efficacy endpoints	96
11.4.2.4	Multiplicity considerations	96
11.4.3	Analyses of safety data	97
11.4.3.1	Analysis of adverse events	98
11.4.3.2	Analyses of hypoglycemia	99
11.4.3.3	Analyses of adverse events of special interest	99
11.4.3.4	Analyses of events of special interest	99
11.4.3.5	Analyses of laboratory variables	99
11.4.3.6	Analyses of vital sign variables	100
11.4.3.7	Analysis of 12-lead electrocardiogram status	100
11.4.3.8	Bone mineral density	100
11.4.4	Analyses of pharmacokinetic variables	100
11.5	INTERIM ANALYSIS	101
<b>12</b>	<b>ETHICAL AND REGULATORY CONSIDERATIONS</b>	<b>102</b>
12.1	ETHICAL AND REGULATORY STANDARDS	102
12.2	INFORMED CONSENT	102
12.3	HEALTH AUTHORITIES AND INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE	102
<b>13</b>	<b>STUDY MONITORING</b>	<b>104</b>
13.1	RESPONSIBILITIES OF THE INVESTIGATOR(S)	104
13.2	RESPONSIBILITIES OF THE SPONSOR OR SERVICE PROVIDER	104
13.3	SOURCE DOCUMENT REQUIREMENTS	104



13.4	USE AND COMPLETION OF CASE REPORT FORMS AND ADDITIONAL REQUEST .....	105
13.5	USE OF COMPUTERIZED SYSTEMS.....	105
<b>14</b>	<b>ADDITIONAL REQUIREMENTS.....</b>	<b>106</b>
14.1	CURRICULUM VITAE.....	106
14.2	RECORD RETENTION IN STUDY SITES .....	106
14.3	CONFIDENTIALITY .....	106
14.4	PROPERTY RIGHTS.....	107
14.5	DATA PROTECTION.....	107
14.6	INSURANCE COMPENSATION.....	108
14.7	SPONSOR AUDITS AND INSPECTIONS BY REGULATORY AGENCIES .....	108
14.8	PREMATURE DISCONTINUATION OF THE STUDY OR PREMATURE CLOSE-OUT OF A SITE .....	108
14.8.1	By the Sponsor.....	108
14.8.2	By the Investigator .....	109
14.9	CLINICAL TRIAL RESULTS .....	109
14.10	PUBLICATIONS AND COMMUNICATIONS .....	109
<b>15</b>	<b>CLINICAL TRIAL PROTOCOL AMENDMENTS .....</b>	<b>111</b>
<b>16</b>	<b>BIBLIOGRAPHIC REFERENCES.....</b>	<b>112</b>
<b>17</b>	<b>APPENDICES.....</b>	<b>114</b>
	APPENDIX A GUIDANCE ON CONTRACEPTIVE METHODS AND COLLECTION OF PREGNANCY INFORMATION .....	115
	APPENDIX B RECOMMENDATIONS ON BASIC GENITO-URINARY HYGIENE, MAINTAINING HYDRATION, AND RECOGNIZING DIABETIC KETOACIDOSIS.....	118
	APPENDIX C MEASUREMENT OF BLOOD PRESSURE AND PULSE RATE.....	121
	APPENDIX D GENERAL GUIDANCE FOR THE FOLLOW-UP OF LABORATORY ABNORMALITIES BY SANOFI.....	123

## 2.1 LIST OF TABLES

Table 1 - Summary of investigational medicinal products during Treatment Period.....	44
Table 2 - Blood safety parameters .....	58
Table 3 - Sotagliflozin samples identification .....	61

## 2.2 LIST OF FIGURES

Figure 1 - Hypoglycemia classification in Study EFC14837.....	87
---	----

### 3 LIST OF ABBREVIATIONS

AEs:	adverse events
AESI:	adverse events of special interest
ALP:	alkaline phosphatase
ALT:	alanine aminotransferase
ANCOVA:	Analysis of Covariance
AST:	aspartate aminotransferase
BMD:	bone mineral density
BMI:	body mass index
BP:	blood pressure
CECs:	Clinical Endpoint Committees
CI:	confidence interval
CKD:	chronic kidney disease
CRF:	case report form
CRO:	contract research organization
CSR:	clinical study report
CV:	cardiovascular
CYP:	cytochrome P450
DBP:	diastolic blood pressure
DEXA:	dual-energy X-ray absorptiometry
DILIs:	drug-induced liver injuries
DKA:	diabetic ketoacidosis
DMC:	Data Monitoring Committee
DRF:	discrepancy resolution form
ECG:	electrocardiogram
e-CRF:	electronic case report form
eGFR:	estimated glomerular filtration rate
EMA:	European Medicines Agency
EOS:	end of study
EOSI:	events of special interest
EOT:	end of treatment
ESRD:	end-stage renal disease
FDA:	Food and Drug Administration
FPG:	fasting plasma glucose
FSH:	follicle stimulating hormone
GCP:	Good Clinical Practice
GI:	gastrointestinal
GLP-1:	glucagon-like peptide-1
GU:	genito-urinary
HbA1c:	Hemoglobin A1c
HLGT:	high-level group term
HR:	heart rate
HRT:	hormonal replacement therapy

IB:	Investigator's Brochure
ICF:	informed consent form
ID:	identification
IEC:	Independent Ethics Committee
IMP:	investigational medicinal product
iPTH:	parathyroid hormone
IRB:	Institutional Review Board
IRT:	Interactive Response Technology
ITT:	intent-to-treat
MACEs:	major adverse cardiovascular events
MDRD:	Modification of Diet in Renal Disease
MI:	myocardial infarction
NIMP:	noninvestigational medicinal product
NT-proBNP:	N-terminal prohormone of brain natriuretic peptide
NTX:	N-terminal telopeptide
P1NP:	type 1 procollagen N terminal
PCSA:	potentially clinically significant abnormality
PD:	pharmacodynamic
P-gp:	P-glycoprotein
PK:	pharmacokinetic
PPG:	postprandial glucose
PT:	preferred term
PYY:	peptide YY
SAEs:	serious adverse events
SAP:	statistical analysis plan
SBP:	systolic blood pressure
SC:	Steering Committee
SD:	standard deviation
SE:	standard error
SGLT1:	sodium-glucose cotransporter type 1
SGLT2:	sodium-glucose cotransporter type 2
SMBG:	self-monitoring of blood glucose
SOC:	system organ class
SUSAR:	suspected unexpected serious adverse reaction
T1D:	Type 1 diabetes
T2D:	Type 2 diabetes
TEAEs:	treatment-emergent adverse events
UACR:	urine albumin:creatinine ratio
UGCR:	urine glucose:creatinine ratio
UGE:	urinary glucose excretion
ULN:	upper limit of normal
UTIs:	urinary tract infections
VTEs:	venous thrombotic events
WOCBP:	women of childbearing potential
β-CTX-1:	beta-C-terminal telopeptide

## 4 INTRODUCTION AND RATIONALE

### 4.1 BACKGROUND: SOTAGLIFLOZIN AND DISEASE

Sotagliflozin is a dual inhibitor of the sodium-glucose cotransporters type 1 and 2 (SGLT1 and SGLT2) being developed for use in Type 2 diabetes (T2D), a metabolic disorder characterized by hyperglycemia that results from a combination of increased insulin resistance and beta-cell dysfunction (1). The micro vascular complications of diabetes are well known and can result in impaired renal function, retinopathy and neuropathy and the macrovascular complications result in coronary disease, amputations and stroke. Other comorbidities that are frequently associated with diabetes are hypertension, obesity, and cardiovascular (CV) disease. According to the most recent International Diabetes Federation Diabetes Atlas, the estimates in 2015 were that 1 in 11 adults have diabetes, which means 415 million people and estimated to be 642 million by 2040 (2).

According to the World Health Organization, there are about 60 million people with diabetes in the European Region, or about 10.3% of men and 9.6% of women aged 25 years and over (3). While these numbers include both people with T2D and Type 1 diabetes (T1D), over 90% of adults with diabetes have T2D. Diabetes is among the leading causes of death by disease and is a leading cause of heart disease, stroke, blindness, kidney disease, and amputation (2, 3). Despite the fact that the population of people with diabetes is growing, none of the current therapies is curative and the results of treatment are variable.

Despite the numerous treatment options available, monotherapy fails in many patients as beta-cell function continues to deteriorate leading to progressively increasing hyperglycemia. Glycemic control with the currently available agents often leads to side effects, most notably weight gain and an increased frequency of hypoglycemia. These concerns emphasize the need to develop new agents that effectively and safely lower glucose in diabetic patients (4).

The SGLT1 is expressed predominantly in the gastrointestinal (GI) tract; SGLT1 is responsible for the majority of glucose absorption by the small intestine (5). Inhibition of SGLT1 in the GI tract delays glucose absorption and lowers peak postprandial glucose levels (6). Additionally, there is accumulating evidence that SGLT1 inhibition stimulates secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), gut hormones involved in pancreatic beta-cell function and appetite control, respectively. Reduced glucose absorption in the proximal intestine leads to more glucose being delivered distally, which allows L cells in both the ileum and the colon to sense glucose and its byproducts, and as a result, they secrete GLP-1 and PYY. Although a complete lack of functional SGLT1 may be associated with symptoms of glucose and galactose malabsorption, (7) pharmacologic inhibition of SGLT1 by sotagliflozin has not produced these effects in preclinical models or patients with T2D. Selective inhibitors of the SGLT1 transporter are in early stages of development.

Extensive clinical studies conducted for selective sodium-glucose cotransporter type 2 (SGLT2) inhibitors have established this class as effective agents for the treatment of T2D (4,8) and have led to approvals by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Studies with sotagliflozin, a, dual inhibitor of SGLT2 and SGLT1, have shown

that this agent produces significant glucosuria in preclinical animal models, healthy human volunteers, and patients with T2D. Single- and multiple-dose administration of sotagliflozin to healthy human patients has resulted in dose-dependent increases in glucosuria. Multiple-dose (28-day) administration in diabetic patients produced improvements in several metabolic parameters, including urinary glucose excretion (UGE), fasting plasma glucose (FPG), Hemoglobin A1c (HbA1c), GLP-1, and PYY (9). These data suggest that sotagliflozin should be of therapeutic benefit to patients with T2D.

Diabetic nephropathy with advancing duration of diabetes and the treatment of T2D in the face of advancing renal insufficiency represents a particular challenge to the clinician. Many agents used to treat T2D, including sulfonylurea, metformin and incretin-based insulin secretagogues, can no longer be used or must be dosed with caution in the clinical setting of renal insufficiency.

The glucose lowering efficacy of selective SGLT2 inhibitors will diminish when renal function (glomerular filtration rate) diminishes because SGLT2 is located exclusively in the renal tubule and selective SGLT2 inhibitors act solely by blocking reabsorption of glucose that has been filtered at the glomerulus (6). For this reason the use of dapagliflozin is restricted to patients with estimated glomerular filtration rate (eGFR)  $\geq 60$  mL/min/1.73 m<sup>2</sup> and that of empagliflozin and canagliflozin is limited to patients with eGFR  $\geq 45$  mL/min/1.73 m<sup>2</sup> (10,11,12). Sotagliflozin, in contrast, lowers glucose by blocking absorption of glucose in the small intestine (SGLT1) as well as by blocking reabsorption at the kidney (SGLT2) and thus would be expected to maintain glucose lowering efficacy as renal function diminishes. In fact this was shown to be the case in an early Phase 1 trial (LX4211.1-107 DM). Patients with T2D and either chronic kidney disease (CKD) stage 3A (eGFR 45-59 mL/min/1.73 m<sup>2</sup>) or CKD stage 3B (eGFR 30 to 44 mL/min/1.73 m<sup>2</sup>) were randomized to sotagliflozin 400 mg once daily or placebo for 7 days while being closely monitored, partly as inpatients.

Sotagliflozin significantly reduced postprandial glucose (PPG) levels relative to placebo in the total population and in patients with an eGFR  $< 45$  mL/min/1.73m<sup>2</sup>, with a placebo-adjusted decrease in incremental area under the concentration versus time curve (AUC)<sub>pre-dose -4 hrs</sub> of 73.5 mg\*h/dL (p=0.009) and 137.2 mg\*h/dL (p=0.001) for the total population and the eGFR  $< 45$  mL/min/1.73 m<sup>2</sup> subgroup, respectively. As expected sotagliflozin caused less increase in UGE in the CKD stage 3B subsets than in the total population subset (placebo-subtracted increase in UGE was 38.7, 53.5, and 20.4 g/24h for the total population, CKD stage 3A subset, and CKD stage 3B subset, respectively [p = 0.007 for all 3]). This suggests that something other than inhibition of SGLT2 mediated renal glucose absorption is being inhibited by sotagliflozin, eg, SGLT1 effect in the GI. In addition, the patients with CKD 4 have decreased insulin clearance and better glucose control. These results also suggest that dual SGLT1 and SGLT2 inhibition with sotagliflozin could prove useful for the treatment of patients with T2D and renal impairment (13).

Sotagliflozin has shown effect in patients with renal impairment and SGLT1 inhibition does not depend on kidney. The purpose of this study is to evaluate the effects of sotagliflozin in glucose lowering in patients with renal impairment.

## 4.2 CLINICAL TRIALS OF SOTAGLIFLOZIN IN HUMANS

Approximately 840 subjects (698 assigned to sotagliflozin and 229 assigned to placebo) have participated in completed clinical studies of sotagliflozin. No significant safety concerns have been identified in the sotagliflozin drug program, and sotagliflozin has been well-tolerated in all studies to date. Serious adverse events (SAEs) and discontinuations due to adverse events (AEs) have been infrequent and have been balanced between treatment and comparator groups. Reports of treatment-emergent AEs (TEAEs) across all sotagliflozin studies for which data are available were generally balanced between treatment and comparator groups. The most frequently reported TEAEs ( $\geq 2.0\%$ ) were headache, nausea, diarrhea, constipation, dizziness, and upper respiratory tract infection, all of which were reported at a frequency greater than placebo. However, the majority were described as mild to moderate, and most resolved spontaneously and without discontinuation of the study drug.

In completed and ongoing clinical trials, no additional safety issues beside those already described in the current Investigator's Brochure (IB) have been observed. In general, no significant imbalances of SAEs/AEs between sotagliflozin and comparators were observed in completed studies. Cumulatively, across the completed studies 8 SAEs were reported in 6 patients (4 T2D and 2 T1D), all of which were assessed as unrelated to study drug; those reported in 4 T2D patients who received sotagliflozin included pulmonary embolism, deep vein thrombosis, bile duct stone, cholangitis and lower limb fracture, while a myocardial infarction (MI) was experienced by a patient receiving placebo. Two SAEs of diabetic ketoacidosis (DKA) were reported in 2 T1D patients in the ongoing (blinded) Phase 2 T1D study LX4211.1-203-TIDM; both SAEs were assessed as due to failure of insulin delivery via insulin pump.

A drug interaction study with digoxin, a sensitive P-glycoprotein (P-gp) substrate, indicated that sotagliflozin acts as a weak P-gp inhibitor. Based on drug-drug interaction studies, the effect of sotagliflozin in competing with compounds metabolized with cytochrome P450 (CYP) 3A4 are minimal. Sotagliflozin was profiled as perpetrator regarding CYP3A4/5 interaction in INT14972, in which a weak induction of CYP3A4/5 was observed at a dose of 400 mg as well as a weak inhibition of CYP2D6. These effects were more pronounced at a higher dose of 800 mg. It was concluded, that for the vast majority of drugs metabolized predominantly by CYP3A4/5 or CYP2D6, the clinical effect is negligible. However, caution is suggested for patients treated with narrow therapeutic index drugs. Patients taking sotagliflozin with concomitant digoxin should have digoxin concentrations monitored and doses reduced as needed. In addition, other P-gp substrates may be affected and the labels of P-gp substrate drugs should be consulted with regards to monitoring and dose adjustments.

In trial 202, it has been demonstrated the systolic blood pressure (SBP) in all the patients was decreased by 5.4 mmHg compared to the placebo while the decrease in patients with SBP  $>130$  mmHg was 14 mmHg.

More information on the safety of sotagliflozin and on the clinical program can be found in the IB.

### 4.3 RATIONALE FOR SELECTION OF DOSE

Both the 200 mg and 400 mg doses are being developed in the Phase 3 program for sotagliflozin for the treatment of T2D. These doses are being tested in several Phase 3 trials, including the current trial in patients with T2D and CKD stage 3.

The proposed sotagliflozin 200 mg and 400 mg once daily doses are based on the results of the Phase 2b study LX4211.1-202-DM. In this study, sotagliflozin doses of 75 mg once daily, 200 mg once daily, 200 mg twice daily, and 400 mg once daily were tested over a 12-week, double-blind period. The sotagliflozin 200 mg and 400 mg once daily doses were chosen for further evaluation based on their HbA1c lowering effects and the overall safety and tolerability observed at these doses. At 12 weeks, the 200 mg and 400 mg once daily doses lowered HbA1c by a mean of 0.52% and 0.93%, respectively ( $p < 0.001$  for both arms), while placebo lowered HbA1c by a mean of 0.14%. Sotagliflozin also produced statistically significant reductions in body weight (200 mg and 400 mg doses) and SBP (400 mg dose).

The overall incidences of AEs on sotagliflozin 200 mg and 400 mg once daily were similar to placebo. A maximum dose of sotagliflozin has not been established in terms of either safety or HbA1c reduction.

From a safety perspective, sotagliflozin was well-tolerated across studies. In healthy subjects sotagliflozin was well-tolerated following single doses up to 2000 mg, and in multiple doses up to 800 mg over 10 days. Furthermore, in a thorough QT study, single doses of sotagliflozin (800 mg and 2000 mg) were well-tolerated and did not prolong the QT interval. Additionally, evaluation of metabolites in urine and plasma of healthy subjects resulted in no safety concerns following single doses of 400 mg sotagliflozin. In patients with T2D, single doses of sotagliflozin 400 mg in combination with sitagliptin, and multiple doses up to sotagliflozin 400 mg in combination with metformin over 12 weeks were also well-tolerated.

Based on the pharmacokinetic (PK) extrapolation and approximation the safety margin based on 400 mg multiple dosing in CKD stage 3 patients ( $eGFR \geq 30$  to  $< 60$  mL/min/1.73m<sup>2</sup>) is 3-fold and in CKD stage 4 patients the margin is 1.9-fold.

### 4.4 RATIONALE FOR STUDY DESIGN AND CONTROL GROUPS

This study is designed to demonstrate the efficacy and safety of sotagliflozin when used as add-on therapy to standard care (any combination of oral agents and/or insulin deemed clinically appropriate) in patients with T2D and CKD stage 3A or 3B who have inadequate glycemic control. Sotagliflozin 200 mg daily, as well as sotagliflozin 400 mg daily, will be compared to placebo in this randomized, double-blind, placebo-controlled, 3-arm, parallel-group trial. The protocol stipulates that patients be provided antidiabetic agent rescue therapy according to a predefined algorithm. Safety, tolerability, PK, and pharmacodynamic (PD) effects of sotagliflozin are supported by Phase 1 and Phase 2 studies and animal toxicology data in rats up to 26 weeks and dogs up to 39 weeks as well as 2 year carcinogenicity data in rats. Efficacy and safety in patients with CKD stages 3A/3B are supported by 7 day PD and safety data in patients with T2D and CKD (Trial LX4211.107).



In a Phase 1 trial 31 patients with T2D and eGFR  $<60$  mL/min/1.73 m<sup>2</sup> were randomized to sotagliflozin or placebo. Despite reduction of more than 50% in UGE, the patients with eGFR  $<45$  mL/min/1.73 m<sup>2</sup> and patients with eGFR  $>45$  mL/min /1.73 m<sup>2</sup> had the same level of reduction in the PPG (the primary endpoint).

Randomization will be stratified by Screening Hb1Ac ( $\leq 8.5\%$  and  $>8.5\%$ ), Screening SBP ( $<130$  mmHg versus  $\geq 130$  mmHg), and CKD stage (3A, 3B) based on Screening eGFR. Since the reduction in the SBP for patients with SBP  $\geq 130$  mmHg was significantly higher than all the patients, these patients will be monitored for blood pressure (BP) reduction closely.

A placebo control will be used to allow for an unbiased assessment of treatment effects and safety data. Bias will be minimized by randomizing the patients to treatment groups, blinding the patients, the Investigators, and the Sponsor to the treatment allocations, and by adjudicating endpoints in a blinded fashion.

A 2-week Run-in phase has been implemented to stabilize HbA1c and minimize response to placebo and effects inherent to participation in a controlled clinical trial.

Sotagliflozin treatment for 26 weeks is likely to be of sufficient duration to observe effects on reduction of HbA1c, BP, and body weight, and is therefore selected as the timepoint for assessment of the primary endpoint HbA1c. Treatment up to 52 weeks will provide additional long-term data on safety and efficacy.

Endpoints for evaluating renal function include eGFR, based on serum creatinine, and urine albumin to creatinine ratio as well as routine monitoring of urine via dipstick and spot urine analyses. At 6 time points during the study (Baseline, Week 2, Week 4, Week 12, Week 26 and Week 52), patients will be instructed to bring overnight/first of the day voids. Cystatin C, UGE, urine glucose:creatinine ratio (UGCR), and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) are other valid markers of renal function and volume status, and will be assessed at appropriate timepoints in this study.

In addition, although clinical outcomes are not expected to occur at a high enough rate to yield statistically significant information in this trial, outcomes such as death will be adjudicated by an independent adjudication committee.

#### **4.5 BENEFIT/RISK OF SOTAGLIFLOZIN**

Sotagliflozin is currently being investigated as an adjunct to diet and exercise to improve glycemic control in adults with T2D. The development program will also provide efficacy and safety data for sotagliflozin in combination with other antidiabetic medications. Sotagliflozin has effects on SGLT2 and SGLT1. Based on the GI contribution of sotagliflozin in reducing the glucose through SGLT1 inhibition and the improvement of glycemia caused by the increase in half-life of insulin (as a result of decreased renal function), efficacy is expected in advanced CKD patients. In addition the clinical outcomes will be evaluated in patients with high CV risk and in patients with renal impairment. Results to date from an earlier Phase 1 study also suggest that patients with T2D and renal impairment stage 3A and 3B could benefit from dual SGLT1 and

SGLT2 inhibition with sotagliflozin as detailed in [Section 4.4](#) without any safety concerns. The use of sotagliflozin in the treatment of T1D is also being studied in a separate development program.

Sotagliflozin may benefit a wide variety of diabetic patients based on multiple potential beneficial effects of dual SGLT2/SGLT1 inhibition, and its insulin-independent mechanism of action. Improvements in HbA1c, FPG, and PPG were observed with sotagliflozin in multiple studies. As anticipated from the mechanism of action, treatment with sotagliflozin resulted in increased UGE (from inhibition of SGLT2) as well as increased levels of the intestinal peptides GLP-1 and PYY (from inhibition of SGLT1). In addition, the improvements in body weight and BP observed with sotagliflozin treatment have the potential to benefit patients with diabetes through their effects on common diabetic comorbidities.

Phase 2 data indicated that sotagliflozin may reduce SBP by 10 to 15 mmHg in patients with SBP  $\geq$ 130 mmHg at Baseline, while having no significant effect in patients with SBP <130 mmHg, and did not induce hypotension in normotensive patients. Since this could be of benefit to patients with T2D, this finding is being followed up as a secondary objective in this trial.

SGLT2 inhibitors class have been associated with small decreases of glomerular filtration rate and increased rate of genital infections, which are usually mild and well tolerated in clinical trials. Overall, sotagliflozin has been well-tolerated in all studies to date, with the majority of events assessed as mild to moderate; most of which resolved spontaneously. Serious AEs and discontinuations due to AEs have been limited and balanced between treatment and comparator groups.

Events of special interest (EOSI) are evaluated based on either their potential link to the drug's mechanism of action, events that occur in other SGLT-inhibitor drugs, or regulatory interest/guidance for diabetes products, but found not to be in imbalance in clinical trials. In addition to the identified and potential risks (genital mycotic infections [male and female], metabolic acidosis, DKA, urinary tract infections [UTIs], volume depletion, severe hypoglycemia) for the sotagliflozin program, other EOSI have been defined. These EOSI are: major adverse cardiac events (MACEs) and other CV events, venous thrombotic events (VTEs), drug-induced liver injuries (DILIs)/alanine aminotransferase (ALT) increase  $>3$  times the upper limit of normal (ULN), diarrhea, pancreatitis, bone fractures, renal events, malignancies of special interest (including but not limited to: breast, bladder, renal cell, Leydig cell, pancreatic, prostate and thyroid cancer), and AEs leading to amputation.

However, reports of these events have been infrequent and have responded to standard treatment. The improvement in glycemic control, the reductions in weight and BP, and the tolerability and safety profile of sotagliflozin to date, demonstrate a favorable benefit-risk assessment for sotagliflozin.

## 5 STUDY OBJECTIVES

### 5.1 PRIMARY

The primary objective of this study is to demonstrate the superiority of sotagliflozin 400 mg and 200 mg versus placebo with respect to HbA1c reduction at Week 26 in patients with T2D who have inadequate glycemic control and moderate renal impairment.

### 5.2 SECONDARY

The secondary objectives of this study are:

- To assess the effects of sotagliflozin 400 mg and 200 mg versus placebo, based on:
  - Change from Baseline in FPG at Week 26
  - Change from Baseline in body weight at Week 26
  - Change from Baseline in SBP at Week 12 for patients with Baseline SBP  $\geq$ 130 mmHg
  - Change from Baseline in SBP at Week 12 for all patients
  - Percentage change in urine albumin: creatinine ratio (UACR) from Baseline to Week 26 (for patients with Baseline UACR  $>$ 30 mg/g)
  - Proportion of patients with HbA1c  $<$ 6.5%,  $<$ 7.0% at Week 26.
- To evaluate the safety of sotagliflozin 400 mg and 200 mg versus placebo over the 52 weeks of treatment.

### 5.3 OTHER

Other objectives of this study are to compare sotagliflozin 400 mg and 200 mg versus placebo with respect to:

- Change from Baseline in SBP at Weeks 26 and 52 for patients with Baseline SBP  $\geq$ 130 mmHg
- Change from Baseline in SBP at Weeks 26 and 52 for all patients
- Change from Baseline in HbA1c at Week 52
- Change from Baseline in FPG at Week 52
- Change from Baseline in body weight at Week 52
- Change from Baseline in eGFR.
- Change from Baseline on the following endpoints:
  - Cystatin C

- UGE
- UGCR
- Fructosamine
- NT-proBNP.
- Progression of kidney disease, based upon changes in eGFR or albuminuria.
- Change from Baseline to Week 12 in SBP for patients with Baseline SBP <130 mmHg.
- Change from Baseline to Week 12 in diastolic blood pressure (DBP) for all patients and the subset of patients with Baseline DBP  $\geq$ 80 mmHg.
- The proportion of patients requiring rescue for hyperglycemia during 26-week double-blind Treatment Period.
- To assess plasma levels of sotagliflozin and sotagliflozin-3-O-glucuronide in the sotagliflozin treatment arms.

## 6 STUDY DESIGN

### 6.1 DESCRIPTION OF THE STUDY

This is a Phase 3, multicenter and multinational, 1:1:1 randomized, double-blind (single-blind Run-in phase), placebo-controlled, parallel-group study that is anticipated to enroll approximately 780 patients.

The study comprises a 4-week Screening Period (consisting of a Screening phase of up to 2 weeks and a 2-week single-blind placebo Run-in phase), a 26-week double-blind Treatment Period, a 26-week double-blind Extension Period, and a 4-week post-treatment Follow-up Period.

The study design is presented graphically in [Section 1.1](#).

#### 6.1.1 Screening Period

##### 6.1.1.1 Screening phase (Visit 1)

The Screening phase will last up to 2 weeks. It must be long enough to collect the data required to establish whether the patient satisfies the inclusion/exclusion criteria.

Patients with T2D (14) who have inadequate glycemic control and documented moderate renal insufficiency (CKD 3A, 3B; defined by an eGFR) (15) plus who do not have a Screening HbA1c of <7.0% or >11% are eligible for enrollment in this study.

At the Screening Visit after signing of the informed consent form (ICF), eligibility criteria will be assessed and Screening assessments will be performed. Women of childbearing potential (WOCBP) not willing to use highly effective method(s) of birth control during the study treatment period and the follow-up period, or who are unwilling or unable to be tested for pregnancy will be excluded from the study; guidance on highly effective contraceptive methods and collection of pregnancy information is provided in [Appendix A](#). If another contraceptive method is used (such as a barrier method), it should be used in combination with one of the highly effective methods in [Appendix A](#) (such as oral contraceptive).

The Interactive Response Technology (IRT); either Interactive Voice Response System or Interactive Web Response System) will be contacted at Visit 1 for notification of Screening and for patient number allocation.

##### 6.1.1.2 Run-in phase (Visit 2)

The Run-in phase will last 2 weeks. Patients will be treated in a single-blind manner with two (2) placebo tablets (identical to sotagliflozin 200 mg in appearance) administered once daily during the Run-in phase, starting from Visit 2.

### **6.1.2 Double-blind Treatment Period (Day 1 to Week 26)**

Eligible patients will be randomized on Day 1 (Visit 3). In order to qualify for randomization, patients must also demonstrate compliance during the single-blind placebo Run-in phase based upon tablet count ( $\geq 80\%$ ) and, as assessed, at the Investigator's discretion.

Randomization will be stratified by:

- HbA1c at Screening ( $\leq 8.5\%$  and  $> 8.5\%$ )
- SBP at Screening ( $< 130$  mmHg and  $\geq 130$  mmHg)
- CKD stage (3A, 3B) based on Screening eGFR (15)(16)(17).

Following randomization, patients will be treated in a double-blind manner for 52 weeks. A total of approximately 780 patients  $\geq 18$  years of age (or  $\geq$  legal age of the majority, whichever is greater) are planned to be randomly assigned 1:1:1 to the following 3 treatment groups:

- Placebo, given as two (2) placebo tablets (identical to sotagliflozin 200 mg in appearance), once daily, before the first meal of the day
- Sotagliflozin 200 mg, given as 2 tablets: 1 sotagliflozin 200 mg tablet and 1 placebo tablet (identical to sotagliflozin 200 mg in appearance), once daily
- Sotagliflozin 400 mg, given as two (2) 200 mg tablets, once daily, before the first meal of the day.

Fasting glucose (plasma or serum) and HbA1c results will be masked to study sites and patients after randomization and until study end. To prevent partial unblinding, UGE and UGCR results will be masked to study sites and patients, and the central laboratory urine dipstick analysis will not include the measurement of urine glucose.

Quantitative urine glucose, albumin, calcium, phosphorus, magnesium, and creatinine will be measured separately at all on-site visits (except for Visits 6, 8, 10, and 12) by the central laboratory.

All visits will be on-site visits.

If a patient discontinues treatment with investigational medicinal product (IMP) early during the Treatment Period, the patient will have Premature End of Treatment (EOT) Visit, and a Follow-up Visit, 4 weeks ( $\pm 5$  days) after the last dose of IMP. In addition, every effort will be made to have all patients return to the site at the time corresponding to their scheduled visits, particularly the Weeks 26 and 52 Visits.

If a patient does not agree to site visits, he/she will be contacted by telephone to inquire their safety information, particularly at the time of the initially scheduled end of study (EOS).

### **6.1.3 Double-blind Extension Period (Week 27 to Week 52)**

From Weeks 27 to 52, patients will be in a 26-week double-blind Extension Period. Patients will continue to receive the blinded medication (sotagliflozin 400 mg, 200 mg, or placebo) to which they were randomized on Day 1. Patients who received rescue medication during the initial

26-week Treatment Period will continue on the same rescue medication during the double-blind Extension Period (unless the Investigator considers a change necessary for safety reasons).

If a patient discontinues treatment with IMP early during the Extension Treatment Period, the patient will have a Premature EOT Visit, and a Follow-up Visit, 4 weeks after the last dose of IMP. In addition, every effort will be made to have all patients return to the site at the time corresponding to their scheduled visits, particularly the Week 52 Visit.

If a patient does not agree to site visits, he/she will be contacted by telephone to inquire about their safety status, particularly at the time of the initially scheduled EOS.

#### **6.1.4 Follow-up Period**

Following the last dose of the IMP (either as scheduled or prematurely), a post-treatment follow-up should be scheduled for all patients 28 days (4 weeks)  $\pm$ 5 days after permanent IMP discontinuation.

### **6.2 DURATION OF STUDY PARTICIPATION**

#### **6.2.1 Duration of study participation for each patient**

The total duration of the study for each patient will be up to 60 weeks and will include a Screening phase of up to 2 weeks, a 2-week single-blind Run-in phase, a 26-week double-blind Treatment Period, a 26-week double-blind Extension Period, and a 4-week Follow-up Period after completion of study treatment.

#### **6.2.2 Determination of end of clinical trial (all patients)**

The end of the study is defined as being the “last patient last visit” planned with the protocol, including the Follow-up Visit.

The Sponsor can terminate the trial prematurely based on the advice of the independent Data Monitoring Committee (DMC) or other unforeseen developments.

### **6.3 STUDY COMMITTEES**

#### **6.3.1 Steering committee**

The Steering Committee (SC) is composed of experts in diabetes and scientists with clinical and methodological expertise. This Committee, led by a Chair, is responsible for producing and conducting a scientifically sound study and for ensuring accurate reporting of the study. In that capacity, the SC must address and resolve scientific issues encountered during the study. The members will remain blinded until completion of the study.

Among its responsibilities, the SC will receive blinded study status reports from Sponsor, and will review the recommendations from the DMC throughout the study. The SC members will participate in face-to-face meetings at regular intervals throughout the study and in regularly scheduled teleconferences.

Detailed activities and responsibilities of the SC are provided in a separate SC Charter.

### **6.3.2 Data monitoring committee**

A DMC with members who are independent from the Sponsor and the Investigator will meet on a regular basis, and will be responsible for:

- Review of accumulating clinical trial safety data by treatment.
- Making a recommendation to the Sponsor regarding the study following each meeting.

Safety data to be reviewed will be unblinded data and include events and outcomes described below for adjudication, as well as any additional safety data considered relevant. To maintain continuous blinding and study integrity, the analysis will be conducted by an independent statistician, and measures will be taken to ensure the validity of the data.

Details describing the DMC processes and procedures are outlined in a separate DMC Charter.

### **6.3.3 Clinical endpoint committee**

The Clinical Endpoint Committees (CECs) is/are comprised of experts in cardiology and nephrology (and other appropriate medical specialties such as neurology and endocrinology as needed) who are independent of the Sponsor and the contract research organization (CRO). The CEC(s) will review and adjudicate all deaths, MACE/selected CV events (MI, stroke, unstable angina leading to hospitalization, and heart failure leading to hospitalization), selected renal events, bone fracture, and DKA.

The details regarding the CEC processes and procedures will be outlined in the CEC Charter(s).

### **6.3.4 Safety adjudication of events requiring ongoing monitoring**

Two independent committees will review safety events that require ongoing monitoring to ensure timing protocol amendments in case a safety signal is identified. These events are: 1) potential cases of DILI, and 2) cases of amputations.

The two committees will review the cases in a treatment-blinded manner and will present their assessments to the DMC.

The members, roles and responsibilities of the two committees will be described in separate Charters.



## 7 SELECTION OF PATIENTS

**Note:** A patient should not be randomized more than once. In cases where original screen failure was due to reasons expected to change at rescreening and based upon the Investigator's clinical judgment, the patient can be rescreened once prior to entering Run-in for this study.

### 7.1 INCLUSION CRITERIA

- I 01. Patients with T2D (drug-naïve or on antidiabetic therapy) and documented moderate renal insufficiency defined by an eGFR (based on the 4 variable Modification of Diet in Renal Disease [MDRD] equation) of  $\geq 30$  and  $< 60$  mL/min/1.73 m<sup>2</sup> (CKD 3A, 3B).
- I 02. Patient has given written informed consent to participate in the study in accordance with local regulations.

### 7.2 EXCLUSION CRITERIA

Patients who have met all the above inclusion criteria listed in [Section 7.1](#) will be screened for the following exclusion criteria which are sorted and numbered in the following 3 subsections:

#### 7.2.1 Exclusion criteria related to study methodology

- E 01. At the time of Screening age  $< 18$  years or  $<$  legal age of majority, whichever is greater.
- E 02. Body Mass Index (BMI)  $\leq 20$  or  $> 45$  kg/m<sup>2</sup> at Screening.
- E 03. Use of systemic glucocorticoids (excluding topical, intra-articular, or ophthalmic application, nasal spray, or inhaled forms) for more than 10 consecutive days within 90 days prior to the Screening Visit.
- E 04. Use of weight loss medications within 12 weeks or weight change of 5 kg or more during the 12 weeks before Screening.
- E 05. Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol (eg, long-term systemic glucocorticoids) and refusing or unable to take alternative treatment.
- E 06. Patients who have previously participated in any clinical trial of sotagliflozin/LX4211.
- E 07. Patients with severe anemia, severe CV (including congestive heart failure New York Heart Association IV), respiratory, hepatic, neurological, psychiatric, or active malignant tumor, or other major systemic disease or patients with short life expectancy that, according to the Investigator, will preclude their safe participation in this study, or will make implementation of the protocol or interpretation of the study results difficult.

- E 08. Current diagnosis of chronic hepatitis and/or other clinically active liver disease requiring treatment.
- E 09. Known presence of factors that interfere with the Central Lab HbA1c measurement (eg, genetic Hb variants) compromising the reliability of HbA1c assessment or medical conditions that affect interpretation of HbA1c results (eg, blood transfusion or severe blood loss in the last 3 months prior to randomization, any condition that shortens erythrocyte survival).
- E 10. History of drug or alcohol abuse within 6 months prior to Screening.
- E 11. Patient is an employee of the Sponsor, or is the Investigator or any Sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in conducting the study.
- E 12. Patient who has taken other investigational drugs or prohibited therapy for this study within 12 weeks or 5 half-lives from prior to Screening, whichever is longer. Current enrollment in any other clinical study involving an investigational study treatment or any other type of medical research.

#### **7.2.2 Exclusion criteria related to the diabetes or CKD history and treatment**

- E 13. Type 1 diabetes mellitus.
- E 14. HbA1c <7% or HbA1c >11% measured by the central laboratory at Screening.
- E 15. Oral antidiabetic agent or insulin use if dose not stable for 8 weeks before randomization (ie, oral agents changed during past 8 weeks or total daily basal insulin dose increased or decreased by more than 20% during the past 4 weeks).
- E 16. Use of a selective SGLT2 inhibitor (eg, canagliflozin, dapagliflozin, or empagliflozin) within 12 months prior to the trial.
- E 17. History of DKA or nonketotic hyperosmolar coma within 12 weeks prior to the Screening Visit.
- E 18. History of severe hypoglycemia that resulted in unconsciousness, coma or hospitalization within 6 months prior to the Screening Visit.
- E 19. Renal disease that required treatment with immunosuppressive therapy within the last 12 months, or renal transplant or initiation of chronic dialysis within 4 weeks prior to the Screening Visit or expected to occur during the study duration.
- E 20. History of hereditary glucose galactose malabsorption or primary renal glucosuria.
- E 21. Chronic dialysis or CKD stage 4 or 5 or requiring chronic dialysis within 6 months of Screening.

E 22. Reversible causes of renal failure such as obstruction within 6 months of Screening.

### **7.2.3 Exclusion criteria related to the current knowledge of sotagliflozin**

E 23. Pregnant (confirmed by serum pregnancy test at Screening) or breastfeeding women.

E 24. Women of childbearing potential not willing to use highly effective method(s) of birth control during the study treatment period and the follow-up period, or who are unwilling or unable to be tested for pregnancy (see [Appendix A](#)), during the study.

E 25. Mean of 3 separate BP measurements  $>180$  mmHg (SBP) or  $>100$  mmHg (DBP) (with or without hypertensive medications).

E 26. Systolic BP  $<120$  mmHg or DBP  $<60$  mmHg if the patient is on antihypertensive medications.

E 27. History of hypertensive emergency within 12 weeks prior to Screening.

E 28. History of gastric surgery including history of gastric banding or inflammatory bowel disease within 3 years prior to the Screening Visit.

E 29. Difficulty swallowing such that the patient cannot take the IMP.

E 30. Known allergies, hypersensitivity, or intolerance to SGLT2 inhibitor or any inactive component of sotagliflozin or placebo (ie, microcrystalline cellulose, croscarmellose sodium [disintegrant], talc, silicone dioxide, and magnesium stearate [nonbovine]), unless the reaction is deemed irrelevant to the study by the Investigator.

E 31. Laboratory findings with the central lab tests at Visit 1.

- ALT or aspartate aminotransferase (AST)  $>3$  times the ULN
- Total bilirubin  $>1.5$  times the ULN (except in case of Gilbert's syndrome)
- Neutrophils  $<1500/\text{mm}^3$  (or according to ethnic group) and/or platelets  $<100\ 000/\text{mm}^3$
- Amylase and/or lipase  $>3$  times the ULN.

E 32. Any country-related specific regulation that would prevent the patient from entering the study (eg, individuals committed to an institution by virtue of an order issued either by the judicial or the administrative authorities).

### **7.2.4 Additional exclusion criteria during or at the end of the Run-in phase before Randomization**

E 33. Patients unwilling or unable to perform self-monitoring of blood glucose (SMBG), complete the patient diary or comply with study visits and other study procedures as required per protocol.

- E 34. Patients insufficiently compliant during Run-in phase. Noncompliance will be based on tablet count (<80%) or based on the opinion of the Investigator.
- E 35. Informed consent withdrawal before randomization (patient who is not willing to continue or fails to return).
- E 36. Any clinically significant abnormality identified on physical examination, laboratory tests, electrocardiogram (ECG) or vital signs at the time of screening or any AE during screening period which, in the judgment of the Investigator or any Sub-investigator, would preclude safe completion of the study or constrains efficacy assessment.
- E 37. Lower extremity complications (such as skin ulcers, infection, osteomyelitis, and gangrene) identified during the Screening period, and still requiring treatment at Randomization.

## 8 STUDY TREATMENTS

### 8.1 INVESTIGATIONAL MEDICINAL PRODUCT(S)

The IMPs are sotagliflozin 400 mg, sotagliflozin 200 mg, and matching placebo. Patients will be provided with:

- Run-in kit containing 1 wallet of 34 placebo tablets (identical to sotagliflozin 200 mg in appearance) for the Run-in phase.
- Treatment kit containing 2 wallets of 38 tablets each (placebo and/or sotagliflozin 200 mg tablets) will be dispensed as needed for the duration of the entire 52-week Treatment Period, in a double-blind manner.

Table 1 provides a summary of the IMP (dose and timing).

**Table 1 - Summary of investigational medicinal products during Treatment Period**

IMP:	Sotagliflozin 200 mg	Sotagliflozin 400 mg	Placebo group
<b>Name of IMP</b>	Sotagliflozin (SAR439954)	Sotagliflozin (SAR439954)	Placebo
<b>Pharmaceutical Form</b>	Sotagliflozin (SAR439954) will be supplied as 200 mg tablets	Sotagliflozin (SAR439954) will be supplied as 200 mg tablets	Placebo will be supplied as tablets (identical to sotagliflozin in appearance)
<b>Dose, timing, and route of administration</b>	<p><b>Sotagliflozin 200 mg group:</b></p> <p>One 200 mg tablet, taken orally once daily, before the first meal of the day</p> <p>One placebo tablet, taken orally once daily, before first meal of the day</p>	<p><b>Sotagliflozin 400 mg group:</b></p> <p>Two 200 mg tablets, taken orally once daily, before first meal of the day</p>	<p><b>Placebo group:</b></p> <p>Two placebo tablets, taken orally once daily, before first meal of the day</p>
<b>Duration of treatment</b>	<p>26-week double-blind Treatment Period following randomization</p> <p>26-week double-blind Extension Period</p>	<p>26-week double-blind Treatment Period following randomization</p> <p>26-week double-blind Extension Period</p>	<p>2 weeks Run-in and 26 weeks following randomization</p> <p>26-week double-blind Extension Period</p>
<b>Storage conditions</b>	Store between +15°C and +30°C (59°F and 86°F)		

#### 8.1.1 Dose reduction

The dose maintenance will be handled according to the renal function assessed by the creatinine measurement throughout the study. If at any visit after Randomization there is a rise in creatinine level (see details in Section 10.6.2), the Investigator should ensure that no reasonable explanation exists for creatinine increase. Sites will be notified by central laboratory alert if a patient has a >50% increase from Baseline level or >50% above the mean of creatinine values from the last

2 visits, where Baseline level is defined as the mean of creatinine values obtained at Screening and Randomization. The IMP should be stopped for 2 weeks. If at creatinine recheck the patient has returned to the below threshold then IMP will be restarted at a reduced dose (ie, dose reduced via IRT to 200 mg for patients randomized to 400 mg, maintained to 200 mg for patients randomized to 200 mg, and to placebo for patients randomized to placebo). Since IMP received is blinded, patients must return to the site and IRT will be contacted for this IMP re-initiation. Dose reduction can only be obtained at on-site visit by IRT. If the creatinine does not return to below the threshold, the IMP will be permanently discontinued but the patient will be asked to continue attending all study visits.

## 8.2 NONINVESTIGATIONAL MEDICINAL PRODUCT

Noninvestigational medicinal product (NIMP) treatment is defined as the rescue medication(s) that will be used to treat hyperglycemia when a patient's hyperglycemia reaches the rescue threshold (see [Section 8.2.1](#) for details).

### 8.2.1 Rescue therapy

The thresholds values are defined as follows, depending on study period:

- From Baseline Visit (V3, Day 1) to Visit 6 (Week 8) (including value at Visit 6): FPG >270 mg/dL (15.0 mmol/L).
- From Visit 6 (Week 8) to Visit 7 (Week 12) (including value at Visit 7): FPG >240 mg/dL (13.3 mmol/L).
- From Visit 7 (Week 12) up to the EOT Period Visit 11 (Week 52) (including value at Visit 11): FPG >200 mg/dL (11.1 mmol/L) or HbA1c  $\geq 8.5\%$  (the 8.5% criterion does not apply if the HbA1c decrease from Baseline was  $\geq 1.0\%$ ).

Routine fasting SMBG and central laboratory alerts on FPG (and HbA1c at Week 12 and onwards) are set up to ensure that glycemc parameters remain under predefined thresholds.

- If one fasting SMBG value exceeds the specific glycemc limit on 1 day, the patient checks it again during the 2 following days. If all the values in 3 consecutive days exceed the specific limit, the patient should contact the Investigator and **a central laboratory FPG measurement (and HbA1c at Week 12 and onwards) is performed** as soon as possible, preferably within 7 days to confirm the hyperglycemia.
- Upon receipt of a central laboratory rescue alert **a central laboratory re-test must be completed and confirmed as exceeding the criterion** for rescue before rescue therapy is initiated. The re-test confirmation should be performed as soon as possible, but within 7 days of receipt by unscheduled visit.

In the event that a confirmatory FPG and/or HbA1c exceed the threshold, the Investigator should ensure that no reasonable explanation exists for insufficient glucose control and in particular that:

- The increased FPG has been tested at a fasting status (ie, no food intake for  $\geq 8$  hours).

- IMP is given at the planned dose.
- Absence of intercurrent disease, which may jeopardize glycemic control (eg, infectious disease).
- Compliance to treatment is appropriate.
- Compliance to diet and lifestyle is appropriate.

If any of the above can reasonably explain the insufficient glycemic control, the Investigator should consider not initiating rescue medication and should undertake appropriate action, ie:

- Assess plasma glucose in fasting condition (ie, after at least 8 hours fast).
- Initiate an evaluation and treatment of intercurrent disease (to be reported in AE/concomitant medication parts of the electronic case report form (e-CRF) and the medical record).
- Stress on the absolute need to be compliant with treatment.
- Organize a specific interview with the patient and a Registered Dietician or other qualified nutrition professional and to reinforce on the absolute need to be compliant to diet and lifestyle recommendations, and schedule an FPG/HbA1c assessment at the next visit.

If none of the above mentioned reasons can be found, or if appropriate action fails to decrease FPG/HbA1c under the threshold values, rescue medication may be introduced (18).

- Open label rescue medication(s) to treat hyperglycemia must be in accordance with local standard of care and prescribing practice for patients with CKD and will be at the discretion of the investigator. Except for SGLT2 inhibitors and medications with specific contraindications in renal impairment, any approved medication(s) including oral antidiabetic drugs or insulin can be considered with appropriate dose modification as indicated.
- The patient continues the IMP (blinded) and stays in the study in order to collect efficacy and safety information. The planned visits and assessments should occur until the last scheduled visit.
- Rescue therapy is considered an NIMP. Rescue therapy is to be reported in the e-CRF. This information should include specific drug name, dose, route of administration, and frequency.

If not covered by health insurance, the cost of rescue therapy will be reimbursed where permitted by local regulations.

### **8.3 BLINDING PROCEDURES**

#### **8.3.1 Methods of blinding**

To maintain blinding sotagliflozin and their matching placebo tablets (including packaging) will be blinded and indistinguishable.

During the double-blind Treatment Period and double-blind Extension Period, each treatment package will be labeled with a number, which is generated by a computer program from Sanofi. Investigators will not have access to the randomization (treatment) code except under circumstances described in [Section 8.3.2](#).

The randomization and the treatment allocation will be performed centrally by an IRT. The study biostatistician provides the randomization scheme to the IRT. Then, the IRT generates the patient randomization list from which it allocates treatment arms to the patients.

Fasting glucose (plasma or serum) and HbA1c will be masked to study sites and patients after randomization and until study end. To prevent partial unblinding, UGE and UGCR results will also be masked to study sites and patients. Additionally, urinalysis by dipstick will not include the measurement of urine glucose.

Quantitative urine glucose, albumin, calcium, phosphorus, magnesium, and creatinine will be measured separately at all on-site visits (except for Visits 6, 8, 10, and 12) by the central laboratory.

The CEC members will perform adjudication in a blinded manner.

#### **8.3.1.1 First step data analysis**

The Sponsor representatives that will be involved in the first step analysis will not be involved in the conduct of the study from that point forward, and unblinded patient level results at the first step analysis will not be provided to the study sites.

#### **8.3.2 Randomization code breaking during the study**

In case of an AE, the randomization code should only be broken in circumstances when knowledge of the IMP is required for treating the patient.

Code breaking can be performed at any time by using the proper module of the IRT and/or by calling any other phone number provided by the Sponsor for that purpose. Code breaking can be performed by a local study Investigator, sponsor physician or healthcare professional with direct responsibility for patient care. If the blind is broken, the Investigator should document the date, time of day and reason for code breaking. The identity of the unblinded personnel, how the code was broken, and the treatment kit number should also be recorded. The Sponsor should also be informed. If the code is broken by the Investigator, (or other medical doctor in emergency situation) the patient must be withdrawn from IMP administration.

Randomization code breaking will also be performed during the analysis of the Pharmacokinetic plasma concentration samples. Only the Project manager and lead scientist at the Bioanalytical laboratory will have access to the randomization code to allow for the sorting of the sotagliflozin plasma samples. The Bioanalytical lab and responsible personnel will follow the standard procedures to ensure the protection of the blind within the Sponsor's clinical team. The randomization code or the individual analytical results will not be disclosed to any clinical team personnel prior to the database lock.



Refer to [Section 10.5](#) for suspected unexpected serious adverse reaction (SUSAR) unblinding by the Sponsor.

#### 8.4 METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP

The randomized treatment kit number list is generated centrally by Sanofi. The IMPs are packaged in accordance with this list.

Patients will be randomized to receive sotagliflozin 400 mg, sotagliflozin 200 mg or matching placebo once daily during the randomized double-blind Treatment Period and Extension Period. Randomization (ratio 1:1:1) will be stratified by Screening HbA1c ( $\leq 8.5\%$  and  $>8.5\%$ ), Screening SBP ( $<130$  mmHg and  $\geq 130$  mmHg), and CKD stage at Screening (3A, 3B).

To ensure sufficient patients in each CKD stratum, enrollment will be capped for the 1st CKD stratum that reaches 390 patients (either CKD stage 3A [screening eGFR of 45 to  $<60$  mL/min/1.73 m<sup>2</sup>] or CKD stage 3B [screening eGFR of 30 to  $<45$  mL/min/1.73 m<sup>2</sup>]). Enrollment for the study will be completed when reaching the target number as planned.

The randomization and the treatment package allocation are performed centrally by an IRT. At the Screening Visit the Investigator or designee will contact the IRT to receive the patient number.

[REDACTED]

[REDACTED] At Visit 2 (Run-in), the IRT will be contacted for dispensing single-blinded placebo Run-in kit. At Visit 3 (Baseline), patient eligibility will be reviewed; the IRT will be contacted and corresponding treatment packages will be allocated.

After Visit 3 (Baseline), with the exception of Visit 4, the IRT is contacted again each time new treatment package(s) allocation is required by the protocol. For each randomized patient, the IRT will allocate treatment package number(s) corresponding to the treatment group assigned.

Treatment packages are allocated by the IRT using their treatment kit number.

A randomized patient is defined as a patient who is registered and assigned with a treatment kit number from the IRT, as documented in the IRT.

A patient may not be enrolled in this study more than once (ie, enter Run-in or be randomized twice). In cases where original screen failure was due to reasons expected to change at rescreening and based upon the Investigator's clinical judgment, the patient can be rescreened prior to entering Run-in once for this study. In these cases, a patient will need to sign a new ICF, be registered as a rescreened in the IRT and assigned a new patient number (first Screening Visit is to be registered as a screen failure in the IRT), and complete again the Screening Visit procedures/assessments again.

## **8.5 PACKAGING AND LABELING**

Packaging will be undertaken in accordance with the administration schedule. The content of the labeling is in accordance with the local regulatory specifications and requirements.

The appropriate number of packages will be dispensed to cover up to the next dispensing visit (please refer to [Section 1.2](#)). Storage conditions and use-by-end date are part of the label text.

Treatment labels will indicate the treatment number (used for treatment allocation and reported in the e-CRF).

## **8.6 STORAGE CONDITIONS AND SHELF LIFE**

Investigators or other authorized persons (eg, pharmacists) are responsible for storing the IMP in a secure and safe place in accordance with local regulations, labeling specifications, policies, and procedures.

Control of IMP storage conditions, especially control of temperature and instructions for handling the Sanofi compound should be managed according to the rules provided by the Sponsor.

The expiry date and storage conditions are written on the IMP labels. The IMP should be stored between +15°C and +30°C (59°F and 86°F).

## **8.7 RESPONSIBILITIES**

The Investigator, the hospital pharmacist, or other personnel allowed to store and dispense the IMP will be responsible for ensuring that the IMP used in the clinical trial is securely maintained as specified by the Sponsor or Delegate and in accordance with applicable regulatory requirements.

All IMPs will be dispensed in accordance with the Investigator's prescription and it is the Investigator's responsibility to ensure that an accurate record of IMP issued and returned is maintained.

Any quality issue noticed with the receipt or use of an IMP (deficiency in condition, appearance, pertaining documentation, labeling, expiration date, etc) should be promptly notified to the Sponsor or Delegate. Some deficiencies may be recorded through a complaint procedure.

A potential defect in the quality of IMP may be subject to initiation of a recall procedure by the Sponsor. In this case, the Investigator will be responsible for promptly addressing any request made by the Sponsor in order to recall the IMP and eliminate potential hazards.

Under no circumstances will the Investigator supply IMP to a third party (except for direct-to-patient shipment, for which a courier company has been approved by the Sponsor), allow the IMP to be used other than as directed by this clinical trial protocol, or dispose of IMP in any other manner.

### 8.7.1 Treatment accountability and compliance

Accounting and compliance for IMPs will be performed at Visit 3 and all subsequent visits.

The Investigator will check the compliance to the study treatments based on the patient diary and will then complete the appropriate site treatment and patient treatment log forms. Returned IMP should be counted by site staff. In addition, the dosing information will be recorded on the appropriate pages of the e-CRF.

If compliance is inadequate as determined by the Principal Investigator, patients will be trained again and mentored. If suboptimal compliance continues after training and mentoring, patients may be discontinued at the discretion of the Principal Investigator after discussion with the Sponsor's/CRO's medical monitor.

### 8.7.2 Return and/or destruction of treatments

Patients are to return all IMP (unused, in-use or empty wallet[s]) at each on-site visit, or at on-site visits after premature treatment discontinuation, as described in [Section 1.2](#).

At Visit 4 (Week 1), because no IMP re-supply is planned during this visit, patients will be sent home after this visit with the in-use wallet dispensed at Randomization.

Patients are to return all the used, in-use and unused IMP at Visit 11 (or final assessment on-treatment visit in case of permanent premature discontinuation).

All used, partially used or unused IMPs will be retrieved by the Sponsor or Delegate. A detailed site and patient treatment log of the returned IMP will be established with the Investigator (or the pharmacist) and countersigned by the Investigator and the monitoring team.

For NIMP not provided by the Sponsor (ie, rescue therapy), tracking and reconciliation is to be undertaken by the Investigator (or pharmacist if appropriate) according to the system proposed by the CRO.

## 8.8 CONCOMITANT MEDICATION

A concomitant medication is any treatment received by the patient concomitantly to any IMP. The IMP includes sotagliflozin 400 mg, sotagliflozin 200 mg, and matching placebo.

**Background antidiabetic medication:** Except for SGLT2 inhibitor (eg, canagliflozin, dapagliflozin, or empagliflozin), at the study entry patients can be treated with any injectable or oral antidiabetic medication(s) in accordance with the local medical care guidance. The type or dose of medication(s) should remain unchanged during the study course. The dose modification or discontinuation of an existing antidiabetic medication is allowed for safety concerns at the Investigator's medical judgment.

All concomitant medications should be documented on the medications page of the e-CRF. This includes all NIMP treatments that are taken by the patients at any time during the clinical study, beginning at Visit 1.

Additionally, all medications taken in the 3 months prior to Visit 1 and any prior use of SGLT2 inhibitor should be reported.

### **8.8.1 Prohibited prior and concomitant medications**

During the study Treatment Period, the following medications are prohibited:

- Initiation of any antidiabetic agents, including oral or injectable antihyperglycemic agents other than the IMP and NIMP is not allowed before the rescue therapy. The existing background medication (NIMP) should not be modified before the rescue.

Note: short term use (<10 consecutive days) of the prohibited medication, eg, short-acting insulin for treatment of acute illness or surgery is allowed.

- SGLT2 inhibitors (eg, canagliflozin, dapagliflozin, or empagliflozin) are not allowed for rescue.
- Systemic use of glucocorticoids for more than 10 consecutive days (topical, intra-articular, ophthalmic, nasal spray or inhaled applications are allowed).
- IMPs in any other clinical study.
- Modification of antihypertensive medication before Week 12 is not allowed unless for safety reasons.
- Initiation of any weight loss drugs (eg, phentermine, orlistat).

Patients taking sotagliflozin with concomitant digoxin should have digoxin concentrations monitored and doses reduced as needed. In addition, other P-gp substrates may be affected and the labels of P-gp substrate drugs should be consulted with regards to monitoring and dose adjustments.

Other medications which are unlikely to interfere with the PK or PD of the IMP or confound interpretation of the study endpoints are allowed as needed following discussion between the Investigator and the Sponsor/CRO. However, doses of chronically administered medicines should be kept fixed during the study if at all possible.

The dose of all antihypertensive agents should be kept constant during the 12 weeks following randomization and no antihypertensive agents should be added or withdrawn for the 12 weeks following randomization unless it is considered necessary for safety reasons.

### **8.8.2 Concomitant diabetes therapy**

Any background antidiabetic therapy (oral or injected including insulin) is permitted with the exception of other SGLT2 inhibitors.

The rescue medication(s) that will be used to treat hyperglycemia (see [Section 8.2.1](#)) when a patient's hyperglycemia reaches the rescue threshold is also defined as NIMPs. Except for SGLT2 inhibitors and medications with specific contraindications in renal impairment, any approved medication(s) including oral/subcutaneous antidiabetic drugs or insulin can be prescribed to treat the hyperglycemia as long as it is used within labeling guidelines for renal impairment. In addition, for patients already prescribed insulin the dose may be increased. If a patient requires glycemic rescue, the IMP received during the randomized, double-blind Treatment Period and Extension Period should continue and must remain blinded until the end of the study. Background medication may need to be adjusted if hypoglycemia occurs.

## **8.9 POSTSTUDY TREATMENT**

Because sotagliflozin may reduce BP, adjustment of antihypertensive medication may be needed during the study in patients with hypertension. Conversely, monitoring for an increase in BP should be performed after withdrawal of study medication. If the BP is elevated after withdrawal of study treatment, the Investigator should consider adding or adjusting antihypertensive medication. Sotagliflozin will not be provided after EOT. Patient's further treatment, for diabetes and other pathologies will be at the Investigator's discretion based on his/her clinical judgment.

## 9 ASSESSMENT OF INVESTIGATIONAL MEDICINAL PRODUCT

### 9.1 EFFICACY ENDPOINT

#### 9.1.1 Primary efficacy endpoint

- Change from Baseline to Week 26 in HbA1c (%) comparing sotagliflozin 400 mg versus placebo in overall population, and in CKD stages 3A and 3B patients sequentially, then comparing sotagliflozin 200 mg versus placebo in overall population, and in CKD stages 3A and 3B patients sequentially.

#### 9.1.2 Secondary efficacy endpoints

To compare sotagliflozin 400 mg and 200 mg versus placebo, respectively, in terms of:

- Change from Baseline in FPG at Week 26.
- Change from Baseline in body weight at Week 26.
- Change from Baseline in SBP at Week 12 for patients with Baseline SBP  $\geq$ 130 mmHg.
- Change from Baseline in SBP at Week 12 for all patients.
- Percentage change in UACR from Baseline to Week 26 for patients with UACR  $>$ 30 mg/g at Baseline.
- Proportion of patients with HbA1c  $<$ 6.5%,  $<$ 7.0% at Week 26.

#### 9.1.3 Other efficacy endpoints

To compare sotagliflozin 400 mg and 200 mg versus placebo, respectively, in terms of:

- Change from Baseline in SBP at Weeks 26 and 52 for patients with Baseline SBP  $\geq$ 130 mmHg
- Change from Baseline in SBP at Weeks 26 and 52 for all patients
- Change from Baseline in HbA1c at Week 52
- Change from Baseline in FPG at Week 52
- Change from Baseline in body weight at Week 52
- Change from Baseline in eGFR.
- Proportion of patients requiring rescue for hyperglycemia during 26-week double-blind Treatment Period.
- Change from Baseline in:
  - Cystatin C

- UGE
  - UGCR
  - Fructosamine
  - NT-proBNP.
- Proportion of patients with progression to end-stage renal disease (ESRD) (dialysis or transplant) at Week 4 or any time later during the trial.
  - Proportion of patients with >50% decline in eGFR from Baseline to Week 26 and Week 52.
  - Proportion of patients with progression from normal to microalbuminuria or from microalbuminuria to macroalbuminuria from Baseline at Week 26 and Week 52.
  - Proportion of patients with improvement from microalbuminuria to normal to or from macroalbuminuria to microalbuminuria from Baseline at Week 26 and Week 52.
  - Change from Baseline in SBP at Week 12 for patients with Baseline SBP <130 mmHg.
  - Change from Baseline in DBP at Week 12 for all patients and the subset of patients with Baseline DBP  $\geq$ 80 mmHg.

#### **9.1.4 Assessment methods of efficacy endpoints**

##### **9.1.4.1 Hemoglobin A1c**

Hemoglobin A1c will be assessed at Screening (Visit 1), Baseline (Visit 3), and all on-site visits during the double-blind Treatment Period and Extension Period, with the exception of Run-in (Visit 2), Week 2 (Visit 4), and Week 4 (Visit 5). HbA1c is measured by a certified Level I “National Glycohemoglobin Standardization Program” central laboratory at time points described in the flow chart ([Section 1.2](#)).

##### **9.1.4.2 Blood pressure measurements**

Systolic BP and DBP will be assessed at all on-site visits. Blood pressure measurements must be taken as described in [Section 9.2.1.5](#), with details provided in [Appendix C](#).

##### **9.1.4.3 Body weight measurement**

Body weight is measured at all on-site visits. Body weight should be obtained with the patient wearing undergarments or very light clothing and no shoes, and with an empty bladder. The same scale should be used throughout the study, and calibrated on a regular basis as recommended by the manufacturer. Calibration should be documented in source documents. The use of balance scales is recommended; if digital scales are used, testing with standard weights is of particular importance. The floor surface on which the scale rests must be hard and should not be carpeted or covered with other soft material. The scale should be balanced with both weights at zero and the balance bar aligned. The patient should stand in the center of the platform as standing off center

may affect measurement. The weights are moved until the beam balances (the arrows are aligned). The weight is read and recorded in the e-CRF and Source Data. Self-reported weights are not acceptable; patients must not read the scales themselves.

#### **9.1.4.4 Fasting plasma glucose measurement**

Plasma glucose is measured in the fasting state at Screening (Visit 1) and all on-site visits during the double-blind Treatment Period and Extension Period with the exception of Visit 4 (see [Section 1.2](#)). For the eligibility and efficacy assessments of the study, FPG is measured at a central laboratory to allow estimation of change from Baseline to Week 26 and Week 52.

#### **9.1.4.5 Kidney function parameter assessments**

Serum creatinine and urine albumin, protein, calcium, creatinine, phosphorus, magnesium, and glucose will be assessed at Baseline (Visit 3) and selected on-site visits ([Section 1.2](#)). A central laboratory will analyze samples and estimate change from Baseline in UACR, UGE, UGCR, serum creatinine, and eGFR. To prevent partial unblinding, UGE and UGCR results will be masked to study sites.

#### **9.1.4.6 Fructosamine, NT-proBNP and Cystatin C**

Fructosamine is measured in the fasting state at Baseline (Visit 3) and all on-site visits during the double-blind Treatment Period and Extension Period with the exception of Week 2 (Visit 4).

Cystatin C and NT-proBNP are measured in the fasting state at Baseline (Visit 3) and all on-site visits during the double-blind Treatment Period and Extension Period with the exception of Week 8 (Visit 6) and Week 18 (Visit 8).

For the eligibility and efficacy assessments of the study, fructosamine, NT-proBNP, and cystatin C are measured at a central laboratory to allow estimation of change from Baseline to Week 26.

#### **9.1.4.7 Use of rescue medication for hyperglycemia**

The use of rescue medications for hyperglycemia will be assessed and reported throughout the double-blind Treatment Period. Routine alerts on FPG will be sent to the Investigator from the central laboratory to ensure that glycemic parameter results remain within predefined thresholds. For details and further actions should FPG values fall above thresholds, refer to [Section 8.2.1](#).

#### **9.1.4.8 Proportion of patients with progression of renal disease**

Patients will be monitored throughout the Treatment Periods for progression of renal disease (>50% decline in eGFR, progression from normal to microalbuminuria, and progression from microalbuminuria to macroalbuminuria).



Patients will be monitored at Week 4, and throughout the remainder of the study for progression to ESRD (progression to dialysis either hemodialysis or peritoneal dialysis, or transplant).

## 9.2 SAFETY ENDPOINTS

Assessments for safety include AEs, SMBG, clinical laboratory assessments, physical examination, ECG, weight, and vital signs. An independent DMC will meet on a regular basis to review accumulating clinical trial safety data by treatment.

Adjudication of all deaths, MACE/other selected CV events, selected renal events, bone fracture, and DKA will be performed in a blinded manner by a CEC(s) comprised of experts. Details will be provided in the charter of the CEC(s). Further details are available in [Section 6.3](#).

Two expert committees will review all potential cases of DILIs and cases of amputation in a treatment-blinded manner to evaluate causality.

The following safety endpoints will be assessed:

- Incidence of TEAEs, AEs leading to discontinuation from the IMP, adverse events of special interest (AESI), EOSI, SAEs and deaths
- Hypoglycemia (all, severe and/or documented symptomatic hypoglycemia)
- Acute renal failure (see [Appendix D](#)).
- Clinical laboratory results (including fasting lipids; see [Section 9.2.1.3](#)), vital signs, ECG and bone mineral density (BMD) results
- Markers of intestinal transit and absorption
- Markers of bone and calcium metabolism.

### **Observation period of safety endpoints**

The observation period of safety data will be divided into 3 segments:

- The pre-Treatment Period is defined as the time between the date of the informed consent and the first dose of double-blind IMP
- The on-Treatment Period (TEAE period) is defined as the time from the first dose of double-blind IMP up to 10 days (1 day for hypoglycemia) after the last dose of double-blind IMP, regardless of the introduction of rescue therapy. The 10-day interval is chosen based on the half-life of the IMP (approximately 5 times the half-life of sotagliflozin) in patients with moderate renal dysfunction
- The post-Treatment Period is defined as the time starting 11 days after the last dose of double-blind IMP (after the on-Treatment Period).

The Baseline value for safety endpoints in the safety population is the last available value (or the average of all values for creatinine or eGFR) prior to the first administration of the double-blind IMP.

## **9.2.1 Assessment methods of safety endpoints**

### **9.2.1.1 Adverse events**

Adverse events including SAEs, AESI, and EOSI will be assessed. Refer to [Section 10.4](#) through [Section 10.7](#).

#### *9.2.1.1.1 Adverse events of special interest*

Adverse events of special interest are listed in [Section 10.4.1.3](#); reporting requirements for AESIs are presented in [Section 10.4.4](#).

#### *9.2.1.1.2 Events of special interest*

Events of special interest are separate from AESI. For a list of events defined as EOSI and their reporting requirements see [Section 10.4.1.4](#) and [Section 10.4.5](#), respectively.

### **9.2.1.2 Hypoglycemia**

Hypoglycemia (all, severe and/or documented symptomatic hypoglycemia) will be assessed starting with signing of the ICF until 4 weeks after the last dose of IMP. Patients will also complete the patient diary, which will be regularly reviewed by Investigators. See [Section 10.6.1](#) for further details.

### **9.2.1.3 Laboratory safety variables**

The clinical laboratory data consist of blood analysis (including hematology and clinical chemistry, amylase lipase, and lipid profile) and urinalysis, according to the schedule presented in [Section 1.2](#). Clinical laboratory values will be evaluated after conversion into standard international units. International units will be used in all listings and tables. [Table 2](#) lists the hematology, clinical chemistry, and other blood safety parameters to be assessed by the central laboratory.

In addition, for WOCBP a serum pregnancy test is performed at Screening and urine pregnancy tests are taken at all on-site visits during the double-blind Treatment Period, excluding Visit 4 (Week 2). Any positive urine test results must be confirmed by a serum pregnancy test. The Investigator may perform additional tests at their discretion or as required by local regulations.

For women of nonreproductive potential ([Appendix A](#)), follicle-stimulating hormone (FSH) and/or estradiol levels should be tested if the definition of postmenopausal or premenopausal cannot be satisfied, eg, no medical document of hysterectomy or cessation of menses <12 months without an alternative medical cause.

**Table 2 - Blood safety parameters**

<b>Clinical chemistry</b>	<b>Hematology</b>	<b>Other blood parameters</b>
Sodium	Complete blood count (CBC)	<b>Lipid profile</b>
Potassium	Differential	Total cholesterol (TC)
Chloride	Platelet count	High-density lipoprotein cholesterol (HDL-C)
Carbon dioxide (bicarbonate)	Hemoglobin	Low-density lipoprotein cholesterol (LDL-C) will be calculated by Friedwald equation
Blood urea nitrogen (BUN)	Hematocrit	Non-HDLC will be calculated as the difference between TC and HDLC
Creatinine (eGFR will be calculated*)		Triglycerides (TG)
Glucose (serum)		<b>Markers of Intestinal Transit and Absorption<sup>a</sup></b>
Alanine aminotransferase (ALT)		Vitamins: B6, B12, K, E, A
Aspartate aminotransferase (AST)		Serum folate
Total bilirubin (TB)		Ferritin
Alkaline phosphatase (ALP)		<b>Markers of bone and calcium metabolism<sup>a</sup></b>
Uric acid		Calcium
Phosphorus		25-hydroxyvitamin D
Total protein		1,25-dihydroxyvitamin D
Albumin		Phosphorus
Magnesium		Parathyroid hormone (PTH)
Creatine phosphokinase (CPK)		Markers of bone resorption: N-terminal telopeptide (NTX), beta-C-terminal telopeptide (β-CTX-1)
Lactic acid dehydrogenase (LDH)		Marker of bone formation: type 1 procollagen N-terminal (P1NP), osteocalcin
		<b>Other chemistry tests</b>
		Amylase
		Lipase

All assessments to be performed by central laboratory. All assessment measured in serum.

<sup>a</sup> To be collected at Baseline (Visit 3), Week 2 (Visit 4), Week 4 (Visit 5), Week 26 (Visit 9), and Week 52 (Visit 11; end of the Extension Period)

\* The recommended equation for estimating eGFR from serum creatinine is the 4 variable Modification of Diet in Renal Disease (MDRD) Study equation (16)(17). The IDMS-traceable version of the MDRD Study equation is used. Either equation below may be used based on whether the laboratory reports conventional units or Standardized International (SI) units.

Conventional Units (for use predominantly in the US): <http://nkdep.nih.gov/lab-evaluation/gfr-calculators/adults-conventional-unit.asp>

SI Units (for use predominately outside the US): <http://nkdep.nih.gov/lab-evaluation/gfr-calculators/adults-SI-units.asp>.

#### **9.2.1.4 Urinalysis**

Urinalysis (urine dipstick with microscopy) by central laboratory will be performed at Run-in (Visit 2), Baseline (Visit 3), at all on-site visits during the double-blind Treatment Period, and at Week 52 (Visit 11) during the Extension Period. To prevent partial unblinding, the central laboratory urine dipstick will not include the measurement of urine glucose. Central urinalysis includes:

- Urine dipstick includes: specific gravity, pH, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase
- Urine microscopy includes, but is not limited to: detection of formed cellular elements, casts, bacteria, yeast, parasites, and crystals in centrifuged urine sediment.

In the event of abnormal urinalysis findings suspicious of UTI, urine culture should be performed. Positive urine culture determination will be based upon the criteria of the reporting laboratory. Additionally, urine culture should be performed if at any point the Principal Investigator suspects the presence of a UTI.

In addition, urine albumin, calcium, phosphorus, glucose, magnesium, and creatinine will be assessed at Baseline (Visit 3) and all subsequent on-site visits during the Treatment Period with the exception of Week 8 (Visit 6) and Week 18 (Visit 8).

If the urine dipstick is positive for blood, the central laboratory will perform reflexive testing to include microscopy. Additional testing will be performed according to the judgment of the Investigator. Referral to urology/urologic evaluation is recommended for new or unexplained cases of confirmed hematuria (urology/urologic evaluation is not required where hematuria is considered to be related to diabetic nephropathy).

#### **9.2.1.5 Vital signs and physical exam**

A complete physical exam (including sitting BP and heart rate [HR], temperature, and respiratory rate) will be performed at Visit 1 (Screening), Visit 9 (Week 26), and Visit 11 (Week 52). Abbreviated physical exams (including sitting BP and HR) will be performed at Visits 2, 3, and 4 (Weeks -2, 0, and 2, respectively), and at the Follow-up Visit (Visit 12, Week 56). The abbreviated physical exam should focus on cardiac and respiratory systems, as well as any areas important for assessment of AEs, if necessary.

Vital signs, including: sitting BP and HR will be assessed at Screening and Run-in (Visits 1 and 2), and all on-site visits. Three separate seated BP and HR measurements should be taken with at least 1 minute between readings, following a 5-minute rest period, and prior to phlebotomy. Full details and directions for the measurement of BP are presented in [Appendix C](#).

#### **9.2.1.6 Electrocardiogram variables**

The ECG assessments will be evaluated as “normal” or “abnormal”.

A 12-lead ECG record is performed locally at Run-in (Visit 2), Week 26 (Visit 9), and Week 52 (Visit 11).

The 12-lead ECG should be performed after at least 10 minutes in supine position and prior to the morning IMP administration. The Investigator should review the ECG and document the interpretation, sign and date it on the ECG print out and report it in the e-CRF. Each ECG trace is analyzed in comparison with the Screening recorded trace. All original traces are kept as source data.

Note: Any new ECG abnormality should be rechecked for confirmation and reported as appropriate for that finding.

### **9.2.1.7 Bone Mineral Density**

Bone mineral density of femoral neck, lumbar spine and total hip will be assessed in all patients at Baseline (Week 0, Day 1  $\pm$ 7 days) and at Visit 11 (Week 52, Day 364  $\pm$ 7 days) using dual-energy X-ray absorptiometry (DEXA). Bone mineral density assessments will be performed locally with central reading. All DEXA scans will be retained as source data.

### **9.2.1.8 Self-monitoring of blood glucose**

A meter for self-assessment of blood glucose will be dispensed at Run-in (Visit 2). In addition to home measurements of SMBG, SMBG will be performed at Run-in (Visit 2), Baseline (Visit 3) and all subsequent on-site visits with the exception of Week 2 (Visit 4).

Patients will also receive a patient diary at all on-site visits from Visit 1 to Visit 9. The diary will be reviewed at all on-site visits from Visit 2 to Visit 12, with the exception of Visit 11. Self-assessed blood glucose levels will be entered into the patient diary.

Patients will be asked to self-assess blood glucose levels at least 3 times a week from the Run-in Visit (Visit 2) to the end of treatment, Visit 11.

Patients will be requested to self-assess blood glucose levels in the fasted state and whenever they experience any illnesses (eg, cold, flu), or symptoms of hyperglycemia or hypoglycemia. Symptoms of hypoglycemia may include shakiness, dizziness, sweating, hunger, headache, pale skin color, sudden moodiness or behavior changes (such as crying for no apparent reason), clumsy or jerky movements, seizure, difficulty paying attention or confusion, or tingling sensations around the mouth. Patients will be instructed to record the presence or absence of hypoglycemic episodes or hypoglycemic symptoms in the patient diary provided.

Patients will also be instructed to record SMBG values that are  $\leq 70$  mg/dL ( $\leq 3.9$  mmol/L) in the patient diary. Patients should be instructed to contact the site if fasting SMBG values over 3 consecutive days are:

- FPG  $>270$  mg/dL (15.0 mmol/L) from Baseline Visit (Visit 3, Day 1) to Visit 6 (Week 8) (including value at Visit 6)

- FPG >240 mg/dL (13.3 mmol/L) from Visit 6 (Week 8) to Visit 7 (Week 12) (including value at Visit 7)
- FPG/fasting SMBG >200 mg/dL (11.1 mmol/L) from Visit 7 (Week 12) up to the EOT Period Visit 11 (Week 52) (including value at Visit 11) or HbA1c  $\geq 8.5\%$  (the 8.5% criterion does not apply if the HbA1c decrease from Baseline was  $\geq 1.0\%$ ).

### 9.3 OTHER ENDPOINTS

#### 9.3.1 Pharmacokinetics of sotagliflozin

The PK endpoints for sotagliflozin are:

- Plasma levels of sotagliflozin and sotagliflozin-3-O-glucuronide in the sotagliflozin treatment arms

Pharmacokinetic sotagliflozin data may be subjected to a population PK analysis, which will be reported separately to the clinical study report (CSR).

##### 9.3.1.1 Sampling time

At Weeks 4, 18, 26, and 52 (Visits 5, 8, 9, and 11, respectively), blood samples for PK assessment are to be drawn with the other laboratory assessments, prior to administration of IMP. An additional blood sample will be drawn at Week 26 (Visit 9) and Week 52 (Visit 11), 3 hours after administering the dose of IMP. The time of the last intake of study drug prior to visits where PK samples are taken should be recorded by the patient in the patient diary. Patients should be reminded of this at visits preceding PK time points to ensure these details are captured. In the case of premature IMP discontinuation, PK samples should not be drawn at the Premature EOT Visit, or at subsequent visits. See [Table 3](#) for identification samples.

**Table 3 - Sotagliflozin samples identification**

Visit	Week	Relative to dosing	PK
Visit 5	Week 4	Pre-dose	P00
Visit 8	Week 18	Pre-dose	P01
Visit 9	Week 26	Pre-dose	P02
Visit 9	Week 26	3 hours post-dose	P03
Visit 11	Week 52	Pre-dose	P04
Visit 11	Week 52	3 hours post-dose	P05

PK: pharmacokinetic

##### 9.3.1.2 Pharmacokinetics handling procedure

Detailed procedures for sample preparation, storage and shipment are described in the specific laboratory manual developed by the central laboratory.

### 9.3.1.3 *Bioanalytical method*

#### **Concentration of sotagliflozin and its 3-O-glucuronide metabolite**

Plasma samples will be analyzed at Covance US using validated high performance liquid chromatography-tandem mass spectrometry, with lower limit of quantification of 2 ng/mL for sotagliflozin and lower limit of quantification of 10 ng/mL for sotagliflozin-3-O-glucuronide.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

## 9.5 APPROPRIATENESS OF MEASURES

Sotagliflozin monotherapy in patients with T2D who have inadequate glycemic control with diet and exercise is expected to lower HbA1c over 26 weeks of treatment (primary efficacy analysis). Sotagliflozin treatment for 26 weeks is likely to be of sufficient duration to observe effects on reduction of HbA1c, BP, and body weight, and is therefore selected as the timepoint for assessment of the primary endpoint HbA1c. Treatment up to 52 weeks will provide additional long-term data on safety and efficacy.

The concentration of HbA1c reflects the glycemic history of the previous 120 days and is thus an index of mean glycemia, documenting glycemic control over the past 2 to 3 months. Hemoglobin A1c has also been shown to correlate with the development of long-term complications of diabetes, and reduction of HbA1c is known to reduce the risk of long-term microvascular complications. Therefore, HbA1c is considered an appropriate primary endpoint for assessing the effect of a treatment on glycemic control. The duration of study treatment (26 weeks for the primary HbA1c endpoint) is considered to be sufficient for achieving stable conditions with IMP and for enabling an adequate assessment of time-dependent changes in HbA1c, as well as changes in fructosamine.

The problem of weight gain in T2D is widely recognized. More than 80% of individuals with T2D are overweight, many at the time of diagnosis. Consequently, iatrogenic weight gain is not only unwelcome, but represents an important clinical issue that can become a barrier to the successful management of glycemic control. Therefore, in this study, assessing change in body weight from Baseline to Week 26 is a secondary endpoint.

Improvements in FPG have been observed with sotagliflozin in multiple studies. Therefore assessment of fasting prandial glucose is relevant in this study. This parameter is also considered by regulatory agencies to be supportive of efficacy of an antidiabetic agent.



The other efficacy and safety assessments in this study are standard, well-established measurements for a Phase 3 study evaluating the treatment of T2D in adult participants.

The length of the study is considered appropriate for detection of the primary endpoint given the power estimates (see [Section 11.1](#)).

Phase 2 data indicated that sotagliflozin may reduce SBP by 10 to 15 mmHg in patients with SBP  $\geq$ 130 mmHg at Baseline, while having no significant effect in patients with SBP <130 mmHg, and did not induce hypotension in normotensive patients. Since this could be of benefit to patients with T2D, this finding is being followed up as a secondary objective in this trial, as well as the potential in patients with DBP >80 mmHg. Although effects on BP in Phase 2 data were observed with the 400 mg dose at 12 weeks, the effects will be examined at Weeks 12, 26, and 52.

Because of potential effects on bone and calcium metabolism, bone density will be measured in all patients in this trial at Baseline and Week 52, and specific biomarkers for bone and calcium metabolism will be assessed at regular timepoints. In view of the SGLT1 inhibitory effects in the GI tract, specific markers of intestinal transit and absorption will also be measured. Because of rat toxicology studies of questionable clinical significance showing tubule dilation in the kidney, high bone density in the sternum, and hyperplasia of stomach glandular cells, the biomarkers for urine, bone, and GI tract will also be measured at early timepoints of 2 and 4 weeks.

## 10 STUDY PROCEDURES

### 10.1 VISIT SCHEDULE

The visit schedule and procedures/assessments are listed in the Study Flow Chart ([Section 1.2](#)). The aim of this section is to provide details on how some of the procedures/assessments should be performed.

This is an out-patient study and consists of 12 on-site visits, although optional on-site and/or telephone visits can be scheduled at any time for any reason during the study whenever considered necessary by the Investigator.

The patients need to be fasting for on-site visits Visit 1 through Visit 11 (Week -4 through Week 52), unless instructed otherwise by the Investigator. Throughout the study, “fasting” is defined as 8 hours without food. **Note:** If the patient is not fasting at the visits specified above, the blood sample will not be collected and a new appointment should be given to the patient for the following day if possible, with instruction to be fasted (other procedures can be performed as scheduled). All laboratory assessments will occur prior to IMP administration on the day of the visit.

The Run-in visit (Visit 2) can be performed as soon as the results of all Screening tests are available and the patient is confirmed to be eligible for participation in the study. The visit window for on-treatment Visit 4 through Visit 11 should occur at the schedule  $\pm 5$  days. Visit 11 (EOT) should occur during Day 364 to 369. For the Follow-up (Visit 12), the visit window should occur within  $\pm 5$  days, 4 weeks after last dose of IMP.

If one visit date is changed, the next visit should occur according to the original schedule, ie, calculated from the date of Baseline visit (Visit 3, Week 0).

For a complete list of procedures scheduled for each study visit please refer to the Study Flow Chart ([Section 1.2](#)), which details the procedures to be performed.

All data obtained during the study visits are reviewed by the Investigator and Sub-Investigators who are qualified in treatment of T2D and are trained on the study.

#### 10.1.1 Screening Period

The Screening Period is up to 4 weeks and includes the Screening phase and the Run-in phase.

##### 10.1.1.1 Screening phase

The Screening phase will be up to 2 weeks in duration and includes Visit 1 (Week -4) only. It must be long enough to collect the data to establish whether the patient satisfies the inclusion/exclusion criteria.

Patients will undergo Screening assessments at Visit 1 (Week -4) following signing of the ICF. Patients, who meet the inclusion criteria as noted in [Section 7.1](#) and have no exclusion criteria as noted in [Section 7.2](#), will be randomized at Visit 3 (Day 1).

The IRT will be contacted at Visit 1 for notification of Screening Visit and to obtain the patient number.

In cases where original screen failure was due to reasons expected to change at rescreening and based upon the Investigator's clinical judgment, the patient can be rescreened once prior to entering Run-in for this study. In these cases, a patient will need to sign a new ICF, be registered as a rescreened in IRT and assigned a new patient number in IRT (first Screening Visit is to be registered as screen failure in IRT), and complete Screening Visit procedures/assessments again.

#### 10.1.1.1.1 On-site Visit 1 (Week -4) Screening Visit

The following procedures/assessments will be performed at Visit 1 (Week -4):

- Obtain the informed consent:
  - The patient will receive verbal information concerning the aims and methods of the study, its constraints and risks, and the study duration. Written information will be provided to the patient. Written informed consent must be signed by the patient and Investigator prior to any investigations
  - [REDACTED]
  - [REDACTED]
- IRT to be notified (allocation of ID, registration of Screening).
- Assessment of all inclusion/exclusion criteria.
- Collection of demographic data (age, gender, race, and ethnic origin).
- Assessment of the patient's medical and surgical history: to include history of T2D, treatment and complications (eye, kidney, history of smoking/tobacco use, history of alcohol, and history of amputation events, etc).
- Patient diary is dispensed and instructions/training are provided.
- Concomitant medication and medication history, including any prior medications for T2D.
- Instruction on basic genito-urinary (GU) hygiene and hydration (see [Appendix B](#)).
- Complete physical examination including height, body weight, and vital signs (SBP and DBP, HR, temperature, and respiratory rate). After 5 minutes resting, seated SBP, DBP, and HR will be assessed 3 times with at least 1 minute between each measurement (see [Appendix C](#) for details).
- The following laboratory testing (by the central laboratory):
  - FPG

- HbA1c
- Serum pregnancy testing for WOCBP or
- Serum FSH and estradiol (for women of nonreproductive potential if definition of postmenopausal or premenopausal cannot be satisfied, see [Appendix A](#))
- Clinical chemistry (including amylase, lipase, and uric acid) and hematology.
- AEs/SAEs/AESI/EOSI and hypoglycemia (if any) are reported.
- Patients are instructed to return to the site in the fasting state for Visit 2 (Week -2).

#### **10.1.1.2 Run-in phase**

The Run-in phase is 2 weeks and includes Visit 2 (Week -2).

##### **10.1.1.2.1 On-site Visit 2 (Run-in, Week -2)**

The following procedures/assessments will be performed at Visit 2 (Week -2):

- Measurement of body weight.
- Abbreviated physical examination (The abbreviated physical examination should focus on cardiac and respiratory systems, as well as any areas important for assessment of AEs, if necessary) and vital signs (SBP and DBP, and HR). After 5 minutes resting, seated SBP, DBP, and HR will be assessed 3 times with at least 1 minute between each measurement (see [Appendix C](#) for details).
- Diet and exercise instruction.
- Blood glucose meter is dispensed and instructions/training are provided.
- Patient diary is collected and reviewed and a new one dispensed. Instructions/training are provided as needed.
- IRT to be notified (registration of Run-in, allocation of single-blind Run-in kit).
- Instruction on basic GU hygiene and hydration (see [Appendix B](#)).
- AEs/SAEs/AESI/EOSI and hypoglycemia occurring since Visit 1 (if any) are reported.
- Run-in kit/placebo is dispensed.
- Changes in concomitant medication are reported.
- 12-lead ECG.
- Fasting SMBG is assessed.
- Urinalysis (dipstick and microscopy).
- Patients are instructed to return to the site in the fasting state with used/not-used single-blind Run-in kit for Visit 3 (Randomization).

### **10.1.2 Double-blind randomized Treatment Period (Day 1 to Week 26)**

Upon successful completion of the Run-in phase, patients will be randomly allocated to either sotagliflozin 400 mg, sotagliflozin 200 mg or matching placebo for the 26-week double-blind Treatment Period. All randomized patients will be followed at regular on-site visits for the duration of the Treatment Period.

In addition to routine laboratory testing, the following will be performed at specified time points: sotagliflozin concentration; markers of intestinal transit and absorption; markers of bone and calcium metabolism; collection of home urine for albumin, calcium, phosphorus, magnesium, glucose, and creatinine, and albumin creatinine ratio.

The date and time of the last intake of IMP prior to visits where PK samples are taken should be recorded by the patient in the patient diary. Patients should be reminded of this at visits preceding PK time points to ensure these details are captured.

In the event of abnormal urinalysis findings suspicious of UTI, urine culture should be performed. Positive urine culture determination will be based upon the criteria of the reporting laboratory. Additionally, urine culture should be performed if at any point the Principal Investigator suspects the presence of a UTI.

#### **10.1.2.1 On-site Randomization Visit 3 on Day 1 (Baseline; Week 0)**

The following procedures will be performed at this visit:

- Exclusion criteria are to be reviewed, including assessment of compliance during Run-in phase.
- Concomitant medications are assessed.
- Measurement of body weight.
- Abbreviated physical examination (The abbreviated physical examination should focus on cardiac and respiratory systems, as well as any areas important for assessment of AEs, if necessary) and vital signs (After 5 minutes resting, seated SBP, DBP, and HR will be assessed 3 times with at least 1 minute between each measurement (see [Appendix C](#) for details).
- IMP accountability and compliance for single-blind placebo Run-in treatment.
- IRT to be notified and randomization will occur.
- AEs/SAEs/AESI/EOSI and hypoglycemia (if any) are reported.
- Diet and exercise instruction.
- Patient diary is collected and reviewed and a new one is dispensed. Instructions/training are provided as needed.
- Instructions on DKA symptoms and basic GU hygiene and hydration (see [Appendix B](#)) is provided.

- Fasting SMBG is assessed.
- Patients are evaluated for glycemic rescue (see [Section 8.2.1](#)).
- Evaluate for 50% increase in creatinine.
- The following laboratory testing (by the central laboratory):
  - FPG
  - HbA1c
  - Urine pregnancy testing for WOCBP
  - Clinical chemistry (including amylase, lipase, fasting lipids, and uric acid) and hematology
  - Cystatin C
  - Fructosamine
  - NT-proBNP
  - Urinalysis (dipstick and microscopy)
  - Urine albumin, calcium, phosphorus, glucose, and creatinine
  - Collection of home urine for analysis of albumin, creatinine, calcium, phosphorus, magnesium, and albumin creatinine ratio.
- Additional laboratory testing at this visit:
  - Markers of intestinal transit and absorption (vitamins B6, B12, K, E, and A, serum folate, and ferritin)
  - Markers of bone and calcium metabolism: serum calcium (adjusted for creatinine), serum 25 hydroxyvitamin D, serum 1,25-dihydroxyvitamin D, serum phosphorus (adjusted for phosphorus), serum magnesium, serum parathyroid hormone (iPTH), markers of bone resorption (serum N-terminal telopeptide (NTX, serum beta-C-terminal telopeptide ( $\beta$ -CTX-1) and bone formation (serum type 1 procollagen N terminal (P1NP) and osteocalcin), and serum alkaline phosphatase (ALP)
  - [REDACTED]
  - [REDACTED]
- Assessment of BMD in all patients. BMD will be assessed locally (with central reading) on Day 1, with a window of  $\pm 7$  days for this assessment.
- IMP is dispensed.
- Patients are instructed to return to the site in the fasting state for their next visit (Visit 4; Week 2).
- Patients should be reminded to record the time of study drug intake on the day before their next visit.
- For accountability and compliance purposes, patients are instructed to return to the site with their used, in-use and not-used wallet(s) dispensed during Visit 3.

#### **10.1.2.2 On-site visit at Week 2 (Visit 4)**

The following procedures will be performed at this visit:

- Measurement of body weight.
- Abbreviated physical examination (The abbreviated physical examination should focus on cardiac and respiratory systems, as well as any areas important for assessment of AEs, if necessary) and vital signs (after 5 minutes resting, seated SBP, DBP, and HR will be assessed 3 times with at least 1 minute between each measurement (see [Appendix C](#) for details).
- IMP accountability and compliance for double-blind IMP.
- AEs/SAEs/AESI/EOSI and hypoglycemia (if any) are reported.
- Patients evaluated for glycemic rescue (see [Section 8.2.1](#)).
- Evaluate for 50% increase in creatinine.
- Diet and exercise instruction.
- Patient diary is collected and reviewed and a new one is dispensed. Instructions/training are provided as needed.
- The following laboratory testing (by the central laboratory):
  - Clinical chemistry (including amylase, lipase, and uric acid) and hematology
  - Cystatin C
  - NT-proBNP
  - Urinalysis (dipstick and microscopy)
  - Collection of home urine for analysis of albumin, creatinine, calcium, phosphorus, magnesium, glucose, and albumin creatinine ratio.
- Additional laboratory testing at this visit:
  - Markers of intestinal transit and absorption (vitamins B6, B12, K, E, and A, serum folate, and ferritin)
  - Markers of bone and calcium metabolism: serum calcium (adjusted for creatinine), serum 25 hydroxyvitamin D, serum 1,25-dihydroxyvitamin D, serum phosphorus (adjusted for phosphorus), serum magnesium, iPTH, markers of bone resorption (serum NTX, serum  $\beta$ -CTX-1) and bone formation (serum P1NP and osteocalcin), and serum ALP.
- Patients are instructed to return to the site in the fasting state for their next visit (Visit 5; Week 4).
- Patients should be reminded to record the time of study drug intake on the day before their next visit.
- For accountability and compliance purposes, patients are instructed to return to the site with their kit(s) at the next visit.

### **10.1.2.3 On-site visits at Week 4 to Week 18 (Visit 5 to Visit 8)**

The following procedures will be performed at Visit 5 (Week 4), Visit 6 (Week 8), Visit 7 (Week 12), and Visit 8 (Week 18), unless indicated otherwise:

- Concomitant medications are assessed.
- Measurement of body weight.
- Vital signs. After 5 minutes resting, seated SBP, DBP, and HR will be assessed 3 times with at least 1 minute between each measurement (see [Appendix C](#) for details).
- IMP accountability and compliance for double-blind IMP.
- IRT to be notified IMP for re-supply.
- AEs/SAEs/AESI/EOSI and hypoglycemia (if any) are reported.
- Patients evaluated for glycemic rescue (see [Section 8.2.1](#)).
- Evaluate for 50% increase in creatinine.
- Diet and exercise instruction (Visit 5 only).
- Patient diary is collected and reviewed and a new one is dispensed. Instructions/training are provided as needed.
- Instructions on DKA symptoms and basic GU hygiene and hydration (see [Appendix B](#)) is provided.
- Fasting SMBG is assessed.
- The following laboratory testing (by the central laboratory):
  - FPG
  - HbA1c (with the exception of Visit 5)
  - Urine pregnancy testing for WOCBP
  - Clinical chemistry (including amylase, lipase and uric acid). Hematology at Visit 5 and Visit 7 only
  - Cystatin C (Visit 5 and Visit 7 only)
  - Fructosamine
  - NT-proBNP (Visit 5 and Visit 7 only)
  - Urinalysis (dipstick and microscopy)
  - Urine albumin, calcium, phosphorus, glucose, and creatinine
  - Collection of home urine for analysis of albumin, creatinine, calcium, phosphorus, magnesium, glucose, and albumin creatinine ratio (Visit 5 and Visit 7 only).
- Additional laboratory testing at this visit:
  - Markers of intestinal transit and absorption (vitamins B6, B12, K, E, and A, serum folate, and ferritin) (Visit 5 only)



- Markers of bone and calcium metabolism: serum calcium (adjusted for creatinine), serum 25 hydroxyvitamin D, serum 1,25-dihydroxyvitamin D, serum phosphorus (adjusted for phosphorus), serum magnesium, serum iPTH, markers of bone resorption (serum NTX, serum  $\beta$ -CTX-1) and bone formation (serum P1NP and osteocalcin), and serum ALP (Visit 5 only)
- [REDACTED]
- PK (plasma concentration samples for sotagliflozin and sotagliflozin-3-O-glucuronide) (Visit 5 and Visit 8, only).
- IMP is dispensed.
- Patients are instructed to return to the site in the fasting state for each subsequent visit.
- Patients should be reminded to record the time of study drug intake on the day before their next visit.
- For accountability and compliance purposes, patients are instructed to return to the site with their kit(s) dispensed during the previous visit.

#### **10.1.2.4 On-site visit at Week 26 (Visit 9)**

The following procedures will be performed at this visit:

- Concomitant medications are assessed.
- Measurement of body weight.
- Complete physical examination. Vital signs. After 5 minutes resting, seated SBP, DBP, and HR will be assessed 3 times with at least 1 minute between each measurement (see [Appendix C](#) for details).
- IMP accountability and compliance for double-blind IMP.
- IRT to be notified IMP for re-supply.
- AEs/SAEs/AESI/EOSI and hypoglycemia (if any) are reported.
- Patients evaluated for glycemic rescue (see [Section 8.2.1](#)).
- Evaluate for 50% increase in creatinine.
- Diet and exercise instruction.
- Patient diary is collected and reviewed and a new one is dispensed. Instructions/training are provided as needed.
- Instructions on DKA symptoms and basic GU hygiene and hydration (see [Appendix B](#)) is provided.
- Fasting SMBG is assessed.
- 12-lead ECG.

- The following laboratory testing (by the central laboratory):
  - FPG
  - HbA1c
  - Urine pregnancy testing for WOCBP
  - Clinical chemistry (including amylase, lipase, fasting lipids, and uric acid) and hematology
  - Cystatin C
  - Fructosamine
  - NT-proBNP
  - Urinalysis (dipstick and microscopy)
  - Urine albumin, calcium, phosphorus, glucose, and creatinine
  - Collection of home urine for analysis of albumin, creatinine, calcium, phosphorus, magnesium, glucose, and albumin creatinine ratio.
- Additional laboratory testing at this visit:
  - Markers of intestinal transit and absorption (vitamins B6, B12, K, E, and A, serum folate, and ferritin)
  - Markers of bone and calcium metabolism: serum calcium (adjusted for creatinine), serum 25 hydroxyvitamin D, serum 1,25-dihydroxyvitamin D, serum phosphorus (adjusted for phosphorus), serum magnesium, iPTH, markers of bone resorption (serum NTX, serum  $\beta$ -CTX-1) and bone formation (serum P1NP and osteocalcin), and serum ALP
  - [REDACTED]
- Pre-dose PK (plasma concentration sample for sotagliflozin and sotagliflozin-3-O-glucuronide); an additional blood sample will be collected 3 hours after IMP administration for the assessment of creatinine (for eGFR) and for assessing plasma concentration of sotagliflozin and sotagliflozin-3-O-glucuronide.
- IMP is dispensed
- Patients are instructed to return to the site in the fasting state for Visit 10 (Week 39).
- For accountability and compliance purposes, patients are instructed to return to the site with their kit(s) dispensed during the previous visit.

### **10.1.3 Double-blind Extension Period (Week 27 to Week 52)**

From Weeks 27 to 52, patients will be in a 26-week double-blind Extension Period, which includes 2 on-site visits, at Week 39 (Visit 10) and Week 52 (Visit 11). Patients will continue to receive the blinded medication (sotagliflozin 400 mg, sotagliflozin 200 mg, or placebo) to which they were randomized on Day 1. All randomized patients will be followed at regular on-site visits for the duration of the Extension Period.

In addition to routine laboratory testing, the following will be performed at specified time points: sotagliflozin concentration; markers of intestinal transit and absorption; markers of bone and calcium metabolism; urine albumin, calcium, glucose, and creatinine.

The date and time of the last intake of IMP prior to visits where PK samples are taken should be recorded by the patient in the patient diary. Patients should be reminded of this at visits preceding PK time points to ensure these details are captured.

In the event of abnormal urinalysis findings suspicious of UTI, urine culture should be performed. Positive urine culture determination will be based upon the criteria of the reporting laboratory. Additionally, urine culture should be performed if at any point the Principal Investigator suspects the presence of a UTI.

#### **10.1.3.1 On-site visit at Week 39 (Visit 10)**

The following procedures will be performed at this visit:

- Concomitant medications are assessed.
- Measurement of body weight.
- Vital signs. After 5 minutes resting, seated SBP, DBP, and HR will be assessed 3 times with at least 1 minute between each measurement (see [Appendix C](#) for details).
- IMP accountability and compliance for IMP.
- IRT to be notified IMP for re-supply.
- AEs/SAEs/AESI/EOSI and hypoglycemia (if any) are reported.
- Patients evaluated for glycemic rescue (see [Section 8.2.1](#)).
- Evaluate for 50% increase in creatinine.
- Diet and exercise instruction.
- Patient diary is collected and reviewed and a new one is dispensed. Instructions/training are provided as needed.
- Instructions on DKA symptoms and basic GU hygiene and hydration (see [Appendix B](#)) is provided.
- Fasting SMBG is assessed.
- The following laboratory testing (by the central laboratory):
  - FPG
  - HbA1c
  - Urine pregnancy testing for WOCBP
  - Clinical chemistry (including amylase, lipase, fasting lipids, and uric acid) and hematology
  - Cystatin C

- Fructosamine
- NT-proBNP.
- Patients are instructed to return to the site in the fasting state for Visit 11 (Week 52).
- For accountability and compliance purposes, patients are instructed to return to the site with their kit(s) dispensed during the previous visit.

#### **10.1.3.2 On-site visit at Week 52 (Visit 11) – End of Treatment**

The following procedures will be performed at this visit:

- Concomitant medications are assessed.
- Measurement of body weight.
- Complete physical examination. Vital signs. After 5 minutes resting, seated SBP, DBP, and HR will be assessed 3 times with at least 1 minute between each measurement (see [Appendix C](#) for details).
- IMP accountability and compliance for double-blind IMP.
- IRT to be notified.
- AEs/SAEs/AESI/EOSI and hypoglycemia (if any) are reported.
- Patients evaluated for glycemic rescue (see [Section 8.2.1](#)).
- Evaluate for 50% increase in creatinine.
- Patient diary is collected and reviewed and a new one is dispensed. Instructions/training are provided as needed.
- Fasting SMBG is assessed.
- 12-lead ECG.
- The following laboratory testing (by the central laboratory):
  - FPG
  - HbA1c
  - Urine pregnancy testing for WOCBP
  - Clinical chemistry (including amylase, lipase, fasting lipids, and uric acid) and hematology
  - Cystatin C
  - Fructosamine
  - NT-proBNP
  - Urinalysis (dipstick and microscopy)
  - Urine albumin, calcium, phosphorus, glucose, and creatinine

- Collection of home urine for analysis of albumin, creatinine, calcium, phosphorus, magnesium, glucose, and albumin creatinine ratio.
- Additional laboratory testing at this visit:
  - Markers of intestinal transit and absorption (vitamins B6, B12, K, E, and A, serum folate, and ferritin)
  - Markers of bone and calcium metabolism: serum calcium (adjusted for creatinine), serum 25 hydroxyvitamin D, serum 1,25-dihydroxyvitamin D, serum phosphorus (adjusted for phosphorus), serum magnesium, serum iPTH, markers of bone resorption (serum NTX, serum  $\beta$ -CTX-1) and bone formation (serum P1NP and osteocalcin), and serum ALP.
- Pre-dose PK (plasma concentration sample for sotagliflozin and sotagliflozin-3-O-glucuronide); an additional blood sample will be collected 3 hours after IMP administration for the assessment of creatinine (for eGFR) and for assessing plasma concentration of sotagliflozin and sotagliflozin-3-O-glucuronide.
- Assessment of BMD in all patients. BMD will be assessed locally (with central reading) on Day 364, with a window of  $\pm 7$  days for this assessment.
- Patients are instructed to return to the site in the fasting state for Visit 12 (Week 56).

#### **10.1.4 Post-treatment Follow-up Period**

The post-treatment Follow-up Period will include an on-site visit, 4 weeks  $\pm 5$  days after the last dose of IMP.

##### **10.1.4.1 Follow-up Visit at Week 56 (Visit 12) – End of Study or 4 weeks after Premature End of Treatment**

The following procedures will be performed at this visit:

- Concomitant medications are assessed.
- Measurement of body weight.
- Abbreviated physical examination (The abbreviated physical examination should focus on cardiac and respiratory systems, as well as any areas important for assessment of AEs, if necessary). Vital signs. After 5 minutes resting, seated SBP, DBP, and HR will be assessed 3 times with at least 1 minute between each measurement (see [Appendix C](#) for details).
- IRT to be notified.
- AEs/SAEs/AESI/EOSI and hypoglycemia (if any) are reported.
- Collect glucose meter.
- Patient diary is collected and reviewed.
- Fasting SMBG is assessed.

- The following laboratory testing (by the central laboratory):
  - Clinical chemistry (including amylase, lipase, and uric acid)
  - Cystatin C.

## **10.2 DEFINITION OF SOURCE DATA**

### **10.2.1 Source data to be found in patient's file**

Evaluations recorded in the e-CRF must be supported by appropriately signed source documentation related but not limited to the following:

- Agreement and signature of ICF with the study identification.
- Study identification (name).
- Patient number, confirmation of randomization, treatment batch number, dates and doses of study medication administration.
- Medical, surgical, diabetes history, including information on:
  - Demography, inclusion, and exclusion criteria
  - Last participation in a clinical trial
  - Contraception method for WOCBP
  - Previous and concomitant medication.
- Dates and times of visits and assessments including examination results.
- Vital signs, height, body weight, laboratory reports, Investigation results (eg, ECG traces, imaging reports).
- AEs and follow-up:
  - In case of SAE, the site should file in the source documents at least copies of the hospitalization reports and any relevant examination reports documenting the follow-up of the SAE.
- Date of premature treatment discontinuation (if any) and reason.
- Date of premature study discontinuation (if any) and reason.
- Nursing notes.
- Dietician's notes.
- Physician's notes.

### **10.2.2 Source data verification requirements for screen failures**

For screen failure patients, the following source data must be verified: patient's identification details, the informed consent signed by the patient, the study identification (name), dates of study visits and the main reasons for screen failure.

### **10.3 HANDLING OF PATIENT TEMPORARY OR PERMANENT TREATMENT DISCONTINUATION AND OF PATIENT STUDY DISCONTINUATION**

The IMP should be continued whenever possible. In case the IMP is stopped, it should be determined whether the stop can be made temporarily; permanent IMP discontinuation should be a last resort. Any IMP discontinuation should be fully documented in the e-CRF. In any case, the patient should remain in the study and followed for the remainder of the study to collect vital safety status and endpoint data.

#### **10.3.1 Temporary treatment discontinuation with investigational medicinal product**

Temporary treatment discontinuation may be considered by the Investigator because of suspected AEs.

Lower extremity complications (such as skin ulcers, infection, osteomyelitis, and gangrene) requiring treatment should lead to temporary discontinuation of IMP.

If at any visit after Randomization up to Week 8 there is a rise in creatinine level (ie, >50% increase from Baseline level, where Baseline level is defined as the mean of creatinine values obtained at Screening and Randomization) or if at any visit after Week 8 there is a rise of >50% above the mean of creatinine values from last 2 visits, the Investigator should ensure that no reasonable explanation exists for creatinine increase.

The IMP should be stopped for 2 weeks.

Reinitiating of treatment with the IMP will be done under close and appropriate clinical/and or laboratory monitoring once the Investigator has considered according to his/her best medical judgment in the occurrence of the concerned event was unlikely to be related to the IMP and if that the selection criteria for the study are still met (refer to [Section 7.1](#) and [Section 7.2](#)).

If at creatinine recheck the patient has returned to the below threshold then IMP will be restarted at a reduced dose (ie, dose reduced via IRT to 200 mg for those randomized to 400 mg; maintained at 200 mg for those randomized to 200 mg). Since the IMP received is blinded, patients must return to the site and IRT will be contacted for IMP re-initiation.

It is in the interest of the patient to monitor their blood glucose during the temporary discontinuation period, therefore regular determination of SMBG is to be performed and documented (see [Section 9.2.1.8](#)).

For all temporary treatment discontinuations, duration should be recorded by the Investigator in the appropriate pages of the e-CRF when considered as confirmed.

Temporary treatment discontinuation decided by the Investigator corresponds to more than 1 dose not administered to the patient.

Use of any other anti-hyperglycemic medication during the time of temporary treatment discontinuation (ie, insulin during a hospitalization) is to be recorded as concomitant medication with the name and dose recorded in the e-CRF.

### **10.3.2 Permanent treatment discontinuation with investigational medicinal product**

Permanent treatment discontinuation defined as any treatment discontinuation associated with the definitive decision from the Investigator or the patient not to re-expose the patient to the IMP at any time.

#### **10.3.3 List of criteria for permanent treatment discontinuation**

Patients may withdraw from treatment with the IMP if they decide to do so, at any time and irrespective of the reason, or this may be the Investigator's decision. Patients should discuss stopping study medication with the site before doing so in order that questions can be addressed, glycemic therapy adjusted, and a follow-up assessment arranged. All efforts should be made to document the reasons for treatment discontinuation; this reason should be documented in the e-CRF.

The following reasons can lead to permanent discontinuation:

- At the patient's own request (ie, withdrawal of consent for treatment).
- If, in the Investigator's opinion, continuation with the administration of the study treatment would be detrimental to the patient's well-being.
- Intercurrent condition that requires permanent discontinuation of the study treatment as long as the abnormality persists and if the casual relationship of the concerned event and the IMP is possible (according to the Investigator's best medical judgment).
- Deterioration of renal function (defined as increase in serum creatinine > 50% from Baseline) that is not recovered after a temporary IMP discontinuation for 2 weeks.
- Patient requires renal replacement therapy (transplant or dialysis).
- Pregnancy (in female patients).
- Specific request of the Sponsor.

Any abnormal laboratory value will be rechecked immediately to confirm the result before a decision is made to permanent discontinue IMP for the concerned patient.

For patients who prematurely discontinue the IMP, the assessments planned at EOT visit ([Section 10.1.3.2](#)) will be performed at the Premature EOT Visit scheduled preferably prior to treatment discontinuation or as soon as possible after the time of discontinuation (at the latest at the next scheduled on-site visit). In the case of premature IMP discontinuation, no sample for measuring plasma concentration should be taken at the Premature EOT Visit, or at any subsequent



visit. The reason(s) for IMP discontinuation will be clearly specified. This Premature EOT assessment may occur at a regularly scheduled or at an unscheduled visit.

#### **10.3.4 Handling of patients after permanent treatment discontinuation**

Every effort should be made to maintain patients in the study. Patients should be followed up according to the study procedures as specified in this protocol up to the scheduled date of study completion, or up to recovery or stabilization of any AE to be followed up as specified in this protocol, whichever comes later.

If a patient decides to discontinue study treatment early, a Premature EOT Visit (see [Section 10.1.3.2](#)) should be scheduled prior to treatment discontinuation, if possible. If not possible, the Premature EOT should be scheduled as soon as possible after treatment discontinuation. In the case of early discontinuation, no sample for measuring plasma concentration should be taken at the Premature EOT Visit, or at any subsequent visits. For patients who discontinue treatment but remain in the study, the remaining study visits should occur as scheduled where possible. The IRT should be notified of EOT.

All cases of permanent treatment discontinuation should be recorded by the Investigator in the appropriate pages of the e-CRF.

#### **10.3.5 Procedure and consequence for patient withdrawal from study**

Patients may withdraw from the study before study completion if they decide to do so, at any time and irrespective of the reason. Withdrawal of consent for treatment should be distinguished from withdrawal of consent for follow-up visits. Patients will be told that they are free to withdraw from the study at any time without any adverse effect on their care; however, if they no longer wish to take the IMP, they will be encouraged to remain in the study and attend the remaining study visits. The value of all their study data collected during their continued involvement will be emphasized as important to the public health value of the study.

If possible, the patients are assessed using the procedure normally planned for the EOS visit.

Patients who withdraw should be explicitly asked about the contribution of possible AEs to their decision to withdraw consent, and any AE information elicited should be documented. Preferably the patient should withdraw consent in writing and, if the patient or the patient's representative refuses or is physically unavailable, the site should document and sign the reason for the patient's failure to withdraw consent in writing.

All confirmed study withdrawals should be recorded by the Investigator in the appropriate screens of the e-CRF and in the patient's medical records. In the medical record, at least the date of the withdrawal and the reason should be documented.

For patients who fail to return to the site, unless the patient withdraws consent for follow-up, the Investigator should make the best effort to contact the patient (eg, contact patient's family or private physician, review available registries or health care databases), and to determine his/her health status, including at least his/her vital status. Attempts (3 phone call attempts followed by a

certified letter) to contact such patients must be documented in the patient's records (eg, times and dates of attempted telephone contact, receipt for sending a registered letter).

Patients who have withdrawn from the study cannot be re-randomized (treated) in the study. Their inclusion and treatment numbers must not be reused.

## **10.4 OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING**

### **10.4.1 Definitions of adverse events**

#### **10.4.1.1 Adverse event**

An **AE** is any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the study treatment.

#### **10.4.1.2 Serious adverse event**

An **SAE** is any untoward medical occurrence that at any dose:

- Results in death, or
- Is life-threatening, or  
Note: The term "life-threatening" in the definition of "serious" refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe.
- Requires inpatient hospitalization or prolongation of existing hospitalization, or
- Results in persistent or significant disability/incapacity, or
- Is a congenital anomaly/birth defect, or
- Is a medically important event.

Medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or may require medical or surgical intervention (ie, specific measures or corrective treatment) to prevent one of the other outcomes listed in the definition above.

Note: The following list of medically important events is intended to serve as a guideline for determining which condition has to be considered a medically important event. The list is not intended to be exhaustive:

- Intensive treatment in an emergency room or at home for:
  - Allergic bronchospasm

- Blood dyscrasias (ie, agranulocytosis, aplastic anemia, bone marrow aplasia, myelodysplasia, pancytopenia, etc)
- Convulsions (seizures, epilepsy, epileptic fit, absence, etc).
- Development of drug dependence or drug abuse.
- ALT >3 times ULN + total bilirubin >2 times ULN or asymptomatic ALT increase >10 times ULN.
- Suicide attempt or any event suggestive of suicidality.
- Syncope, loss of consciousness (except if documented as a consequence of blood sampling).
- Bullous cutaneous eruptions.
- Cancers diagnosed during the study or aggravated during the study.
- Chronic neurodegenerative diseases (newly diagnosed) or aggravated during the study.

#### **10.4.1.3 Adverse event of special interest**

An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor is required. Such events may require further investigation in order to characterize and understand them. Adverse events of special interest may be added, modified or removed during a study by protocol amendment.

The AESI for this study are:

- Pregnancy of a female patient entered in a study as well as pregnancy occurring in a female partner of a male patient entered in a study with IMP/NIMP:
  - Pregnancy occurring in a female patient included in the clinical trial or in a female partner of a male patient entered in the clinical trial. It will be qualified as an SAE only if it fulfills one of the seriousness criteria (see [Section 10.4.1.2](#))
  - In the event of pregnancy in a female patient, IMP should be discontinued
  - Follow-up of the pregnancy in a female patient or in a female partner of a male patient is mandatory until the outcome has been determined (see [Appendix A](#)).
- Symptomatic overdose (serious or nonserious) with IMP/NIMP
  - A symptomatic overdose (accidental or intentional) with the IMP/NIMP is an event suspected by the Investigator or spontaneously notified by the patient and resulting in clinical symptoms and/or signs accompanied by administration of more than twice the intended daily dose within a 24-hour period. It will be recorded in the e-CRF as an AESI with immediate notification "Symptomatic OVERDOSE (accidental or intentional)" in all cases and will be qualified as an SAE only if it fulfills the SAE criteria

Note that an asymptomatic overdose with the IMP/NIMP, accidental or intentional, defined as administration of more than twice the intended daily dose within a 24-hour period, without clinical symptoms and/or signs, either suspected by the Investigator or spontaneously notified by the patient, not based on accountability assessment. It will be recorded as an AE "Asymptomatic OVERDOSE, accidental or intentional."

- ALT increase >3 times ULN.

#### **10.4.1.4 Events of special interest**

An EOSI is a serious or nonserious AE of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring may be appropriate. Such events may require further investigation in order to characterize and understand them. These events should be reported on the specific e-CRF page (where applicable) and will only qualify for expedited reporting when serious (fulfilling SAE criteria).

The EOSI for this study are:

- MACE (CV death, MI, or stroke) and other specific CV events (eg, heart failure leading to hospitalization).
- Severe hypoglycemia (see [Section 10.6.1](#)).
- Genital mycotic infections (to include vulvovaginal candidiasis in females and candidal balanitis in males).
- Urinary tract infections.
- Clinically relevant volume depletion and events related/possibly related to volume depletion.
- Diarrhea.
- Pancreatitis.
- Bone fractures.
- Venous thrombotic events, to include deep venous thrombosis and thromboembolism (to include pulmonary embolism).
- DKA.
- Renal events, to include 50% decline in eGFR, end-stage kidney disease, renal death.
- Malignancies of special interest (breast, bladder, renal cell, Leydig cell, pancreatic, prostate, and thyroid cancer).
- AE leading to an amputation.

#### **10.4.2 General guidelines for reporting events**

- All AEs, regardless of seriousness or relationship to IMP/NIMP, spanning from the signature of the ICF until the end of the study as defined by the protocol for that patient, are to be recorded on the corresponding page(s) or screen(s) of the e-CRF.

- Whenever possible, diagnosis or single syndrome should be reported instead of symptoms. The Investigator should specify the date of onset, intensity, action taken with respect to IMP, corrective treatment/therapy given, additional investigations performed, outcome, and his/her opinion as to whether there is a reasonable possibility that the AE was caused by the IMP or by the study procedure(s).
- In this study, the use of concomitant medications including antidiabetic medications may make it difficult to assess the causal relationship, particularly for hypoglycemia. The Global Safety Officer, with input from other appropriate study team members, will determine the causal relationship when it is not clearly provided by the Investigator.
- The Investigator should take appropriate measures to follow all AEs until clinical recovery is complete and laboratory results have returned to normal, or until progression has been stabilized, or until death, in order to ensure the safety of the patients. This may imply that observations will continue beyond the last planned visit per protocol, and that additional investigations may be requested by the monitoring team up to as noticed by the Sponsor.
- When treatment is prematurely discontinued, the patient's observations will continue until the end of the study as defined by the protocol for that patient.
- Laboratory, vital signs, or ECG abnormalities are to be recorded as AEs if they are medically relevant based on the investigator's medical judgment, eg:
  - Symptomatic, and/or
  - Requiring either corrective treatment or consultation, and/or
  - Leading to IMP discontinuation or modification of dosing, and/or
  - Fulfilling a seriousness criterion, and/or
  - Defined as an AESI or EOSI.

#### **10.4.3 Instructions for reporting serious adverse events**

In the case of occurrence of an SAE, the Investigator or any designees must immediately:

- ENTER (within 24 hours) the information related to the SAE in the appropriate screens of the e-CRF; the system will automatically send the notification to the Monitoring team and Pharmacovigilance after approval of the Investigator within the e-CRF.
- SEND (preferably by fax or e-mail) a photocopy of all examinations carried out and the dates on which these examinations were performed, to the representative of the monitoring team whose name, fax number, and e-mail address appear on the clinical trial protocol. Care should be taken to ensure that the patient's identity is protected and the patient's identifiers in the clinical trial are properly mentioned on any copy of a source document provided to the Sponsor. For laboratory results, include the laboratory normal ranges.
- All further data updates should be recorded in the e-CRF as appropriate, and further documentation as well as additional information (for laboratory data, concomitant medications, patient status, etc) should be sent (by fax or e-mail) to the monitoring team within 24 hours of knowledge of the SAE. In addition, every effort should be made to

further document any SAE that is fatal or life-threatening within a week (7 days) of the initial notification.

- A back-up plan (using a paper case report form [CRF] process) is available and should be used when the e-CRF system does not work.

Any SAE brought to the attention of the Investigator at any time after the end of the study for the patient and considered by him/her to be caused by the IMP with a reasonable possibility, should be reported to the monitoring team.

#### **10.4.4 Guidelines for reporting adverse events of special interest**

For AESIs, the Sponsor/CRO must be informed immediately (ie, within 24 hours), as per SAE notification guidelines described in [Section 10.4.3](#), even if not fulfilling a seriousness criterion, using the corresponding pages of the CRF (to be sent) or screens in the e-CRF.

#### **10.4.5 Guidelines for reporting events of special interest**

If an EOSI fulfills the criteria of an SAE, reporting should be performed according to the instructions for reporting of SAEs (see [Section 10.4.3](#)). Otherwise, reporting should follow the instructions for an AE (see [Section 10.4.2](#)).

#### **10.4.6 Guidelines for management of specific laboratory abnormalities**

Decision trees for the management of certain laboratory abnormalities by Sanofi are provided in [Appendix D](#).

The following laboratory abnormalities should be monitored, documented, and managed according to the related flow chart in protocol appendices:

- Neutropenia
- Thrombocytopenia
- Increase in ALT
- Acute renal insufficiency
- Suspicion of rhabdomyolysis.

### **10.5 OBLIGATIONS OF THE SPONSOR**

During the course of the study, the Sponsor will report in an expedited manner:

- All SAEs that are both unexpected and at least reasonably related to the IMP (SUSAR), to the regulatory authorities, IECs/ IRBs as appropriate and to the Investigators.
- All SAEs that are expected and at least reasonably related to the IMPs to the regulatory authorities, according to local regulations.

- The following AESIs to those regulatory authorities who require such reporting:
  - Pregnancy
  - Symptomatic overdose
  - ALT increase >3 times ULN.

Adverse events that are considered expected will be specified by the reference safety information provided in the current IB.

If required, unblinding of SUSARs will be the responsibility of the Sponsor.

The Sponsor will report all safety observations made during the conduct of the trial in the CSR.

## **10.6 SAFETY INSTRUCTIONS**


### **10.6.1 Hypoglycemia**

During the study, patients are instructed to document any hypoglycemic episodes in their study diary. The hypoglycemia will be reported in the specific e-CRF page with onset date and time, symptoms and/or signs, the SMBG value if available, and the treatment. If the event fulfills SAE criteria, hypoglycemia will also be reported as an SAE.

Hypoglycemia is categorized according to the ADA workgroup on hypoglycemia classification (19)(20) and summarized in [Figure 1](#).

In addition of the threshold of less than or equal to 70 mg/dL (3.9 mmol/L), hypoglycemia episodes with a plasma glucose of <54 mg/dL (3.0 mmol/L) will be analyzed separately.

**Figure 1 - Hypoglycemia classification in Study EFC14837**



\*The patient is not able to treat her/himself because of the acute neurological impairment and requires another person to actively administer sugar, glucagon or intravenous glucose

PG: plasma glucose; SAE: serious adverse event.

### Severe hypoglycemia

Severe hypoglycemia is an event requiring assistance of another person to actively administer carbohydrate, glucagon, intravenous glucose, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure, unconsciousness or coma. Self-monitored blood glucose values may not be available, but neurological recovery attributable to the restoration of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

**Note:** “Requiring assistance of another person” means that the patient could not help himself or herself to treat the hypoglycemia. Assisting a patient out of kindness, when assistance is not required, should not be considered a “requires assistance” incident.

Any hypoglycemic event which leads to unconsciousness, coma, or seizure should also be reported as an **SAE**.

### Documented symptomatic hypoglycemia

Documented symptomatic hypoglycemia is an event during which typical symptoms of hypoglycemia accompanied by a measured plasma glucose concentration of  $\leq 3.9$  mmol/L ( $\leq 70$  mg/dL).



Clinical symptoms that are considered to result from a hypoglycemic episode include increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, or coma.

### **Asymptomatic hypoglycemia**

Asymptomatic hypoglycemia is an event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration  $\leq 3.9$  mmol/L ( $\leq 70$  mg/dL).

**Note:** low plasma glucose values without symptoms or signs should not be reported more than once within 30 minutes. Repeated low glucose values within a short period could be due to malfunction of the device, error testing or following up a low glucose reading. The Investigator should try not to document false low SMBG values or redundant low glucose values as asymptomatic hypoglycemic events. Further clarification with the patients is needed.

### **Probable symptomatic hypoglycemia**

Probable symptomatic hypoglycemia is an event during which symptoms of hypoglycemia are not accompanied by a plasma glucose determination, (but that was presumably caused by a plasma glucose concentration  $\leq 3.9$  mmol/L [ $\leq 70$  mg/dL]), ie, symptoms treated with oral carbohydrate without a test of plasma glucose.

### **Relative hypoglycemia**

Relative hypoglycemia, recently termed “pseudo-hypoglycemia” (20), is an event during which the patient reports typical symptoms of hypoglycemia, and interprets the symptoms as indicative of hypoglycemia, but with a measured plasma glucose concentration  $> 3.9$  mmol/L ( $> 70$  mg/dL).

## **10.6.2 Deterioration of renal function**

Patients will be monitored throughout the double-blind Treatment Period and Extension Period for signs of deterioration in renal function (eg, decrease in eGFR or increase in creatinine as defined below) as well as other routine clinical and laboratory findings (see Study Flowchart, [Section 1.2](#)). If at any visit after Randomization up to Week 8 there is a rise in creatinine level (ie,  $> 50\%$  increase from Baseline level, where Baseline level is defined as the mean of creatinine values obtained at Screening and Randomization) or if at any visit after Week 8 there is a rise of  $> 50\%$  above the mean of creatinine values from last 2 visits, the Investigator should ensure that no reasonable explanation exists for creatinine increase and in particular the following causes:

- Medications that increase creatinine
- Decrease in cardiac output
- Obstructive uropathy
- Urinary tract infection
- Volume depletion.

If addressing these causes does not reduce the creatinine level below the above stated threshold, the IMP will be stopped for 2 weeks. The dose will be handled according to the renal function assessed by the creatinine measurement throughout the study and as detailed in [Section 10.3.1](#).

If the creatinine dose not return to below the threshold, then the IMP will be permanently discontinued but the patient will be asked to continue attending all study visits

## **10.7 ADVERSE EVENTS MONITORING**

All events will be managed and reported in compliance with all applicable regulations, and included in the final CSR.

## 11 STATISTICAL CONSIDERATIONS

### 11.1 DETERMINATION OF SAMPLE SIZE

The sample size/power calculations were performed based on the primary endpoint. Assuming a common standard deviation (SD) of 1.2% and using a 2-sided test at a 0.05  $\alpha$ -level, 130 patients in each CKD stratum (3A or 3B) in each treatment group will provide the following power:

- To detect a treatment difference of 0.6% in mean HbA1c change from Baseline to Week 26 between sotagliflozin 400 mg versus placebo:
  - 98% power comparing sotagliflozin 400 mg versus placebo in patients in CKD 3A stratum.
  - 98% power comparing sotagliflozin 400 mg versus placebo in patients in CKD 3B stratum.
  - 99% power comparing sotagliflozin 400 mg versus placebo in overall patient population.
- To detect a treatment difference of 0.5% in mean HbA1c change from Baseline to Week 26 between sotagliflozin 200 mg versus placebo:
  - 91% power comparing sotagliflozin 200 mg versus placebo in patients in CKD 3A stratum
  - 91% power comparing sotagliflozin 200 mg versus placebo in patients in CKD 3B stratum
  - 99% power comparing sotagliflozin 200 mg versus placebo in overall patient population
- At least 80% overall power to have all 6 above statistical inferences statistically significant based on above treatment effect assumptions.

### 11.2 DISPOSITION OF PATIENTS

The total number of patients for each of the following categories will be presented in the CSR.

- Screened patients: patients who have signed the ICF.
- Run-in patients.
- Randomized patients: patients with a treatment kit number allocated and recorded in IRT database, regardless of whether the treatment kit was used or not.
- The safety population (ie, randomized and treated patients).
- The ITT population, as defined in [Section 11.3.1.1](#).

- The randomization strata (HbA1c at Screening [ $\leq 8.5\%$ ,  $> 8.5\%$ ], Screening SBP [ $< 130$  mmHg,  $\geq 130$  mmHg], and CKD stage [3A, 3B]). The discrepancy between the strata assigned by IRT and the information reported on e-CRF will be listed for all randomized patients.
- Patients who have completed the 26-week double-blind Treatment Period.
- Patients who discontinued the IMP during the 26-week double-blind Treatment Period, and the reasons for treatment discontinuation.
- Patients who have completed the 52-week entire Treatment Period.
- Patients who discontinued the IMP during the 52-week entire Treatment Period, and the reasons for treatment discontinuation.
- Patients who have completed the study.
- Patients who discontinued the study, and the reasons for study discontinuation.

For all categories of patients except screened, percentages will be calculated using the number of randomized patients as denominator for each treatment group.

A list of patients prematurely discontinued from the treatment, along with reasons for discontinuation, will be provided. Similarly, a list of patients prematurely discontinued from the study, along with reasons for discontinuation, will be provided.

Patients treated but not randomized, patients randomized but not treated and patients randomized but not treated as randomized will be identified and described in separate listings. The safety experience of patients treated and not randomized will be reported separately, and these patients will not be in the safety population.

For any patient randomized more than once, only the data associated with the first randomization will be used in any analysis population. The safety experience associated with any later randomization will be assessed separately.

## **11.3 ANALYSIS OF POPULATIONS**

### **11.3.1 Efficacy populations**

Efficacy analyses will be based on the treatment group allocated by the IRT according to the randomization schedule at the Randomization Visit (as randomized), irrespective of the treatment actually received.

#### ***11.3.1.1 Intent-to-treat population***

Efficacy analyses will be based on the intent-to-treat (ITT) population, defined as all randomized patients irrespective of compliance with the study protocol and procedures. Patients will be analyzed for efficacy analyses according to the treatment group to which they are randomized.

### **11.3.2 Safety population**

Safety analyses will be based on the safety population, defined as all randomized patients who receive at least 1 dose of double-blind IMP (regardless of the amount of treatment administered).

Patients will be analyzed for safety analyses according to the treatment actually received.

In addition:

- Non-randomized but treated patients will not be part of the safety population, but their safety data will be presented separately.
- Randomized patients for whom it is unclear whether they took the study medication will be included in the safety population as randomized.
- When a patient is exposed to both sotagliflozin and placebo, the patient will be analyzed in the sotagliflozin group (depending on the treatment kit taken [400 mg or 200 mg]).
- When a patient is exposed to both sotagliflozin 400 mg (treatment kit) and 200 mg (treatment kit), the patient will be analyzed in the sotagliflozin 200 mg group.
- Randomized patients will be excluded from the safety population only if there is documented evidence (ie, all study dates recorded as no medication taken) that patients have not taken the study medication.

## **11.4 STATISTICAL METHODS**

Continuous data will be summarized by treatment group using the number of observations available (N), mean, SD, minimum, median, and maximum. Categorical data will be summarized by treatment group using count and percentage.

In general, descriptive statistics of quantitative efficacy and safety parameters (result and change from Baseline) by scheduled visits will be provided.

The Baseline value is defined generally as the last available value before the first dose of double-blind IMP or the last available value prior to randomization for patients who were randomized but never exposed to IMP.

For serum creatinine and eGFR, the Baseline value is defined as the average of all values before the first dose of double-blind IMP for those randomized and exposed or before randomization for those who were randomized but never exposed to IMP.

Analysis of demographics and Baseline characteristics, prior and concomitant medications will be provided in detail in the statistical analysis plan (SAP).

### **11.4.1 Extent of study treatment exposure and compliance**

The extent of study treatment exposure and compliance will be assessed and summarized by actual treatment received in the safety population.

#### **11.4.1.1 Extent of investigational medicinal product exposure**

The extent of study treatment exposure will be assessed by the duration of treatment exposure during the study.

The duration of treatment exposure will be the total number of days of administration of the double-blind IMP, regardless of unplanned intermittent discontinuations. The duration of IMP exposure will be calculated as:

$$(\text{Date of the last double-blind IMP taken} - \text{Date of the first double-blind IMP taken}) + 1$$

The number (%) of patients randomized and exposed to double-blind IMP will be presented by specific time periods for each treatment group. The time periods of interest will be defined in the SAP.

Descriptive statistics of duration of treatment exposure (number, mean, SD, minimum, median, and maximum) and cumulative exposure in patient years will also be presented by treatment group in the safety population.

#### **11.4.1.2 Compliance**

A given administration will be considered noncompliant if the patient did not take the planned dose of treatment as required by the protocol. No imputations will be made for patients with missing or incomplete data.

Treatment compliance, above-planned and under-planned dosing percentages will be summarized descriptively (N, mean, SD, median, minimum, and maximum). The percentage of patients with compliance <80% will be summarized. In addition, the number and percentage of patients with at least 1 above-planned dosing administration will be given, as well as the number and percentage of patients with 0, 0 to 20%, and >20% under-planned dosing administrations.

#### **11.4.2 Analyses of efficacy endpoints**

Efficacy analyses will be performed on the ITT population.

Statistical testing will be performed for primary endpoint and secondary endpoints at Week 26 (or Week 12 for SBP). All efficacy endpoints after Week 26 will only be summarized by descriptive statistics without formal statistical testing.

##### **11.4.2.1 Analysis of primary efficacy endpoint(s)**

The statistical test will be two-sided tests at a nominal 5% significance level.

Analysis of the primary efficacy endpoint (change from Baseline to Week 26 in HbA1c; see [Section 9.1.1](#)) will be performed on the ITT population, using HbA1c measurements obtained from visits during the study, including those obtained after IMP discontinuation or introduction of rescue therapy.

The primary efficacy endpoint of change in HbA1c from Baseline to Week 26 will be analyzed with missing values imputed by control-based multiple imputation method under the missing not at random framework:

- For placebo patients, missing data will be imputed based on the placebo group data.
- For patients in the sotagliflozin group, missing data will be imputed as if the patients were on placebo throughout the study, where all patients' measurements including the on-treatment measurements will be considered as if the measurements were from the placebo group in the imputation model.

Each of the complete datasets will be analyzed by an Analysis of Covariance (ANCOVA) model.

To compare sotagliflozin 400 mg and 200 mg, respectively, versus placebo in overall patient population (ie, CKD 3A and 3B patients combined), the model will include treatment (sotagliflozin 400 mg, sotagliflozin 200 mg, and placebo), randomization stratum of Screening HbA1c ( $\leq 8.5\%$ ,  $> 8.5\%$ ), randomization stratum of Screening SBP ( $< 130$  mmHg,  $\geq 130$  mmHg), randomization stratum of CKD stage (3A, 3B), and country as fixed effects, and Baseline HbA1c value as a covariate.

To compare sotagliflozin 400 mg and 200 mg, respectively, versus placebo in each CKD stratum, the model will include treatment (sotagliflozin 400 mg, sotagliflozin 200 mg, and placebo), randomization stratum of Screening HbA1c ( $\leq 8.5\%$ ,  $> 8.5\%$ ), randomization stratum of Screening SBP ( $< 130$  mmHg,  $\geq 130$  mmHg), randomization stratum of CKD stage (3A, 3B), treatment by randomization stratum of CKD stage, and country as fixed effects, and Baseline HbA1c value as a covariate.

Results from each complete dataset will be combined to provide the adjusted mean change in HbA1c from Baseline to Week 26 for each treatment group, as well as the between-group difference (comparing each sotagliflozin group versus placebo) and its associated 95% confidence interval (CI) using appropriate contrast statements.

Summary statistics (for Screening value, Baseline value, observed values, and observed changes from Baseline) at scheduled visits will be provided for each treatment group and by CKD stages (3A, 3B). The summary will include the number of observations, mean, SD, standard error (SE), minimum, median, and maximum. Graphical presentations will also be used to examine trends over time using mean values ( $\pm$  SE) and mean changes from Baseline ( $\pm$  SE) at each of the scheduled visits (using OC).

### **Assessment of treatment effect by subgroup**

Descriptive analyses will be performed on the primary endpoint to summarize the treatment effects across subgroups defined by the following Baseline or Screening factors:

- Race
- Ethnicity (Hispanic, Not Hispanic)
- Age group ( $< 50$  years,  $\geq 50$  to  $< 65$  years,  $\geq 65$  years)

- Gender
- Baseline BMI level ( $<30$ ,  $\geq 30$  kg/m<sup>2</sup>)
- Baseline HbA1c ( $\leq 8.5\%$ ,  $> 8.5\%$ )
- Baseline SBP ( $<130$  mmHg,  $\geq 130$  mmHg)
- Country.

The treatment effects across the subgroups defined for each of these factors will be estimated for the change from Baseline to Week 26 in HbA1c in the ITT population, and using a similar approach to the analysis for the primary efficacy endpoint. The adjusted estimates of treatment mean differences (each sotagliflozin group versus placebo) with SE and 95% CIs will be provided as appropriate across the subgroups.

In the event that the subgroup factor is identical or similar to a randomization strata factor (eg, Baseline HbA1c category), only the subgroup factor (as a single factor and/or an interaction term) will be included in the model in order to avoid the issue of collinearity in the analysis. The corresponding strata factor will not be included in the model.

#### **11.4.2.2 Analyses of secondary efficacy endpoints**

The secondary endpoints (see [Section 9.1.2](#)) will be analyzed using a similar approach to the primary efficacy endpoint with missing values imputed by control-based multiple imputation method under the missing not at random framework.

- For placebo patients, missing data will be imputed based on the placebo group data.
- For patients in the sotagliflozin group, missing data will be imputed as if the patients were on placebo group throughout the study, where all patients' measurements including the on-treatment measurements will be considered as if the measurements were from the placebo group in the imputation model.

For each of the continuous secondary endpoints, each of the complete datasets will be analyzed by an ANCOVA model with treatment (sotagliflozin 400 mg, sotagliflozin 200 mg, placebo), randomization stratum of HbA1c ( $\leq 8.5\%$ ,  $> 8.5\%$ ), randomization stratum of Screening SBP ( $<130$  mmHg,  $\geq 130$  mmHg), CKD stage at Screening (3A, 3B), and country as fixed effects, and Baseline secondary endpoint value as a covariate. Results from each complete dataset will be combined to provide the adjusted mean change from Baseline to Week 26 (or Week 12 for SBP) for each treatment group, as well as the between-group difference (comparing each sotagliflozin group versus placebo) and its associated 95% CI using appropriate contrast statements.

The categorical secondary efficacy variables of HbA1c  $<6.5\%$ ,  $<7\%$  at Week 26 will be analyzed using a Cochran-Mantel-Haenszel method stratified by the randomization stratum of Screening HbA1c ( $\leq 8.5\%$ ,  $> 8.5\%$ ), randomization stratum of Screening SBP ( $<130$  mmHg,  $\geq 130$  mmHg), and CKD stage at Screening (3A, 3B). The proportion in each treatment group will be provided, as well as the difference of proportions between sotagliflozin and placebo with associated 2-sided 95% CI. For HbA1c responders at Week 26 ( $<6.5\%$ ,  $<7\%$  respectively), all values at Week 26 will be used to determine whether a patient is a responder or not, even if they are measured after IMP



discontinuation or rescue medication use. Patients who have no HbA1c measurement at Week 26 will be treated as non-responders.

For all secondary endpoints, summary statistics at scheduled visits will be provided for each treatment group. The summary will include the number of observations, mean, SD, SE, minimum, median, and maximum. Graphical presentations will also be used to examine trends over time using mean values ( $\pm$  SE) and mean changes from Baseline ( $\pm$  SE) at each of the scheduled visits (using OC).

#### **11.4.2.3 Analyses of other efficacy endpoints**

The analysis of other endpoints (see [Section 9.1.3](#)) will be descriptive with no formal testing. Summary statistics at scheduled visits using OC will be provided by each treatment group. Graphical presentations will also be used to illustrate trends over time.

#### **11.4.2.4 Multiplicity considerations**

To control the family-wise type I error, a hierarchical testing procedure will be applied.

For the primary efficacy endpoint (change from Baseline to Week 26 in HbA1c), the hypotheses of statistical superiority of sotagliflozin versus placebo will be tested at 2-sided 5% significance level in the following population and order. The testing will stop as soon as the endpoint is found to be not statistically significant at  $\alpha = 0.05$  (2-sided).

- Comparing sotagliflozin 400 mg versus placebo, in:
  - The overall patient population (ie, patients in stratum CKD 3A and stratum CKD 3B)
  - Patients in stratum CKD 3A
  - Patients in stratum CKD 3B.
- Comparing sotagliflozin 200 mg versus placebo, in:
  - The overall patient population (ie, patients in stratum CKD 3A and stratum CKD 3B)
  - Patients in stratum CKD 3A
  - Patients in stratum CKD 3B.

Once the primary variable (change from Baseline to Week 26 in HbA1c) is statistically significant at  $\alpha = 0.05$  (2-sided) in all 6 populations in the order above, a hierarchical testing procedure will be performed to test the following main study secondary efficacy variables in the overall population by the following prioritized order. The testing will stop as soon as an endpoint is found to be not statistically significant at  $\alpha = 0.05$  (2-sided).

- Comparing sotagliflozin 400 mg versus placebo, in:
  - Change from Baseline to Week 26 in FPG
  - Change from Baseline to Week 26 in body weight
  - Change from Baseline to Week 12 in SBP for patients with Baseline SBP  $\geq 130$  mmHg

- Change from Baseline to Week 12 in SBP for all patients
- Proportion of patients with HbA1c <7.0% at Week 26.
- Comparing sotagliflozin 200 mg versus placebo, in:
  - Change from Baseline to Week 26 in FPG
  - Change from Baseline to Week 26 in body weight
  - Change from Baseline to Week 12 in SBP for patients with Baseline SBP  $\geq 130$  mmHg

Once the above secondary variables are statistically significant at  $\alpha = 0.05$  (2-sided), Hochberg's step-up procedure (21) will be performed to test the remaining 4 secondary variables: order a number of  $m$  ( $m=4$  here) tests by p-values (from lowest to highest)  $P_{(1)} \dots, P_{(m)}$  associated with tests  $H_{(1)} \dots, H_{(m)}$ , find the largest  $k$  (called  $R$ ) so that, for all  $k = 1, \dots, R$ ,  $P_{(k)} \leq \alpha / (m+1-k)$ , conclude  $H_{(1)} \dots, H_{(R)}$  statistically significant.

- Percentage change in UACR from Baseline to Week 26 for patients with UACR >30 mg/g at Baseline, comparing sotagliflozin 400 mg and 200 mg, respectively, versus placebo
- Proportion of patients with HbA1c <7.0% at Week 26, comparing sotagliflozin 200 mg versus placebo
- Change from Baseline to Week 12 in SBP for all patients comparing sotagliflozin 200 mg versus placebo

No multiplicity adjustment will be made on efficacy variables other than those mentioned above.

#### 11.4.3 Analyses of safety data

Safety endpoints are presented in [Section 9.2](#). The summary of safety results will be presented by treatment group. The safety data will be summarized for the 26-week double-blind Treatment Period and the entire treatment period separately, unless specified otherwise. All safety analyses will be performed on the safety population as defined in [Section 11.3.2](#) using the following common rules:

The following definitions will be applied to laboratory parameters and vital signs:

- The potentially clinically significant abnormality (PCSA) values for clinical laboratory tests and vital signs are defined as abnormal values considered medically important by the Sponsor's Global Pharmacovigilance and Epidemiology department and in effect at the time of the final SAP approval. The PCSA criteria for parameters not cited in the protocol as safety parameters will not be analyzed.
- The PCSA criteria will determine which patients had at least 1 PCSA during the on-Treatment Period, taking into account all evaluations performed during the on-Treatment Period, including unscheduled or repeated evaluations. The number of all such patients will be the numerator for the on-treatment PCSA percentage.

The “observation periods” defined in [Section 9.2](#) are applicable for classification of AEs, determination of on-treatment PCSA values and the last on-treatment value for the laboratory, vital sign and ECG parameters.

#### **11.4.3.1 Analysis of adverse events**

**Pre-treatment AEs** are AEs that developed or worsened or became serious during the pre-Treatment Period.

**Treatment-emergent AEs** are AEs that developed or worsened (according to the Investigator’s opinion) or became serious during the on-Treatment Period.

**Post-treatment AEs** are AEs that developed or worsened or became serious during the post-Treatment Period.

The primary focus of AE reporting in the CSR will be on TEAEs. Pre- and post-treatment AEs will be described separately.

#### **All adverse events**

Adverse event incidence tables will present by system organ class (SOC) (sorted by internationally agreed order), high-level group term (HLGT) and preferred term (PT) sorted in alphabetical order for each treatment group, the number (n) and percentage (%) of patients experiencing an AE. Multiple occurrences of the same event in the same patient will be counted only once in the tables within a treatment phase. The denominator for computation of percentages is the safety population within each treatment group.

Summaries of all TEAEs in each treatment group will include:

- The overview of AEs, summarizing number (%) of patients with any
  - TEAE
  - Serious TEAE
  - TEAE leading to death
  - TEAE leading to permanent treatment discontinuation.
- The number (n) and percentage (%) of patients with at least one TEAE by primary SOC, HLGT, HLT, and PT.
- Summary of TEAEs by maximal severity (severe, moderate, mild), presented by primary SOC and PT.
- Summary of TEAEs possibly related to IMP, presented by primary SOC, HLGT, HLT and PT.

A detailed listing of TEAE summaries will be provided in the SAP.

## **Death and serious adverse events**

Death and treatment-emergent SAEs will be summarized and presented as number and percent of patients in each treatment group.

The following deaths summaries will be generated:

- Number (%) of patients who died by study period (on-study, on-treatment, post-study) summarized on the safety population by treatment received.
- Death in non-randomized patients or randomized and not treated patients.
- TEAE leading to death (death as an outcome on the AE e-CRF page as reported by the Investigator) by primary SOC, HLG, HLT and PT showing number (%) of patients sorted by internationally agreed order of SOC and alphabetic order of HLG, HLT, and PT.

## **Adverse events leading to permanent treatment discontinuation**

Treatment-emergent AEs leading to permanent treatment discontinuation will be summarized and presented as number and percent of patients in each treatment group.

### **11.4.3.2 Analyses of hypoglycemia**

The number (%) of patients and rate in patient years (2 types: the number of patients with events or the total number of events per 100 patient-year) of all, severe and documented symptomatic hypoglycemia will be summarized by treatment group respectively. Their pattern of occurrence over time will also be assessed, as appropriate.

### **11.4.3.3 Analyses of adverse events of special interest**

Pregnancy and overdose will be included in overall AE summaries if any are reported. Alanine aminotransferase increase  $>3 \times$  ULN is included in laboratory PCSA summary if any.

### **11.4.3.4 Analyses of events of special interest**

The number (%) of patients with each EOSI event will be summarized by treatment group. All events reported by the Investigators on the AE forms for special interest will be listed along with the adjudication outcome (if applicable).

### **11.4.3.5 Analyses of laboratory variables**

The number and percentage of patients with PCSA or by the predefined categories (if no PCSA criterion is defined) at any evaluation during the on-Treatment Period will be summarized for each clinical laboratory test within each treatment group. The summaries will include patients in the safety population who have at least one laboratory test performed during the on-Treatment Period and, when required by the definition of the abnormality, with an available Baseline value and available laboratory normal ranges.

Descriptive statistics will be used to summarize the laboratory results and the changes from Baseline by visit and for the last on-treatment value within each treatment group. Shift tables and other tabular and graphical methods may be used to present the results for laboratory tests of interest. Listings will be provided with flags indicating the out of laboratory range values as well as the PCSA values.

The liver function tests, namely ALT, AST, alkaline phosphatase, and total bilirubin, are used to assess possible drug-induced liver toxicity. The proportion of patients with PCSA values at any postbaseline visit by Baseline status will be displayed by treatment group for each parameter.

#### **11.4.3.6 Analyses of vital sign variables**

The number and percentage of patients with PCSA at any evaluation during the on-Treatment Period will be summarized for each vital sign parameter within each treatment group. The summaries will include patients in the safety population who have at least one parameter to be analyzed during the on-Treatment Period. Descriptive statistics will be used to summarize the results and the changes from Baseline by visit and for the last on-treatment value within each treatment group. Tabular and graphical methods may be used to present the results for parameters of interest. Listings will be provided with flags indicating the PCSA values.

#### **11.4.3.7 Analysis of 12-lead electrocardiogram status**

A shift table will be provided to present the ECG on-treatment status according to the Baseline status within each treatment group.

#### **11.4.3.8 Bone mineral density**

Descriptive summary will be provided for BMD and its change from Baseline at Week 52 for each treatment group.

#### **11.4.4 Analyses of pharmacokinetic variables**

The PK endpoints are presented in [Section 9.3.1](#). Pharmacokinetic sotagliflozin data may be subjected to a population PK analysis, which will be reported separately to the CSR.

Individual plasma concentrations of sotagliflozin and of sotagliflozin-3-O-glucuronide at nominal sampling times will be listed.

Concentration data will be summarized by visit and, if appropriate, within visit by nominal sampling times (pre-dose, 3 hours post-dose), using descriptive statistics by N, geometric mean, coefficient of variation, median, minimum and maximum at each visit/nominal sampling time point for sotagliflozin-treated patients.

## 11.5 INTERIM ANALYSIS

No formal interim analysis for efficacy is planned since analysis of primary and key secondary efficacy endpoints will be considered final at the time of first step analyses described below. The study analyses will be conducted in 2 steps.

- First step: Efficacy analyses up to Week 26 and interim safety analyses

The first step analyses will be conducted when all patients have been randomized and have their data at the minimum up to Week 26 collected and validated. The first step analyses will include:

- Efficacy analyses up to Week 26, which are considered as the final analyses for primary and key secondary efficacy endpoints.
- Interim safety analyses which will be performed on all safety data collected and validated at the time of the first step analyses.

The first step analyses will not be used to change the conduct of the ongoing study in any aspect. Since the primary and key secondary efficacy analyses would have been concluded at the time of the first step analyses, the significance level for the study remains at 0.05 (see [Section 11.4.2.4](#)). The first step analyses will be included in the submission dossier to health authorities.

- Second step: Final analyses

The second step analyses will be conducted at the end of the study. The second step analyses will include the final analyses of efficacy endpoints at Week 52 and safety endpoints, which will be descriptive only.

Individuals who are involved in the unblinding of the first step analysis will not be involved in the conduct of the study afterwards.

An independent DMC will monitor and assess the safety of patients from this trial through periodic review of the accumulated safety data provided by an independent statistical group.

Related details are provided in separate documents (DMC charter and DMC SAP).

## **12 ETHICAL AND REGULATORY CONSIDERATIONS**

### **12.1 ETHICAL AND REGULATORY STANDARDS**

This clinical trial will be conducted by the Sponsor, the Investigator, and delegated Investigator staff and Sub-investigator, in accordance with consensus ethics principles derived from international ethics guidelines, including the Declaration of Helsinki, and the International Council for Harmonisation guidelines for Good Clinical Practice (GCP), all applicable laws, rules and regulations.

This clinical trial will be recorded in a free, publicly accessible, internet-based registry, no later than 21 days after the first patient enrollment, in compliance with applicable regulatory requirements and with Sanofi public disclosure commitments.

### **12.2 INFORMED CONSENT**

The Investigator (according to applicable regulatory requirements), or a person designated by the Investigator, and under the Investigator's responsibility, should fully inform the patient of all pertinent aspects of the clinical trial including the written information giving approval/favorable opinion by the ethics committee (IRB/IEC). All participants should be informed to the fullest extent possible about the study, in language and terms they are able to understand.

Prior to a patient's participation in the clinical trial, the written ICF should be signed, name filled in and personally dated by the patient or by the patient's legally acceptable representative, and by the person who conducted the informed consent discussion. A copy of the signed and dated written ICF will be provided to the patient.

The ICF used by the Investigator for obtaining the patient's informed consent must be reviewed and approved by the Sponsor prior to submission to the appropriate ethics committee (IRB/IEC) for approval/favorable opinion.

### **12.3 HEALTH AUTHORITIES AND INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE**

As required by local regulation, the Investigator or the Sponsor must submit this clinical trial protocol to the health authorities (competent regulatory authority) and the appropriate IRB/IEC, and is required to forward to the respective other party a copy of the written and dated approval/favorable opinion signed by the chairman with IRB/IEC composition.

The clinical trial (study number, clinical trial protocol title and version number), the documents reviewed (clinical trial protocol, ICF, IB with any addenda or labeling documents, summary of

product characteristics, package insert, Investigator's curriculum vitae, etc) and the date of the review should be clearly stated on the written (IRB/IEC) approval/favorable opinion.

The IMP will not be released at the study site and the Investigator will not start the study before the written and dated approval/favorable opinion is received by the Investigator and the Sponsor.

During the clinical trial, any amendment or modification to the clinical trial protocol should be submitted to the health authorities (competent regulatory authority), as required by local regulation, in addition to the IRB/IEC before implementation, unless the change is necessary to eliminate an immediate hazard to the patients, in which case the health authorities (competent regulatory authority) and the IRB/IEC should be informed as soon as possible. They should also be informed of any event likely to affect the safety of patients or the continued conduct of the clinical trial, in particular any change in safety. All updates to the IB or labeling information, will be sent to the IRB/IEC and to health authorities (competent regulatory authority), as required by local regulation.

A progress report is sent to the IRB/IEC at least annually and a summary of the clinical trial's outcome at the end of the clinical trial.



## **13 STUDY MONITORING**

### **13.1 RESPONSIBILITIES OF THE INVESTIGATOR(S)**

The Investigator is required to ensure compliance with all procedures required by the clinical trial protocol and with all study procedures provided by the Sponsor (including security rules). The Investigator agrees to provide reliable data and all information requested by the clinical trial protocol (with the help of the e-CRF, Discrepancy Resolution Form [DRF] or other appropriate instrument) in an accurate and legible manner according to the instructions provided and to ensure direct access to source documents by Sponsor representatives.

If any circuit includes transfer of data particular attention should be paid to the confidentiality of the patient's data to be transferred.

The Investigator may appoint such other individuals as he/she may deem appropriate as Sub-investigators to assist in the conduct of the clinical trial in accordance with the clinical trial protocol. All Sub-investigators shall be appointed and listed in a timely manner. The Sub-investigators will be supervised by and work under the responsibility of the Investigator. The Investigator will provide them with a copy of the clinical trial protocol and all necessary information.

### **13.2 RESPONSIBILITIES OF THE SPONSOR OR SERVICE PROVIDER**

The Sponsor and/or service provider of this clinical trial is responsible to regulatory authorities for taking all reasonable steps to ensure the proper conduct of the clinical trial as regards ethics, clinical trial protocol compliance, and integrity and validity of the data recorded on the e-CRFs. Thus, the main duty of the monitoring team is to help the Investigator and the Sponsor maintain a high-level of ethical, scientific, technical and regulatory quality in all aspects of the clinical trial.

At regular intervals during the clinical trial, the site will be contacted, through monitoring visits, letters or telephone calls, by a representative of the monitoring team to review study progress, Investigator and patient compliance with clinical trial protocol requirements and any emergent problems. These monitoring visits will include but not be limited to review of the following aspects: patient informed consent, patient recruitment and follow-up, SAE documentation and reporting, AESI documentation and reporting, AE and EOSI documentation, IMP allocation, patient compliance with the IMP regimen, IMP accountability, concomitant therapy use and quality of data.

### **13.3 SOURCE DOCUMENT REQUIREMENTS**

According to the ICH GCP, the monitoring team must check the e-CRF entries against the source documents, except for the pre-identified source data directly recorded in the e-CRF. The ICF will include a statement by which the patient allows the Sponsor's duly authorized personnel, the

ethics committee (IRB/IEC), and the regulatory authorities to have direct access to original medical records which support the data on the e-CRFs (eg, patient's medical file, appointment books, original laboratory records, etc). These personnel, bound by professional secrecy, must maintain the confidentiality of all personal identity or personal medical information (according to confidentiality and personal data protection rules).

#### **13.4 USE AND COMPLETION OF CASE REPORT FORMS AND ADDITIONAL REQUEST**

It is the responsibility of the Investigator to maintain adequate and accurate e-CRFs (according to the technology used) designed by the Sponsor/service provider to record (according to Sponsor instructions) all observations and other data pertinent to the clinical investigation in a timely manner. All e-CRFs should be completed in their entirety in a neat, legible manner to ensure accurate interpretation of data.

Should a correction be made, the corrected information will be recorded into the e-CRF by the authorized person and explained (if necessary). All corrected data will be tracked through an audit trail.

Data are available within the system to the CRO as soon as they are entered in the e-CRF.

The computerized handling of the data by the CRO/service provider may generate additional requests (DRF) to which the Investigator is obliged to respond by confirming or modifying the data questioned. The requests with their responses will be managed through the e-CRF.

#### **13.5 USE OF COMPUTERIZED SYSTEMS**

The complete list of computerized systems used for the study is provided in a separate document which is maintained in the Sponsor and Investigator study files.

## **14 ADDITIONAL REQUIREMENTS**

### **14.1 CURRICULUM VITAE**

A current copy of the curriculum vitae describing the experience, qualification and training of each Investigator and Sub-investigator will be signed, dated and provided to the Sponsor prior to the beginning of the clinical trial.

### **14.2 RECORD RETENTION IN STUDY SITES**

The Investigator must maintain confidential all study documentation and take measures to prevent accidental or premature destruction of these documents.

The Investigator should retain the study documents at least 15 years after the completion or discontinuation of the clinical trial.

However, applicable regulatory requirements should be taken into account in the event that a longer period is required.

The Investigator must notify the Sponsor prior to destroying any study essential documents following the clinical trial completion or discontinuation.

If the Investigator's personal situation is such that archiving can no longer be ensured by him/her, the Investigator shall inform the Sponsor and the relevant records shall be transferred to a mutually agreed upon designee.

### **14.3 CONFIDENTIALITY**

All information disclosed or provided by the Sponsor (or any company/institution acting on their behalf), or produced during the clinical trial, including, but not limited to the clinical trial protocol, personal data in relation to the patients, the CRFs, the IB, and the results obtained during the course of the clinical trial, is confidential, prior to the publication of results. The Investigator and any person under his/her authority agree to undertake to keep confidential and not to disclose the information to any third party without the prior written approval of the Sponsor.

However, the submission of this clinical trial protocol and other necessary documentation to the ethics committee (IRB/IEC) is expressly permitted, the IRB/IEC members having the same obligation of confidentiality.

The Sub-investigators shall be bound by the same obligation as the Investigator. The Investigator shall inform the Sub-investigators of the confidential nature of the clinical trial.

The Investigator and the Sub-investigators shall use the information solely for the purposes of the clinical trial, to the exclusion of any use for their own or for a third party's account.

#### 14.4 PROPERTY RIGHTS

All information, documents and IMP provided by the Sponsor or its designee are and remain the sole property of the Sponsor.

The Investigator shall not and shall cause the delegated Investigator staff /Sub-investigator not to mention any information or the Product in any application for a patent or for any other intellectual property rights.

All the results, data, documents and inventions, which arise directly or indirectly from the clinical trial in any form, shall be the immediate and exclusive property of the Sponsor.

The Sponsor may use or exploit all the results at its own discretion, without any limitation to its property right (territory, field, continuance). The Sponsor shall be under no obligation to patent, develop, market, or otherwise use the results of the clinical trial.

As the case may be, the Investigator and/or the Sub-investigators shall provide all assistance required by the Sponsor, at the Sponsor's expense, for obtaining and defending any patent, including signature of legal documents.

#### 14.5 DATA PROTECTION

- The patient's personal data, which are included in the Sponsor database shall be treated in compliance with all applicable laws and regulations.
- When archiving or processing personal data pertaining to the Investigator and/or to the patients, the Sponsor shall take all appropriate measures to safeguard and prevent access to this data by any unauthorized third party.
- The Sponsor also collects specific data regarding Investigator as well as personal data from any person involved in the study which may be included in the Sponsor's databases, shall be treated by both the Sponsor and the Investigator in compliance with all applicable laws and regulations.

Patient race and ethnicity (race: American Indian or Alaska Native, Asian, Black of African American, Native Hawaiian or Other Pacific Islander, White, not reported, unknown; ethnicity: Hispanic, Not Hispanic) will be collected in this study because these data are required by several regulatory authorities (eg, on Afro-American population for FDA, on Japanese population for the Pharmaceuticals and Medical Devices Agency in Japan, or on Chinese population for the China FDA in China).

[REDACTED]

The data collected in this study will only be used for the purpose(s) of the study and to document the evaluation of the benefit/risk ratio, efficacy, and safety of the product(s). They may be further processed if they have been anonymized.

## **14.6 INSURANCE COMPENSATION**

The Sponsor certifies that it has taken out a liability insurance policy covering all clinical trials under its sponsorship. This insurance policy is in accordance with local laws and requirements. The insurance of the Sponsor does not relieve the Investigator and the collaborators from any obligation to maintain their own liability insurance policy. An insurance certificate will be provided to the IECs/IRBs or regulatory authorities in countries requiring this document.

## **14.7 SPONSOR AUDITS AND INSPECTIONS BY REGULATORY AGENCIES**

For the purpose of ensuring compliance with the clinical trial protocol, GCP, and applicable regulatory requirements, the Investigator should permit auditing by or on the behalf of the Sponsor and inspection by regulatory authorities.

The Investigator agrees to allow the auditors/inspectors to have direct access to his/her study records for review, being understood that these personnel are bound by professional secrecy, and as such will not disclose any personal identity or personal medical information.

The Investigator will make every effort to help with the performance of the audits and inspections, giving access to all necessary facilities, data, and documents.

As soon as the Investigator is notified of a planned inspection by the authorities, he/she will inform the Sponsor and authorize the Sponsor to participate in this inspection.

The confidentiality of the data verified and the protection of the patients should be respected during these inspections.

Any result and information arising from the inspections by the regulatory authorities will be immediately communicated by the Investigator to the Sponsor.

The Investigator shall take appropriate measures required by the Sponsor to take corrective actions for all problems found during the audit or inspections.

## **14.8 PREMATURE DISCONTINUATION OF THE STUDY OR PREMATURE CLOSE-OUT OF A SITE**

### **14.8.1 By the Sponsor**

The Sponsor has the right to terminate the participation of either an individual site or the study at any time, for any reason, including but not limited to the following:

- The information on the product leads to doubt as to the benefit/risk ratio.
- Patient enrollment is unsatisfactory.

- The Investigator has received from the Sponsor all IMP, means, and information necessary to perform the clinical trial and has not included any patient after a reasonable period of time mutually agreed upon.
- Noncompliance of the Investigator or Sub-investigator, delegated staff with any provision of the clinical trial protocol, and breach of the applicable laws and regulations or breach of the ICH GCP.
- The total number of patients is included earlier than expected.

In any case the Sponsor will notify the Investigator of its decision by written notice.

#### **14.8.2 By the Investigator**

The Investigator may terminate his/her participation upon thirty (30) days' prior written notice if the study site or the Investigator for any reason becomes unable to perform or complete the clinical trial.

In the event of premature discontinuation of the study or premature close-out of a site, for any reason whatsoever, the appropriate IRB/IEC and regulatory authorities should be informed according to applicable regulatory requirements.

#### **14.9 CLINICAL TRIAL RESULTS**

The Sponsor will be responsible for preparing a CSR and to provide a summary of study results to the Investigator.

#### **14.10 PUBLICATIONS AND COMMUNICATIONS**

The Investigator undertakes not to make any publication or release pertaining to the study and/or results of the study prior to the Sponsor's written consent, being understood that the Sponsor will not unreasonably withhold its approval.

As the study is being conducted at multiple sites, the Sponsor agrees that, consistent with scientific standards, a primary presentation or publication of the study results based on global study outcomes shall be sought. However, if no multicenter publication is submitted, underway, or planned within twelve (12) months of the completion of this study at all sites, the Investigator shall have the right to publish or present independently the results of this study in agreement with other Investigators and stakeholders. The Investigator shall provide the Sponsor with a copy of any such presentation or publication for review and comment at least 30 days in advance of any presentation or submission for publication. In addition, if requested by the Sponsor, any presentation or submission for publication shall be delayed for a limited time, not to exceed 90 days, to allow for filing of a patent application or such other justified measures as the Sponsor deems appropriate to establish and preserve its proprietary rights.

The Investigator shall not use the name(s) of the Sponsor and/or its employees in advertising or promotional material or publication without the prior written consent of the Sponsor. The Sponsor shall not use the name(s) of the Investigator and/or the collaborators in advertising or promotional material or publication without having received his/her and/or their prior written consent(s).

The Sponsor has the right at any time to publish the results of the study.

## **15 CLINICAL TRIAL PROTOCOL AMENDMENTS**

All appendices attached hereto and referred to herein are made part of this clinical trial protocol.

The Investigator should not implement any deviation from, or changes to the clinical trial protocol without agreement by the Sponsor and prior review and documented approval/favorable opinion from the IRB/IEC and/or notification/approval of health authorities (competent regulatory authority) of an amendment, as required by local regulation, except where necessary to eliminate an immediate hazard(s) to clinical trial patients, or when the change(s) involves only logistical or administrative aspects of the trial. Any change agreed upon will be recorded in writing, the written amendment will be signed by the Investigator and by the Sponsor, and the signed amendment will be filed with this clinical trial protocol.

Any amendment to the clinical trial protocol requires written approval/favorable opinion by the IRB/IEC prior to its implementation, unless there are overriding safety reasons.

In case of substantial amendment to the clinical trial protocol, approval from the health authorities (competent regulatory authority) will be sought before implementation.

In some instances, an amendment may require a change to the ICF. The Investigator must receive an IRB/IEC approval/favorable opinion concerning the revised ICF prior to implementation of the change and patient signature should be re-collected if necessary.



## 16 BIBLIOGRAPHIC REFERENCES

1. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future *Lancet*. 2014;383:1068-83.
2. International Diabetes Federation. *IDF Diabetes Atlas, 7th ed.* Brussels, Belgium: International Diabetes Federation, 2015. Available from URL: <http://www.diabetesatlas.org> [Accessed December 2016].
3. World Health Organization, Regional Office for Europe, Data and Statistics. Available from URL: <http://www.euro.who.int/en/health-topics/noncommunicable-diseases/diabetes/data-and-statistics>. [Accessed December 2016].
4. Bailey CJ. The current drug treatment landscape for diabetes and perspectives for the future. *Clin Pharmacol Ther*. 2015;98(2):170-84.
5. Hediger MA, Coady MJ, Ikeda TS, Wright EM. Expression cloning and cDNA sequencing of the Na<sup>+</sup>/glucose co-transporter. *Nature*. 1987;330(6146):379-81.
6. Mudaliar S, Polidori D, Zambrowicz B, Henry RR. Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside. *Diabetes Care*. 2015;38(12):2344-53.
7. Wright EM. I. Glucose galactose malabsorption. *Am J Physiol*. 1998;275:G879-82.
8. Raskin P. Sodium–glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus. *Diabetes Metab Res Rev*. 2013;29(5):347-56.
9. Zambrowicz B, Freiman J, Brown PM, Frazier KS, Turnage A, Bronner J, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. *Clin Pharmacol Ther*. 2012;92(2):158-69.
10. Canagliflozin [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; July 2016:1-15.
11. Dapagliflozin [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; June 2016:1-10.
12. Empagliflozin [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., and Indianapolis, IN, Eli Lilly and Company; July 2016:1-25.
13. Zambrowicz B, Lapuerta P, Strumph P, Banks P, Wilson A, Ogbaa I, et al. LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion. *Clin Ther*. 2015;37(1):71-82.

14. American Diabetes Association. Standards of Medical Care in Diabetes – 2017. *Diabetes Care*. 2017;40(Suppl 1):S1-S135.
15. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney inter., Suppl.* 2013;3:1-150.
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med.* 1999;130(6):461-70.
17. Florkowski CM, Chew-Harris JS. Methods of Estimating GFR - Different Equations Including CKD-EPI. *Clin Biochem Rev.* 2011;32(2):75-9.
18. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. *Am J Kidney Dis.* 2012;60(5):850-86.
19. FDA Guidance for Industry: Diabetes Mellitus - Developing Drugs and Therapeutic Biologics for Treatment and Prevention. Lines 1144 – 1215. Available from: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071624.pdf>. Accessed July 12, 2016.
20. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. *Diabetes Care.* 2013;36(5):1384-95.
21. Hochberg Y. A Sharper Bonferroni Procedure for Multiple Tests of Significance. *Biometrika.* 1988;75(4):800–2.
22. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J.* 2013;34(28):2159-219.

## **17 APPENDICES**

## **Appendix A    Guidance on contraceptive methods and collection of pregnancy information**

### **DEFINITIONS**

#### **Nonreproductive potential**

1. Premenopausal female with 1 of the following:
  - Documented hysterectomy
  - Documented bilateral salpingectomy
  - Documented bilateral oophorectomy
2. Postmenopausal
  - A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormone replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
  - Females on HRT and whose menopausal status is in doubt will be required to use 1 of the highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.

#### **Reproductive potential (WOCBP)**

A woman is considered of reproductive potential (WOCBP), ie, fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.

### **CONTRACEPTIVE GUIDANCE**

Women of reproductive potential (WOCBP) must use a highly effective method of contraception during the treatment period and the post-treatment follow up period (28 ±3 days). If another contraceptive method is used (such as a barrier method), it should be used in combination with one of the highly effective methods (such as an oral contraceptive).

**Female patients:**

<p><b>Highly Effective Contraceptive Methods That Are User Dependent</b></p> <p><i>Failure rate of &lt;1% per year when used consistently and correctly<sup>a</sup></i></p>
<ul style="list-style-type: none"> <li>• Combined (estrogen- and progestogen-containing ) hormonal contraception associated with inhibition of ovulation <ul style="list-style-type: none"> <li>- oral</li> <li>- intravaginal</li> <li>- transdermal</li> </ul> </li> </ul>
<ul style="list-style-type: none"> <li>• Progestogen-only hormone contraception associated with inhibition of ovulation <ul style="list-style-type: none"> <li>- oral</li> <li>- injectable</li> </ul> </li> </ul>
<p><b>Highly Effective Methods That Are User Independent</b></p>
<ul style="list-style-type: none"> <li>• Implantable progestogen-only hormone contraception associated with inhibition of ovulation</li> </ul>
<ul style="list-style-type: none"> <li>• Intrauterine device (IUD)</li> </ul>
<ul style="list-style-type: none"> <li>• Intrauterine hormone-releasing system (IUS)</li> </ul>
<ul style="list-style-type: none"> <li>• Bilateral tubal occlusion</li> </ul>
<ul style="list-style-type: none"> <li>• Vasectomized partner</li> </ul> <p><i>(Vasectomized partner is a highly effective contraceptive method provided that the partner is the sole sexual partner of the woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional highly effective method(s) of contraception should be used. Spermatogenesis cycle is approximately 90 days.)</i></p>
<ul style="list-style-type: none"> <li>• Sexual abstinence</li> </ul> <p><i>(Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study drug. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the patient.)</i></p>
<p>NOTE:</p> <p><sup>a</sup> Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent with local regulations regarding the use of contraceptive methods for patients participating in clinical studies.</p>

## COLLECTION OF PREGNANCY INFORMATION

### Male patients with partners of reproductive potential who become pregnant

- The Investigator will attempt to collect pregnancy information on any female partner of a male study patient who becomes pregnant while participating in this study. This applies only to patients who receive study treatment.
- After obtaining the necessary signed informed consent from the pregnant female partner directly, the Investigator will record pregnancy information on the appropriate form and submit it to the Sponsor within 24 hours of learning of the partner's pregnancy.
- Partner will also be followed to determine the outcome of the pregnancy. Information on the status of the mother and child will be forwarded to the Sponsor.
- Generally, follow-up will be no longer than 6 to 8 weeks following the estimated delivery date. Any termination of the pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or indication for procedure.

### Female patients who become pregnant

- The Investigator will collect pregnancy information on any female patient, who becomes pregnant while participating in this study.
- Information will be recorded on the appropriate form and submitted to the Sponsor within 24 hours of learning of a participant's pregnancy.
- Participant will be followed to determine the outcome of the pregnancy. The Investigator will collect follow-up information on participant and neonate, which will be forwarded to the Sponsor. Generally, follow-up will not be required for longer than 6 to 8 weeks beyond the estimated delivery date.
- Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for procedure.
- While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or elective termination of a pregnancy will be reported as an AE or SAE.
- A spontaneous abortion is always considered to be an SAE and will be reported as such.
- Any SAE occurring as a result of a post-study pregnancy which is considered reasonably related to the study treatment by the Investigator, will be reported to the Sponsor as described in [Section 10.4.3](#). While the Investigator is not obligated to actively seek this information in former study patients, he/she may learn of an SAE through spontaneous reporting.

## **Appendix B Recommendations on basic genito-urinary hygiene, maintaining hydration, and recognizing diabetic ketoacidosis**

Patients with T2D are at risk for developing GU infections. The following guidelines should be communicated to females and uncircumcised males regarding GU infections. Patient communication cards will be printed with the following:

For females:

“The following advice may be useful in helping you to keep your bladder and urethra free from infection:

- Go to the toilet as soon as you feel the need to urinate, rather than holding it in.
- Wipe from front to back after going to the toilet.
- Practice good hygiene by washing your genitals every day, and before having sex.
- Empty your bladder after having sex.”

For uncircumcised males:

“The following advice may be useful in helping you to keep the foreskin free from infection:

- Wash the end of your penis and foreskin with soap and water (do not let soap get in the opening).
- After your shower or bath, dry the end of your penis and foreskin properly and replace the foreskin.
- Also, when you urinate, slide the foreskin back enough so that urine does not get on the foreskin-this helps to keep it clean.”

### **Maintaining Hydration:**

Sodium-glucose cotransporter type 2 inhibitors are associated with osmotic diuresis and volume depletion, which may lead to dizziness or hypotension, especially in the elderly. Before initiating study drug (at Screening, Run-in and Randomization) and during all on-site study visits thereafter, assess volume status in patients with renal impairment, the elderly, in patients with low SBP, or if receiving diuretics, angiotensin-converting-enzyme inhibitors, or angiotensin receptor blockers. All patients will be advised to maintain proper fluid intake and to consider increasing it if they sense greater thirst, more urine production, or if they feel dizzy or faint.

Patient communication cards will be printed with the following for patients with T2D:

“The following advice may be useful in helping you to maintain proper hydration and prevent dehydration:

- Dehydration is when your body loses too much fluid, frequently due to diarrhea or increased urination

- Consider increasing the amount of fluids you drink if:
  - You sense greater thirst than usual
  - You have a dry mouth or cracked lips
  - You have a fever
  - You have diarrhea or vomiting
  - You urinate more frequently or in larger amounts than usual
  - You get up in the middle of the night to urinate (more than usual)
  - You feel dizzy or light-headed
  - You exercise, or when it is hot outside”

### **Recognizing Diabetic Ketoacidosis**

Potential gastrointestinal (GI) AEs occurring with sotagliflozin may mask presenting symptoms of diabetic ketoacidosis (DKA). Patient communication cards will be printed with the following:

“If you have any of these symptoms on the list, then contact your study site immediately for assistance with managing your diabetes:

- Inability to maintain oral intake
- Generalized weakness
- Abdominal (belly) pain
- Increased weight loss
- Fever
- Frequent urination, including at night
- Fruity-scented breath
- Confusion
- Acute illness
- Consistently elevated blood glucose
- Feeling very thirsty or drinking a lot
- Nausea or vomiting
- Having trouble thinking clearly or feeling tired

It is possible to have DKA even if your blood glucose is not elevated. Regardless of your blood glucose level, if you have any of these symptoms on the list, then contact your study site regarding the need to be evaluated for possible DKA, which will include specific blood testing. If your study site is closed and your study doctor is not available, go to the nearest emergency room for evaluation.



If you are scheduled for a procedure or surgery that requires you to not take any food or liquids, please contact your study doctor for instructions on continuing study drug. In such cases your study doctor may advise you NOT to take your study drug from the day prior to the procedure or surgery until after the procedure or surgery is complete, and you are taking food and liquids as you normally do.”

Whenever AE data is collected or the patient reports DKA or intercurrent illness (including infections), generalized weakness, increased weight loss, GI symptoms including nausea, vomiting, or abdominal pain or other symptoms or signs that the Investigator believes may be consistent with DKA, then the site will determine if an assessment for DKA is appropriate. If laboratory testing confirms presence of metabolic acidosis, then the “Possible DKA” e-CRF will be completed.

## **Appendix C Measurement of Blood Pressure and Pulse Rate**

### **Equipment**

1. Blood pressure measurements will be taken by an automated BP monitor or a manual sphygmomanometer
2. Bladder Length – Should nearly or completely encircle the patient’s arm. For many adults, the standard “adult” size bladder is not long enough and the “large” size bladder is recommended
3. Bladder Width – Should be at least 40% of the bladder length

### **Patient Factors**

Extraneous variables associated with the measurement of BP should be minimized. These include:

1. Food intake, caffeine-containing beverages, cigarette smoking, or strenuous exercise within 2 hours prior to measurement
2. Full urinary bladder
3. The patient should not be allowed to talk while BP is being measured
4. The patient should be placed in the examination room and the cuff should be placed on the patient’s nondominant arm. The proper sized cuff should fit snugly with the lower edge 2 to 3 cm above the antecubital fossa
5. The patient should be allowed to sit quietly in a comfortably warm place (temperature around 25°C or 77°F) for 5 minutes with the arm supported at heart level, preferably with the cuff in place and with no restrictive clothing on the arm. The patient should be encouraged not to tense his or her muscles.

### **Determination of the arm with the highest blood pressure**

At Visit 1 (week -4), seated BP should be measured in both arms after 5-minute rest period, and then again after 1 minute in both arms in seated position. The arm with the highest SBP will be determined at this visit, and BP should be measured in this arm throughout the study.

### **Measurement Technique (22)**

At Visit 1, immediately following arm selection, with the patient in the same position, an additional seated BP should be measured in the selected arm (at least 1 minute after last measurement).


At all other on-site visits, following the 5-minute rest period, 3 separate seated BPs should be measured in the arm selected at Visit 1, with at least 1 minute between BP measurements and with the cuff fully deflated between measurements.

All 3 BPs will be recorded in the patient's e-CRF. The mean of the 3 seated BPs will constitute the BP value for that visit.

Three seated pulse rate measurements will also be obtained. The mean of the 3 seated pulse rate measurements will constitute the pulse rate value for that visit.

## Appendix D General guidance for the follow-up of laboratory abnormalities by Sanofi

### NEUTROPENIA




#### Note:

- The procedures described in the above flowchart are to be discussed with the patient only in case the event occurs. If applicable (according to local regulations), an additional consent (e.g., for HIV testing) will only be obtained in the case the event actually occurs.
- For individuals of African descent, the relevant value of concern is <1000/mm<sup>3</sup>

Neutropenia is to be recorded as an AE only if at least 1 of the criteria listed in the general guidelines for reporting AEs in [Section 10.4.2](#) is met.


### THROMBOCYTOPENIA



**Note:**

The procedures above flowchart are to be discussed with the patient only in case described in the the event occurs. If applicable (according to local regulations), an additional consent (e.g., for HIV testing) will only be obtained in the case the event actually occurs.

Thrombocytopenia is to be recorded as an AE only if at least 1 of the criteria listed in the general guidelines for reporting AEs in [Section 10.4.2](#) is met.




- In ANY CASE, FOLLOW** the instructions listed in the box below:
1. **INFORM** the Site Monitor who will forward the information to the Study Manager
  2. **INVESTIGATE** specifically for malaise with or without loss of consciousness, dizziness, and/or hypotension and/or episode of arrhythmia in the previous 72 hours; rule out muscular injury
  3. **PERFORM** the following tests:
    - LFTs: AST, ALT, alkaline phosphatase, total and conjugated bilirubin and prothrombin time / INR
    - CPK, serum creatinine, complete blood count
    - Anti-HAV IgM, anti-HBc IgM (HBV-DNA if clinically indicated), anti-HCV and HCV RNA, anti-CMV IgM and anti-HEV IgM antibodies
    - Depending on the clinical context, check for recent infection with EBV, herpes viruses, and toxoplasma
    - Hepatobiliary ultrasonography (or other imaging investigations if needed)
  4. **CONSIDER** Auto-antibodies: antinuclear, anti-DNA, anti-smooth muscle, anti-LKM
  5. **CONSIDER** consulting with hepatologist
  6. **CONSIDER** patient hospitalisation if INR>2 (or PT<50%) and/or central nervous system disturbances suggesting hepatic encephalopathy
  7. **MONITOR** LFTs after discontinuation of IMP:
    - As closely as possible (or every 48 hours) until stabilization, then every 2 weeks until return to normal/baseline or clinical resolution.
  8. **FREEZE** serum sample (5ml x 2)

\*If unable to re-test in 72 hours, use original lab results to decide on further reporting/monitoring/discontinuation.  
Note:


- “Baseline” refers to ALT sampled at Baseline Visit; or if Baseline value unavailable, to the latest ALT sampled before the Baseline Visit. The algorithm does not apply to the instances of increase in ALT during Screening.
- See [Section 10.4](#) for guidance on safety reporting.
- Normalization is defined as ≤ULN or Baseline value, if Baseline value is >ULN.

### ACUTE RENAL FAILURE



Acute renal failure is to be recorded as an AE only if at least 1 of the criteria listed in the general guidelines for reporting AEs in [Section 10.4.2](#) is met.

### SUSPICION OF RHABDOMYOLYSIS



Suspicion of rhabdomyolysis is to be recorded as an AE only if at least 1 of the criteria in the general guidelines for reporting AEs in [Section 10.4.2](#) is met.



# EFC148387 Amended Protocol 01

## ELECTRONIC SIGNATURES

<b>Signed by</b>	<b>Meaning of Signature</b>	<b>Server Date (dd-MMM-yyyy HH:mm)</b>
██████████	Regulatory Approval	21-Dec-2017 20:02 GMT+0100
██████████████████	Clinical Approval	21-Dec-2017 20:27 GMT+0100
██████████	Clinical Approval	22-Dec-2017 11:52 GMT+0100